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Abstract 
Smokers with asthma represent an important sub-group of asthmatics displaying 
both reduced response to inhaled and oral corticosteroids as well as demonstrating 
accelerated decline in lung function and increased use of health care services.  Clinical 
and laboratory studies have suggested that macrolide antibiotics may exhibit anti-
inflammatory properties in a variety of airways disease including asthma. The anti-
inflammatory properties of macrolides have been recognised for almost 50 years. 
Indirect evidence from both pre-clinical and clinical studies suggests that the 
mechanism of action may be of particular benefit in smokers with asthma.  A proof of 
concept study was designed to test the hypothesis that the macrolide antibiotic 
azithromycin improves measures of asthma control, airway inflammation and 
bacterial colonisation in smokers with asthma.  Azithromycin was chosen for its 
convenience of once daily dosing and its oral tolerability in addition to its more 
limited interactions. 
Seventy-seven adults with allergic asthma were recruited to a 12-week parallel group 
randomised controlled trial comparing the effects on asthma control, airway 
inflammation and bacterial colonisation of oral azithromycin 250 mg daily with 
matched placebo.  The primary outcome measure was peak expiratory flow at the 
final study visit.  Secondary outcome measures included spirometry, asthma control 
questionnaire [ACQ] score, asthma quality of life questionnaire [AQLQ], Leicester 
cough questionnaire [LCQ] score, provocation concentration to methacholine PC20, 
and inflammatory markers: exhaled nitric oxide, sputum differential cell counts, 
sputum supernatant and serum inflammatory markers such as interleukin-1β [IL-1β], 
IL-2, -4, -5, -6, -10, TNF-α, IFN-γ, GM-CSF, Leukotriene B4, and high sensitivity C-
reactive protein.  Microbiological culture and PCR of sputum was also performed to 
assess for any changes associated with treatment. 
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At 12 weeks, the change in PEF at the final study visit, as  compared with baseline, 
did not differ significantly between the azithromycin and placebo treatment groups 
[mean difference azithromycin-placebo -10.3L/min, 95% CI -47.1 to 26.4, p=0.58].  No 
statistically significant difference was observed between the azithromycin and 
placebo groups in each of the measures of spirometry, ACQ, AQLQ, LCQ, PC20, or 
evening PEF.  The LCQ-psychological domain did reach statistical significance, [mean 
difference azithromycin-placebo -0.46, 95%CI -0.9 to 0.02 p=0.04], however this 
indicates a deterioration in the treatment group. 
No change was seen in exhaled nitric oxide.  The total cell counts recovered from 
sputum were similar following treatment with azithromycin compared to placebo.  In 
addition, differential cell counts remained unchanged and lymphocyte proliferation 
assays did not demonstrate any statistically significant changes following 12 weeks of 
treatment with azithromycin when compared to placebo.  There was no substantial 
difference in any of the measured sputum supernatant or plasma cytokines.  
Peripheral blood monocyte stimulation was performed, with supernatant being 
measured against a panel of cytokines.  There was again no substantial difference in 
any of the measured panel of cytokines collected from the monocyte stimulation 
assays when the azithromycin group was compared to placebo.   
There was no correlation between changes in ACQ, AQLQ, LCQ, PC20, sputum 
macrophage count, sputum neutrophil count, sputum eosinophil count, and PEF.   
Adverse event rates were similar in patients taking azithromycin compared with 
placebo.  A total of 4 patients were lost to follow up [1 in the azithromycin group, 3 in 
the placebo group].  One patient died of a cardiovascular cause.  This occurred 
following completion of the study but within the pre-specified regulatory reporting 
period.   
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In conclusion there were no clinically important improvements in a range of clinical 
indices of asthma control, airway inflammation or bacterial colonisation following 12 
weeks treatment with azithromycin when compared with placebo in smokers with 
asthma.   
The lack of any evidence of clinical benefit of azithromycin in smokers with asthma is 
a new finding and extends the current knowledge base and evidence for the use of 
macrolides in asthma.  There exists no firm evidence to suggest the widespread use of 
macrolides in asthma and the current study suggests that no benefit will be observed 
in the sub-group of asthmatics whom are current smokers.   
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1. Introduction 
1.1. Asthma 
1.1.1. Definition 
Asthma represents a diagnostic challenge, in many instances more difficult to prove 
than is generally appreciated.  The diagnosis is ultimately a clinical one; there is no 
standard definition of the type of asthma, the frequency or severity of the symptoms 
nor the findings on clinical examination [1].  At the organ level, asthma is a chronic 
inflammatory condition of the airways in which many cells and cell mediators play a 
role.  Whilst the clinical spectrum of disease is highly variable the single most 
consistent feature is the presence of airway inflammation [2].  In a not too dissimilar 
fashion we are now beginning to appreciate that this underlying airways 
inflammation is heterogeneous [3] and this may be informative of the reasons for the 
disease phenotype. 
The diagnosis of asthma in adults is therefore based on the recognition of a pattern of 
symptoms in the absence of an alternative explanation.  Even with a classical case, it 
is important to obtain objective evidence in support of the diagnosis. There is a 
considerable burden of treatment, and consequent cost in healthcare provision.  The 
best confirmatory evidence is the objective demonstration of reversible airflow 
obstruction.  Further supporting evidence can be obtained from other tests of airways 
responsiveness and inflammation.   
The aims of asthma management are to control the disease and hence render the 
patient symptom free [1, 2]  The mainstays of treatment are inhaled bronchodilators 
and inhaled corticosteroids [ICS].  The majority of patients can achieve these 
treatment goals with inhaled corticosteroid alone or additionally with other inhaled 
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or oral therapies, but there still exists a sub-population who remain symptomatic 
despite this.   
1.1.2. Diagnosis 
1.1.2.1. Clinical features 
Central to the diagnosis is the description of symptoms such as wheeze, coughing, 
chest tightness, breathlessness and the finding of variable airflow obstruction on 
objective testing.  There may be a diurnal or seasonal pattern of wheezing.  Family 
history may be present.   
These symptoms are frequently episodic in nature which is as much part of the 
clinical syndrome as it is a confounding factor to the physician when seeing the 
patient, particularly if the physical findings are absent.   
1.1.2.2. Physical examination 
The episodic nature of asthma means that no abnormal findings may be present.  
Commonly the most frequent finding when symptoms are present is polyphonic 
wheeze, present on auscultation of the chest.  There exists the possibility that 
significant airflow limitation may be present with no apparent wheeze.   
1.1.2.3. Objective testing 
Whilst a diagnosis can be made on clinical grounds, this is not always the case, 
particularly when subjects present to the out-patient clinic with few symptoms.  In 
such instances objective measurements of lung function and airway hyper-
responsiveness are required, not only to support the diagnosis but also to give the 
clinician an impression of disease severity in terms of both airflow limitation and 
bronchial hyper-responsiveness.   
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Reduction in FEV1 is not exclusively found in asthma and may be present in other 
diseases than those which cause airflow limitation.  Therefore a more useful 
assessment is based on the ratio of FEV1 to FVC.  Normal spirometric measurements 
will yield a ratio of FEV1/FVC of greater than 80% with values less than this 
suggestive of some form of airflow limitation [2, 4].   
Reversibility testing [with nebulised β2-agonists] is also utilised and is most useful in 
patients who are symptomatic with evidence of a reduced FEV1, but not exclusively 
so.  Various guidance exists, but it is generally accepted that improvements in FEV1 of 
12% with an absolute volume improvement of ≥200ml is required following treatment 
with nebulised bronchodilator or oral corticosteroids [2, 4].   
Broncho-provocation testing is another method to test the responsiveness of the 
airways to various stimulants [e.g. methacholine, histamine or mannitol].  
Standardised testing has been adopted with inhalation of aerosol for timed periods of 
tidal breathing or delivery of a pre-determined amount via a dosimeter [5].  When a 
reduction in FEV1 of 20% is measured a positive result is determined [2, 5] and 
subsequently the concentration [PC20] or dose [PD20] or drug required to achieve this 
drop can be calculated.  The calculated concentration or dose gives an overall 
impression as to the degree of airway hyper-responsiveness.  These tests are sensitive 
for a diagnosis of asthma, but have limited specificity.  This is because airway hyper-
responsiveness has been described in patients with other respiratory diseases [2].   
Peak expiratory flow diary measurements are extremely useful along with the 
documented presence of nocturnal/early morning symptoms.  A diurnal variation of 
PEF of 20% or more is thought to be highly characteristic of asthma [2]. 
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Table 1.1: Key diagnostic features of asthma 
 
Symptoms Signs 
Episodic/variable None [common] 
Shortness of breath Wheeze – bilateral, diffuse 
Wheeze Expiratory [± inspiratory] 
Chest tightness Tachypnoea 
Cough  
Helpful additional information 
Personal and family history of asthma or atopy [eczema, allergic rhinitis] 
History of sensitivity to aspirin/NSAIDs or β blockers [including eye drops] 
Recognised triggers – pollen, dust, animals, exercise, viral infections 
Pattern and severity of symptoms and exacerbations 
Objective measurements 
>20% diurnal variation on ≥3 days in a week for two weeks on PEF diary or 
FEV1 ≥ 12% [and 200ml] increase after short acting β2 agonist or 
FEV1 ≥ 15% [and 200ml] increase after a trial of steroids or 
FEV1 ≥ 15% [and 200ml] increase after a trial of steroids or 
FEV1 ≥ 15% decrease after 15 minutes of vigorous exercise 
Bronchoprovocation testing positive 
 
1.1.2.4. Quality of life measures and asthma control 
There are various ways to classify asthma control; however no classification has been 
universally accepted.  Overall, asthma control consists of two domains; one is 
achieving day-to-day control [or current] asthma control, indicated by the absence of 
asthma symptoms, minimal reliever use, normal activity levels and lung function 
values close to normal.  The second domain is to minimise future risk to patients by 
ensuring the absence of asthma exacerbations, the prevention of accelerated lung 
function decline over time and minimal side effects from medication. 
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The goals of asthma control [defined by GINA [2]] are: 
 No daytime symptoms [maximum occurring twice or less/week] 
 No limitation of activity 
 No nocturnal symptoms/wakening 
 No requirement for reliever/rescue medication [max twice or less/week] 
 Normal lung function – PEF or FEV1 
 No exacerbations 
The evidence demonstrates that despite these aspirations, large numbers of patients 
with asthma, 74% in a European study [6] are not fully controlled.  Similar numbers 
are found in the United States [7]. 
1.1.2.4.1. Numeric measures of asthma control 
The Asthma Control Questionnaire [8] was developed to assess asthma control in 
clinical trials and clinical practice.  The ACQ has been validated against quality of life 
and physician global assessment [9].  The score is an arithmetic mean based on 7 
questions marked on a 7-point scale [0-6], with a minimal important difference of 0.5 
[10].  The optimal cut-point for “Well-controlled” using the Gaining Optimal Asthma 
Control [GOAL] [11] classification is less than or equal to 0.75, and a value of greater 
than or equal to 1.50 reflects “not Well-Controlled” asthma [11].  A copy of the ACQ 
can be found in Appendix 1. 
1.1.2.4.2. Quality of life 
Measuring health related quality of life [HRQOL] can add valuable information to 
better assess the impact of poor asthma control and/or its severity.  HRQOL 
questionnaires were not intended to be used as endpoints in clinical trials but many 
studies now include and assessment of HRQOL [9].   
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Generic questionnaires exist, for example the Medical Outcomes Short Form-36, but 
this questionnaire was designed for use in chronic illness such as tiredness and 
lethargy hence the clinical utility is questionable in asthma [9].  Asthma specific 
questionnaires are therefore preferable and the Juniper-Asthma Quality of Life 
Questionnaire [AQLQ] [12] is frequently used.  The AQLQ has 4 domains: physical, 
social, emotional and occupational.  A copy of the AQLQ can be found in Appendix 
2.  Patients score their experiences during the last 2 weeks on a 7-point scale [1 = 
severe impairment to 7 = no impairment].  The overall score and the means for the 
different domains are calculated.  The minimal important difference [MID] is 
reported to be 0.5 [13]. 
1.1.3. Global Burden of Asthma 
Estimates report that 300 million people worldwide are affected by asthma [14].  
Sadly, Scotland is the world leader in prevalence rates amongst children [35%] and 
also has a high proportion of affected adults [18%].  Across the UK, over 5 million 
people receive treatment for asthma [15].  The economic cost of asthma is 
considerable both in direct medical costs [hospital admissions and purchase of 
pharmaceuticals] and indirect medical costs [time off work and premature death].  It 
is also estimated that 1 in every 250 deaths worldwide is due to asthma, many being 
preventable and resultant due to long-term sub-optimal care and delay in seeking 
help during the terminal attack [14].   
1.1.4. Pathogenesis 
Asthma is an airways disease that involves airway inflammation and impaired 
airflow.  It affects the conducting airways causing them to spontaneously contract too 
much, too easily, and in response to a wide range of exogenous and endogenous 
stimuli.  The reduced airway calibre causes increased turbulence during breathing 
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resulting in the characteristic wheeze.  The airways undergo structural and functional 
changes, leading to airway hyper-responsiveness.  The inflammation of asthma is 
heterogeneous but generally consists of varying levels of acute and chronic 
inflammation, smooth muscle contraction, mucosal oedema, tissue remodelling and 
mucus hyper-secretion.   
Most, but not all asthma is associated with atopy [the genetic predisposition to 
generate Immunoglobulin E against common environmental allergens].  This has led 
asthma to be recognised as an allergic disorder along with other atopic diseases.  
However, there are phenotypes of asthma that appear independent of atopy, for 
example late onset asthma or intrinsic asthma] [16]. 
1.1.4.1. Cells of the respiratory immune system 
Airway inflammation in asthma is a multi-cellular process with the most striking 
feature being eosinophilic infiltration [17].  Other cells involved include neutrophils, 
CD4+ T-lymphocytes and mast cells.  It is important to note that eosinophilic 
infiltration is pathognomonic of asthma, and subtypes of asthma are also well 
described based on the relative absence of eosinophils and predominance on 
neutrophils [18, 19]. 
1.1.4.1.1. Eosinophils 
Eosinophils are not only a prominent cell in the airway mucosa of asthmatics [20], but 
are also found in large numbers in the sputum and broncho-alveolar lavage fluid [17, 
21].  Importantly there is a correlation between eosinophil counts in sputum and 
asthma exacerbations [22].  Eosinophils are recruited to inflammatory tissues in 
response to chemotactic and trophic cytokines such as eotaxin, Interleukin [IL]-5 and 
IL-8, with egress from the vascular tree being mediated by the cell surface expression 
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of CD11b/CD18 and VLA-4 on eosinophils and epithelial expression of ICAM-1 and 
VCAM-1 [23].  Eosinophils can secrete an array of cytokines [IL-2, IL-4, IL-6 and 
others] which, acting as pro-inflammatory mediators can promote T-cell proliferation 
and activation [24].  As an effector cell, eosinophils can release pre-formed lytic 
enzymes such as major basic protein, eosinophil peroxidise, and eosinophil cationic 
protein, as well as release potentially tissue damaging superoxide [25].  In addition to 
these pro-inflammatory roles, eosinophils also play a central role in airway 
remodelling, releasing growth factors and stimulating the production of extracellular 
matrix proteins [26, 27].  Eosinophils are sensitive to corticosteroid, a common 
treatment for asthma.  Corticosteroids can induce apoptosis of eosinophils and also 
increase the tissue clearance of these apoptotic cells by resident macrophages [28]. 
1.1.4.1.2. T lymphocytes 
T lymphocytes are present in the airways of both atopic and non-atopic asthmatic 
individuals [29, 30].  Immature naïve T-helper lymphocytes are classified as TH0.  In 
stable asthmatics these TH0 cells can be found in the airways [31].  Stimulation in the 
correct cytokine environment and/or in the presence of antigen presenting cells 
[typically dendritic cells] will lead to final differentiation towards a specific functional 
activity [32].  T-lymphocyte functional subsets can be defined by their ability to 
produce characteristic cytokines.  T-helper CD4+ lymphocytes can be categorised as 
either as TH1 or TH2 – asthma is considered to be predominantly a TH2 cell driven 
disease [29, 33].  CD4+ TH2 cells produce IL-4, IL-5 and IL-13 which drive an immune 
response that can initiate and maintain the key pathophysiological features of asthma 
[34]. 
Other lymphocyte subsets have received less attention in asthma, but their presence 
in the mucosa of asthmatics is well documented.  Cytotoxic CD8+ T-cells and innate 
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lymphocytes, or nuocytes are present in the mucosa of asthmatics.  Together they can 
produce a range of cytokines [32].  The exact role that these lymphocytes play in 
airway inflammation is less clear and there still remains many uncertainties as to 
their relative roles, for example a subset of CD8+ T lymphocytes with the γδ T-cell 
receptor has been found to be inhibitory to the allergic response but this is not the 
case with CD8+ cells bearing the T-cell receptor [32, 35]. 
1.1.4.1.3. Macrophages 
In chronic asthma macrophages are prominent cells in the airway mucosa and 
undoubtedly play an important role in disease pathogenesis [25].  The alveolar 
macrophage is the predominant immune effector cell, responsible for homeostatic 
removal of particles and apoptotic cells without inflammatory activation [36].  
However, with the appropriate stimulation for example with bacterial endotoxin, 
macrophages can respond by producing inflammatory cytokines.  In addition they 
can act as antigen presenting cells for primed T-lymphocytes [36], although this is 
much more efficiently done by lung dendritic cells.  Thus macrophages may have two 
distinct phenotypes.  M1 Macrophage [M] phenotype 1 [M1] are described as 
classically activated by their response to bacterial endotoxin.  They secrete pro-
inflammatory cytokines, chemokines, exhibit enhanced phagocytosis and have 
increased oxidative burst to kill phagocytosed organisms [37].  In contrast, 
macrophages stimulated with IL-4/IL-13 [M2 phenotype] display a distinct pattern of 
activation and play a role in directing TH2 humoral and allergic responses, and the co-
ordination of repair following an inflammatory reaction [38].  The precise role of the 
macrophage is likely to be complex in asthma, but they appear to preferentially 
infiltrate the mucosa in steroid refractory disease [25] and there is evidence of their 
corticosteroid resistance [39]. 
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1.1.4.1.4. Neutrophils 
Increasing use of induced sputum and broncho-alveolar lavage has revealed that 
some patients with asthma have a sputum neutrophilia in the absence of eosinophils 
[19, 40].  Neutrophils traffic to the airway mucosa in response to various chemokines 
the most potent being IL-8 [also known as CXCL8] [41].  Egress from the bloodstream 
is undertaken by the expression of adhesion molecules such as LFA-1 and Mac-1, 
binding to their ligand ICAM-1 on the surface of the endothelium [41].   
Once at the site of inflammation, the neutrophil can act to recruit more neutrophils by 
the release of chemoattractants and pro-inflammatory cytokines or operate as an 
effector cell by release of potent oxidative enzymes.  Examples of the main mediators 
released by activated neutrophils are summarised on Table 1.2: Mediators produced 
by neutrophils. 
Table 1.2: Mediators produced by neutrophils 
 
Mediator Function 
TNFα Promotes bronchial hyper-responsiveness 
Activates epithelium 
IL-8 Potent neutrophil chemo-attractant 
Neutrophil activator 
Down regulates IgE production 
Reactive Oxygen Species Cytotoxic to epithelium 
Promotes IL-8 release 
Promotes mucus hypersecretion 
Myeloperoxidase Produces HO-CL and cytotoxic to epithelium 
Activates mast cells 
Matrix Metalloproteinase 9 Predominant MMP in asthmatic airways 
Neutrophil elastase Cytotoxic to epithelium 
Promotes mucus hypersecretion 
Promotes bronchial hyper-responsiveness 
Lipid mediators – leukotrienes Recruits neutrophils and monocytes to airway epithelium 
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Better understanding of this is of particular importance because chronic asthmatics 
with a predominant airway neutrophilia appear to be insensitive towards 
corticosteroids [40].  In keeping with this, evidence is now available that airway 
neutrophilia plays a role in the progression of persistent airflow limitation in asthma 
[42]. 
Tobacco smoking is also associated with an increased airway neutrophil proportion 
and, importantly, corticosteroid refractoriness in airways [43, 44] and systemically 
[45].  Corticosteroids appear to reduce neutrophil apoptosis and lead to prolonged 
survival [42] which could provide a possible explanation for steroid resistance in 
asthma.  Conversely, eosinophils which become apoptotic in response to 
corticosteroids are removed from the inflamed airway leaving the neutrophil as a 
“substitute granulocyte” [46]. 
1.1.4.1.5. Mast Cells 
The mast cell has long been associated with asthma.  Of particular interest is the 
finding that in chronic asthma, mast cells are markedly increased in association with 
airway smooth muscle in both the large and small airways [47].  Mast cells possess 
the high affinity receptor for IgE – FcεRI, with binding and cross-linking of this 
receptor by allergen leading to mast cell activation [25].  Mast cells contain pre-
formed inflammatory mediators in granules which are released following activation.  
These include histamine, tryptase, other proteases, most known cytokines including 
those associated with asthma pathogenesis e.g. IL-4, IL-5 and IL-13.  In addition 
following activation mast cells can synthesise newly formed prostanoid mediators 
from arachidonic acid metabolites e.g. the powerful pharmacologically active 
molecules cysteinyl leukotrienes [LTC4 and LTD4] [48].  Mast cells are also a rich 
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source of matrix metalloproteinases [MMP3 and MMP9] which are involved in tissue 
remodelling.   
1.1.4.2. Inflammatory mediators 
There are multiple mediators of inflammation in asthma which are produced from a 
variety of sources, some listed above.   
1.1.4.2.1. Cytokines 
Cytokines are a descriptive category for small [glycol-]proteins whose main role is as 
signalling molecules between cells of the immune system, although their role extends 
to all biological functions.  Their effects are multiple, pleiotropic and can exhibit 
redundancy.  Cytokines are critical not only to mounting an inflammatory response 
but also in developing an appropriately measured response, with excessive 
inflammation causing harm and insufficient leading to failure to resolve the initiating 
inflammatory stimulus.  Thus cytokines can be generally classified into two groups of 
pro-inflammatory and anti-inflammatory.   
The cellular responses to cytokines are mediated by cell surface receptors. The 
receptors are made up of several sub-units.  Several of these receptors share similar 
sub-units but elicit their specific effects by aggregating with either a unique co-
receptor, or unique intracellular subunit.  This also explains why certain families of 
cytokines will elicit similar downstream signalling events.   
Cytokines can be produced by cells of the immune system as well as tissue stromal 
cells such as airway epithelium, smooth muscle cells, fibroblasts and endothelial cells 
[49].  Some examples of the variety of cytokines and their functions are listed in Table 
1.3. 
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Table 1.3: Cytokines and their involvement in asthma 
 
Cytokine General function Functional association with asthma 
IL-1 Increase in epithelial and 
inflammatory cell adhesion molecules 
Activation of T-cell and epithelial cells 
Neutrophil accumulation 
Eosinophil accumulation 
Promotes bronchial- hyper-
responsiveness 
IL-4 Growth, differentiation and activation 
of B-cells. 
Potentiates IgE production and enhances 
IgE mediated responses 
IL-5 Regulates most aspects of eosinophil 
behaviour – growth, maturation, 
differentiation, survival and activation, 
Central role in the accumulation and 
activation of eosinophils in the lungs. 
Potent eosinophil chemoattractant 
IL-6 Activates eosinophils and 
macrophages 
B and T cell growth factor 
Increases IgE production 
IL-8 T cell chemoattractant Potent chemoattractant of neutrophils 
Down regulates IgE production 
Promotes eosinophils chemoattractant 
IL-10 Reduces monocyte and macrophage 
activation 
Inhibits TH1 cytokine production 
Reduces IgE production 
Decreased eosinophils survival 
TNF-α Generalised activation of cells – 
epithelium, endothelium, monocytes, 
macrophages 
Promotes bronchial hyper-
responsiveness 
IFN-γ Activates endothelium and epithelium 
Activates fixed alveolar and circulating 
macrophages/monocytes 
Reduces bronchial hyper-responsiveness 
Reduces IgE production 
GM-CSF Mast cell, macrophage, epithelial cell, 
eosinophil and neutrophil 
differentiation and activation 
Neutrophil survival 
Promotes bronchial hyper-
responsiveness 
LTB4 Neutrophil and monocyte 
chemoattractant and activator 
Recruits neutrophils and monocytes in 
to airway 
 
Probably the most important cytokines in asthmatic airways disease are TH2 family of 
cytokines which include – IL-4, IL-5, IL-9, IL-13 and IL-25. 
1.1.4.2.2. Chemokines 
Chemokines are a subgroup of cytokines that have a specific function to act as 
attractants of inflammatory cells of the immune system.  They are small, therefore can 
diffuse rapidly from sites of inflammation where they are synthesised in abundance.  
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Cells recognise a particular chemokine by its binding to a specific receptor, which 
then restructures the internal actin cytoskeleton towards this bound receptor and to 
moves up the concentration gradient of the chemokine leading to the site of 
inflammation. The chemokines are generally categorised according to a specific motif 
within their protein structure and this divides chemokines in to four groups – CXC, 
CC, C and CX3C.  The two main groups are CXC [α chemokines] and CC [β 
chemokines] [49].  The membrane receptors for these proteins are 7-transmembrane 
G-protein coupled.  Like cytokines, chemokines can influence the immune response 
by activation and differentiating different cell populations involved in allergic 
diseases, such as TH1 and TH2 cells.  A selection of chemokines have relevant to the 
pathogenesis of asthma can be found in Table 1.4. 
Table 1.4: Chemokines and their role in asthma 
 
Chemokine General/function Functional association with asthma 
IL-5 Potent eosinophil chemoattractant Enhances eosinophil survival by 
preventing apoptosis 
IL-8 Potent neutrophil chemoattractant Significant role in neutrophilic asthma 
IP-10 Monocyte/macrophage, T cell and NK 
cell chemoattractant 
Increases adhesion molecules on 
surface of eosinophils for trafficking to 
airway epithelium 
Eotaxin Potent eosinophil chemoattractant. 
Leads to expression of α4 and β1 
integrins for trafficking to inflammatory 
sites 
Produced in high concentrations in the 
lungs of asthmatics 
RANTES Monocyte and T cell chemo-attractant Produced in high concentrations in the 
lungs of asthmatics 
Potent eosinophils chemoattractant 
Enhances IgE production 
MCP-1 Monocyte/macrophage chemoattractant 
and activating factor 
Increase T cell production of IL-4 
MCP-4 Monocyte/macrophage chemoattractant 
and activating factor 
Increase T cell production of IL-4 
Potent eosinophil chemoattractant 
MIP-1α Monocyte/macrophage chemoattractant 
and activating factor 
Chemotactic for T cells and eosinophils 
MIP-1β Monocyte/macrophage chemoattractant 
and activating factor 
Chemotactic for T cells and eosinophils 
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1.1.4.2.3. Apoptosis 
Apoptosis or programmed cell death is a mechanism within the immune system for 
switching off inflammation.  In essence it is a mechanism whereby a cell will die 
without releasing its potentially pro-inflammatory contents.  The cell can then be 
“mopped-up” without inducing an inflammatory response.  The apoptotic cell will 
first become senescent before displaying cell surface recognition markers e.g. Fas, 
which direct macrophages to engulf and remove the cell in a non-inflammatory 
manner.  The perpetuation of inflammation is therefore due to a balance of cell 
survival and activity with apoptosis.  Experimentally engineered Fas deficiency can 
lead to persistence of inflammation [50].  Both eosinophils and neutrophils, two of the 
predominant cell types in asthma both express Fas constitutively [51] and may be 
primed for rapid apoptosis by expression of an additional apoptotic ligand.  Evidence 
exists in severe asthma that neutrophil apoptosis is dysregulated and neutrophil 
survival is enhanced [52]. 
Of interest to the present thesis is the finding that some macrolides can induce 
apoptosis in immune cells.  Roxithromycin can promote apoptosis in sensitised 
lymphocytes [53], with additional evidence that clarithromycin, azithromycin and 
josamycin can do the same with peripheral blood lymphocytes in vitro [54].  There is 
also evidence of macrolides inducing apoptosis in neutrophils [55], as well as the  
described evidence for glucocorticoids inducing eosinophil apoptosis and delaying 
the neutrophil apoptotic programme [56, 57]. 
1.1.4.3. Acute inflammation in asthma 
An acute inflammatory episode in asthma is characterised by an influx of 
inflammatory cells to the injured or infected tissue followed by the release of a self-
amplifying network of pro-inflammatory mediators that perpetuate cell recruitment 
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and activation.  At the same time there is a coordinated delayed production of anti-
inflammatory cytokines that help to resolve the inflammation when the initiating 
stimulus is removed.  Inflammation in asthma can be divided in to early and late 
phase [58] and can be prompted by a number of insults, from allergens, to viruses or 
pollutants.  Following on from the acute inflammation we then observe airway 
remodelling and the process of tissue repair [59] 
1.1.4.3.1. Early Phase and Late Phases 
Early phase [acute] inflammation in atopic asthma is typified by the activation of cells 
bearing the high affinity IgE receptor – FcεRI.  IgE is critical to the development of the 
early phase reaction with most IgE pre-bound to FcεRI on the surface of mast cells 
and basophils [60].  Cross-linking of these cell surface receptors with allergen or 
antigen leads to cellular activation and degranulation and release of pre-formed 
mediators such as histamine one of the main mediators of the early phase 
pharmacological reaction [58, 61].  The late phase inflammatory response occurs 
between a timeframe of 6-9 hours and involves contraction of smooth muscle cells 
within the airways and tissue oedema [58].  The delay is primarily due to the de novo 
synthesis of mediators and the recruitment and activation of eosinophils [58] with the 
ultimate consequence being the development of airflow obstruction. 
1.1.4.4. Chronic inflammation in asthma 
Chronic inflammation occurs when the normal homeostatic “stop-processes” of acute 
inflammation fail and the initial inflammatory response fails to resolve normally.  
Persistent asthma, where chronic inflammation is present can be seen as a disorder in 
which a dysregulation of each individual phase in the resolution process could be an 
important contributory factor to the chronicity [59].  All cells within the airway are 
involved, from infiltrating leukocytes to resident structural cells such as epithelial 
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cells, fibroblasts and smooth muscle cells, which all become activated and secrete an 
array of pro-inflammatory mediators [58, 59] 
Chronic inflammation is accompanied by structural changes in the airways, such as 
sub-epithelial fibrosis and smooth muscle hyperplasia.  Chronic inflammation and 
remodelling are thought to be two interdependent processes [59]. 
1.1.4.4.1. Remodelling 
There is ample evidence that after inflammation, changes in the airway contribute 
significantly to the pathophysiology of asthma.  The most obvious change is in the 
airway smooth muscle, which not only increases in amount due to hypertrophy and 
hyperplasia, but also spreads both up and down the airways [25].  In chronic asthma 
the airways become thickened, not only due to an increase in airway smooth muscle, 
but also as a consequence of the laying down of new extracellular matrix proteins 
including collagen fibres, and increased proliferation of micro-vessels along with 
vascular leakage and deposition of proteoglycans [25]. 
1.1.4.5. Systemic inflammation in asthma 
The evidence for systemic inflammation in COPD is now well described; however 
there is less evidence for systemic inflammation in asthma is [62].  Asthma does not 
demonstrate the consistently abnormal systemic inflammatory responses that are 
now well defined in COPD but probably the most widely sustained biomarker is CRP 
[62].  Combination inhaled therapy has been shown to lower CRP in association with 
improved asthma control [63].  Studies with other biomarkers are perhaps not as 
clear-cut and so further investigation to identify a reliable biomarker is required. 
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1.2. Non-invasive methods of assessment of inflammation 
1.2.1. Rationale for use of non-invasive methods 
Whilst measurement of asthma outcome indices can be performed in the clinic what 
has become more apparent in recent years is the importance of the cellular changes 
that the asthmatic airway undergoes.  Examining tissue at the cellular level poses a 
problem.  Previously this was almost wholly based on autopsy specimens, and 
although useful, has the caveat that it is generally the endpoint changes that are seen 
and not the dynamic changes observed in life.  Bronchoscopy is a safe procedure, 
particularly in those with normal lung function.  Unfortunately in difficult asthma 
this is not always the case and has associated risk.  In addition, it is an expensive 
investigation, utilising significant human resource as well as specialist equipment. 
1.2.2. Induced sputum 
Spontaneously produced sputum is widely used to assess bacterial carriage however, 
the vast majority of asthma patients do not regularly produce spontaneous sputum.  
The use of spontaneously produced sputum for studying airway cytology is not 
without caveats; there can be high proportions of necrotic cells or squamous cells 
from the oropharynx.  Induced sputum is now a well validated technique to provide 
a representation of the cytology of the underlying inflammatory pathology within the 
airways [3, 64].  However, induced sputum requires specific training in order to 
obtain and identify and quantify the cells.  This has significant cost implications and 
hence induced sputum is used mainly for clinical trials or research and debate 
surrounds its use out-with specialist centres [65]. 
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1.2.3. Induced sputum methodology 
1.2.3.1. Induction method 
There are various differing protocols for the induction of sputum from study subjects.  
Commonly the subject is pre-treated with salbutamol, followed by inhalation of 
sterile saline nebulised via a high output nebuliser.  Regular monitoring of patient 
symptoms and FEV1 is also undertaken to ensure subject safety [64, 66].  There are 
some differences in the procedures, for example, different inhalation times and 
different saline concentrations.  Our group currently uses 3 inhalation periods of 7 
minutes with concentrations escalating from 3% to 4% then 5% for each period.  After 
each period the lung function is measured and the subject continues with the next 
saline concentration if the lung function remains within set safety parameters [64, 66].   
1.2.3.2. Sputum processing 
Methods of sputum processing are also the subject of much discussion with some 
groups recommending the use of the whole sputum sample whilst others suggest that 
individual mucus plugs be separated from the rest of the expectorate fluid for 
analysis [67].  An international working group found that both methods were 
acceptable and that in keeping with good scientific practice a single method should 
be used for the duration of a clinical trial [67].  Our group has consistently used the 
“plug-method” and hence our experience base would favour its continued use for 
this study.  Once selected the sputum plugs are added to a known volume of the 
reducing agent dithiothreitol to break down the disulphide rich mucin protein and to 
disperse the cells.  These can now be counted by haemocytometer and cytocentrifuge 
specimens can be prepared on slides, stained and counted to provide a differential 
profile for the cytology.  Specific parameters are utilised to determine sample quality.  
The current consensus is that a minimum of number of 400 non-squamous cells are 
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required for a representative cell count [67].  The count should consist of a total cell 
count, squamous cell count and a differential for non-squamous cells with samples 
being discarded when the leukocyte viability is less than 40% and/or the percentage 
of squamous cells is greater than 80% [68].  Expressing the results in terms of 
percentage of the non-squamous cells reduces the effect of dilution or sputum 
mucous plug volume and allows for good reproducibility [68, 69] 
1.2.4. Induced sputum – Clinical Trials 
Induced sputum analysis has been found to be highly reproducible in asthma [70].  
Further studies have demonstrated that changes in cell counts respond appropriately 
to corticosteroid treatment and allergen challenge [64] and correlates with broncho-
provocation and exhaled nitric oxide levels in adults [71]. 
1.2.4.1. Induced sputum – eosinophilia 
The information generated by the cytology from induced sputum has contributed to 
the understanding that asthma is not just a single disease but can be sub-categorised 
based on the underlying type of inflammation.  This sub-categorisation allows the 
clinician to define groups that may respond better to conventional treatment based on 
the predominant cell type.  This advancement can lead to more informed decision 
making by the clinician.  Sputum eosinophilia indicates better corticosteroid 
responsiveness [3, 72] and has been found to negatively correlate with FEV1 [73].  
Therefore induced sputum is widely used as a study endpoint in clinical trials.  
Treating subjects with sputum eosinophilia with corticosteroids to reduce the 
percentage to below a pre-set target has resulted in a greater improvement in asthma 
control relative to standard clinical measures [74].  Conversely the absence of sputum 
eosinophilia indicates that dose reduction of corticosteroid can be undertaken with 
relative safety [74].   
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1.2.4.2. Induced sputum – neutrophilia and paucicellular sputum 
Sputum neutrophilia is associated with a reduced response to corticosteroid 
treatment in asthma.  Sputum neutrophilia is also described in smokers with asthma 
[75] and in subjects with severe asthma [76-78].  Prospective clinical trials also 
demonstrate that sputum neutrophilia correlates with steroid resistant inflammation 
[40, 79]. 
In subjects with raised sputum neutrophil counts there is evidence of an inverse 
correlation with FEV1 [73, 80] and irreversible airflow obstruction [80].  In some 
subjects with asthma an induced sputum profile is observed which has neither a 
raised eosinophil or neutrophil count.  This group has been described as 
“paucicellular” and appears to indicate a milder form of asthma as it is associated 
with better asthma control [79]. 
1.2.4.3. Induced sputum – definition of eosinophilia and neutrophilia 
Research studies using sputum profiles from healthy subjects have provided a 
definition for sputum eosinophilia.  The current consensus utilises a cut-off value of 
>2% eosinophils to be greater than normal [30, 40, 79].  Defining sputum neutrophilia 
is not as straightforward given the finding that sputum neutrophil percentage rises 
with age [80, 81].  A pragmatic approach suggests that to define neutrophilia a 
sample must be >50% neutrophils.  There is a clear need to better define this area with 
increasing study evidence. 
1.2.4.4. Induced sputum – reproducibility of cytology 
Induced sputum demonstrates good reproducibility with intraclass correlation co-
efficients [ICC] for eosinophils of 0.85 and neutrophils of 0.57 [68] for whole sputum 
sampling. Selected sputum processing has been associated with ICCs of 0.63 for 
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eosinophils and 0.57 for neutrophils [82] in one study and 0.94 for eosinophils and 
0.81 for neutrophils in another [83]. 
1.2.5. Sputum supernatant cytokines 
The relative accessibility of sputum sampling in severe asthma has led to research 
interest in identifying and quantifying the soluble factors within induced sputum 
fluid.  The large numbers of inflammatory cells is sputum is associated with a variety 
of cytokines and chemokines.  As research progresses the significance of these cells 
and cytokines are being identified and better understood.  The associated 
inflammatory pathways and mechanisms for the development of asthma are being 
elucidated in both human and animal models as well as in vitro systems. 
Advanced analysis techniques with more specific antibodies and multiple testing 
systems [such as the Luminex®  Multiplex System] has allowed for multiple testing 
concurrently from the same volume of sample, giving faster and more accurate 
results for panels of many cytokines. 
1.2.5.1. Effect of sputum processing on supernatant cytokines 
The technique to disperse sputum plugs utilises the reducing agent dithiothreitol 
[DTT] [64, 84-86].  This allows the cells and fluid in the sputum plugs to be separated 
by centrifugation.  The caveat of this procedure unfortunately is that since DTT is a 
reducing agent, that reduces sulfhydryl [thiol] bonds it can disrupt the tertiary 
structure of protein cytokines thus modifying its immunoreactivity [85, 86] and 
measurements by immunoassay.  Methods to overcome this include removal of the 
fluid phase from sputum plugs by centrifugation before addition of DTT, or 
reduction in the concentration of DTT, or addition of an oxidisation agent to 
neutralise this effect.  The effect of DTT on individual assays is now being identified 
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and hence the effect can be controlled in the results [86] but despite this knowledge a 
consistent cytokine profile predictive of treatment response has yet to be identified.   
1.2.6. Exhaled markers of inflammation – nitric oxide 
Nitric oxide was first demonstrated to be produced in the airways in 1991 [87].  Its 
clinical utility was enhanced by the finding that it can be measured non-invasively in 
exhaled breath and that levels are high in asthma [88] and decrease after steroid 
treatment [89].  NO production from its precursor, L-arginine is mediated by nitric 
oxide synthase [NOS].  Three different forms of nitric oxide synthase iso-enzymes 
have been described in mammals: 
 Endothelial NOS [eNOS or NOS1] 
 Inducible NOS [iNOS or NOS2] 
 Neuronal NOS [nNOS or NOS3] 
All three exist in the human respiratory system [90].  Inducible-NOS is up-regulated 
in response to immunological and inflammatory stimulation and produces much 
larger amounts than either of the constitutively produced eNOS or nNOS.  Where 
eNOS and nNOS responsd to increases in intracellular calcium concentrations, iNOS 
is calcium independent [91]. 
Orally exhaled NO can be measured in the low parts per billion [ppb] range [87] and 
this is in contrast to the high concentrations found in air sample from the nose and 
paranasal sinuses [88, 92, 93].  Although the mRNA expression levels for iNOS is very 
low in the normal peripheral airways, expression of this enzyme has been found in 
the central lower airways [94, 95].  The difference in NO output between the lower 
and upper airways can be attributed to more dense iNOS expression in the 
epithelium of the nasal airways.   
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Bronchial epithelial cells, airway smooth muscle cells, macrophages, neutrophils and 
alveolar cells all express iNOS and contribute to the production of NO.  However, the 
majority of the production is provided by the bronchial epithelium and these other 
cells contribute very little [91, 96, 97].  NO has important functions in the respiratory 
system, including promotion of vascular and bronchial dilatation, medication of 
ciliary beat frequency, promoting mucus secretion and acting as a neurotransmitter 
for non-adrenergic, non-cholinergic neurons [98-101].  NO can also have a toxic effect 
in the lung where it is oxidised to peroxynitrite, a potent anti-microbial toxin which 
can also damage epithelium and is found in asthmatic airways after allergen 
exposure.   
1.2.7. Nitric Oxide in asthma 
The measurement of exhaled nitric oxide is now established as a method of 
monitoring asthma control.  This arises from the observation that the concentration of 
nitric oxide is raised in exacerbations of asthma and decreases in response to steroid 
treatment and improved asthma control.  Not only is it used in disease monitoring 
but it has also become an established endpoint in clinical trials assessing new 
therapies to reduce airway inflammation [9].  The fractional concentration of exhaled 
nitric oxide [FENO] measurements provide easily obtainable information on 
underlying disease activity when it is characterised by eosinophilic airway 
inflammation, but the positive and negative predictive values for eosinophilia are 
suboptimal [9].  This is best illustrated by the finding that a raised NO is observed in 
other inflammatory diseases such as liver cirrhosis, SLE, lung transplantation and 
COPD [102].  Nevertheless, measuring FENO in the clinic setting can help guide the 
physician in making more appropriate management decisions.   
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1.2.7.1. Employment in asthma control algorithms 
The employment of FENO in asthma control has been investigated and explored, but 
there remains debate over its usefulness.  Data is conflicting with some groups 
demonstrating the ability to reduce therapy successfully [103].  Other groups have 
shown very little benefit in using FENO to guide asthma management [104] and a 
much larger randomised, controlled trial demonstrated that the use of FENO as a 
measure of asthma control does not improve control or enable reduction in dose of 
inhaled corticosteroid [105].  Clearly measuring FENO in the clinic does not always 
add a great deal to decision making and results must be interpreted in the clinical 
context presented before the physician. 
1.2.7.2. Reference ranges 
Reference values for FENO are not yet fully established but the most recent consensus 
guidelines determine the range between 5ppb and 35ppb for adults and between 
5ppb and 25 ppb for children.  97% of healthy individuals have levels of <35ppb; this 
drops to <22.4 if outliers and subjects with atopy are removed.  Providing a single 
cut-off is difficult and detailed analysis of receiver operator curves is required in 
order to do so.  In keeping with the overall uncertainty in reference ranges, a variety 
of cut-off values have been derived in order to determine the presence of underlying 
eosinophilia, ranging from >8.3ppb [250ml/s flow rate] [106] with sensitivity and 
specificity of 72% and 71% respectively with another giving a cut-off >42ppb at the 
more commonly and easily measure 50ml/s [107], sensitivity and specificity of 65% 
and 79%.   
ATS/ERS guidelines suggest reference ranges are difficult to apply to asthmatics 
because in this population the FENO can be high even when the patient is 
asymptomatic and has good disease control [9].  It has been suggested that 
 51 
 
 
comparisons for individual patients are best made against serial measurements 
compared with when the patient is clinically stable [9]. 
Clearly, debate exists in this area and perhaps larger population based studies are 
required to gain further insight. 
1.2.7.3. Effects of cigarette smoking 
FENO is lower in current smokers [108-110].  However, NO can rise acutely 
immediately following cigarette smoke exposure, most likely reflecting the nitric 
oxide within the cigarette [111] but this is a transient effect.  Recent evidence 
demonstrated that not only is FENO reduced in the airways of chronic smokers but 
even following treatment with oral corticosteroid FENO measurements in asthmatic 
smokers respond as they do in non-smoking asthmatics [112].  Even passive smoking 
can lead to transient lowering of NO levels and so recommendations in smokers 
would be to remain abstinent from cigarettes for at least 1 hour before the test and to 
avoid smoke-filled environments during this time [9].  Another noted effect in 
smokers is the loss of association of FENO being an estimate of underlying 
eosinophilic inflammation [106]. 
1.2.7.4. Extended flow Nitric Oxide analysis 
Research in nitric oxide measurement demonstrated that asthmatic subjects have 
inflammation throughout the airway tree [113].  A proposed non-invasive means of 
measuring peripheral airways inflammation is to estimate alveolar NO concentration 
[Calv], or the contribution from peripheral airways to exhaled NO.  The estimation of 
Calv is based on the measurement of NO at multiple exhalation flow rates [usually in 
the range of 100-300ml/s].  Exhaled NO follows an exponential curve, with lower 
FENO at higher exhalation flow rates, indicative of NO originating from two sources: 
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alveoli/small airways, where steady state is reached and a bronchial origin, where the 
NO diffuses from the airway wall.  The estimation of alveolar NO is commonly based 
on simplified models of the airways’ anatomy: a two compartment model of the 
airways where the conductive airways are a cylinder and an expandable alveolar 
region - Figure 1.1a [114].  Alveolar NO is thought to reflect inflammation of the 
smaller airways [115]. 
This two compartment model allows for the derivation of estimates for alveolar NO 
levels [Calv, ppb], airway wall diffusion [Daw, pl/s/ppb], airway wall nitric oxide flux 
[Jaw, pl/s] and airway wall NO concentration [Caw, ppb] depending on the flow rates 
used and the regression model employed - Figure 1.1b.  Plotting of the production of 
NO against a variety of flow rates, allows derivation of these parameters using linear 
and non-linear regression.  The 2005 ATS/ERS guidelines recommended measuring 
FENO at a flow of 50ml/s [102]. 
Figure 1.1: a] Two compartment model of NO production b] NO output [VNO] as a function of VE 
in a healthy subject 
[114] 
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1.3. Smokers with asthma 
1.3.1. Prevalence of active smoking in asthma 
In the United Kingdom in 2007, 22% of adults aged 16 and over smoked with a 
further 27% being ex-smokers.  Whilst the percentage of active smokers has decreased 
in prevalence since 1996 [28%] the overall proportions have changed little [116].  
These figures are similar to most westernised nations [117].  It is disappointing to find 
that smoking prevalence rates have changed little despite extensive public health 
measures.  The UK smoke-free legislation has been well received by the public and 
greater than 95% compliance rates within premises have been demonstrated [118].  
Whether or not this will lead to a long-term reduction in smoking prevalence remains 
to be seen. 
In terms of visits to hospital emergency departments the impact of smoking in 
asthma is clearly demonstrated with the finding the prevalence of smoking is higher 
in asthmatics attending with an exacerbation [119, 120]; and in those asthmatics who 
die as a result of asthma [121, 122]. 
1.3.2. Reduced corticosteroid sensitivity in smokers with asthma 
International guidelines in asthma management emphasise inhaled corticosteroids as 
the most effective anti-inflammatory therapy for chronic asthma [2].  The evidence for 
these guidelines is based on clinical studies performed predominantly in asthmatic 
patients whom have never smoked or are former smokers.  Several studies have 
suggested that the efficacy of corticosteroids is attenuated in asthmatics who are 
active smokers [43, 123-125].   
The earliest evidence for impaired response to inhaled corticosteroids was found in 
1993.  A study designed to identify factors which predicted response to inhaled 
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corticosteroids in obstructive airways disease [asthma and COPD] found that current 
smoking predicted an impaired FEV1 response to inhaled beclometasone 800mcg q.d. 
at 3 months [123].  Although this study was a randomised controlled trial, this 
unexpected finding led to questioning over which group [or both] demonstrated this 
impairment, as the study was not designed to look for this.   
Further to this, in a randomised placebo controlled crossover study of corticosteroid 
naïve adult asthmatics, high dose inhaled corticosteroid [1000mcg fluticasone per 
day] did not demonstrate any improvement in mean morning peak expiratory flow, 
mean FEV1, methacholine bronchial reactivity [measured by PC20] or sputum 
eosinophil counts in current smokers when compared with non-smokers [125].   
This resistance to steroid is still present even when high doses [40mg] of oral 
prednisolone is used [43].  The efficacy of short term [2 weeks] of oral prednisolone, 
40mg was assessed in a randomised controlled crossover trial in asthmatic smokers, 
ex-smokers and never smokers.  All subjects had clinical asthma as evidenced by 
international standards.  There was a significant improvement following oral 
prednisolone compared with placebo in FEV1, morning PEF and asthma control score 
in asthmatic never-smokers, but no change in asthmatic smokers. 
1.3.3. Asthma treatments 
1.3.3.1. Pharmacological treatments 
Medications for asthma can be classified in two ways either as controllers or relievers.  
Controllers are medications taken regularly and long-term to provide sustained 
control of airway inflammation and hence improved clinically relevant symptoms.  
Relievers are used as-required to deal with episodes of symptom deterioration.  They 
generally act much more quickly to provide rapid relief of the clinical worsening.   
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Asthma treatments can be delivered in a variety of methods – inhaled, oral, or by 
injection.  The prime method of drug delivery remains the inhaler.  Inhalers 
contribute the majority of asthma treatment and inhaled corticosteroid is the 
mainstay of controller therapy in mild to moderate asthma [1, 2].   
Relievers constitute a group of medications that require a rapid onset of action to 
reduce the immediate duration of symptoms.  Short-acting-β2-agonists [SABA’s] fulfil 
this requirement and act principally on airway smooth muscle to promote relaxation, 
thus reducing airflow obstruction and hence relieving symptoms of wheeze and 
breathlessness.  Longer acting derivatives of these drugs are also in clinical use, 
known as long- acting-β2-agonists [LABA’s].  They have the benefit of reduced 
frequency of dosing due to their longer duration of action but as a consequence of 
their altered pharmacology do not have the rapid onset necessary to provide 
immediate relief of symptoms. Short-acting-β2-agonists do not reduce underlying 
airway inflammation [126] but the same is not true for LABA’s [127, 128].  
Combination devices are also available and confer a greater degree of benefit in terms 
of asthma control [129, 130], and due to the pharmacological properties of formoterol, 
can also be used as a single maintenance and reliever inhaler.   
A less used form of inhaled therapy is anticholinergics.  A meta-analysis found 
ipratropium bromide to have benefit, albeit modest when used in acute asthma [131]. 
Oral medication can also be prescribed for asthma in the form of leukotriene receptor 
antagonists, theophyllines or oral glucocorticocoids [1, 2].  Parenteral injections of the 
monoclonal antibody omalizumab [a recombinant humanised monoclonal antibody 
directed against IgE] has also been shown to reduce exacerbations in patients with 
raised IgE in allergic asthma [132]. 
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1.4. Macrolides antibiotics and anti-inflammatory properties 
1.4.1. Macrolide antibiotics 
Erythromycin was the first macrolide antibiotic and has been used since 1952.  This 
prototypical macrolide consists of a 14-membered macrocyclic lactone ring with two 
sugar moieties.  Based on this, several other semi-synthetic macrolides have been 
developed, including clarithromycin; by substituting a methoxy group for the C-6 
hydroxyl group of erythromycin [133], and azithromycin; by inserting a methyl-
substituted nitrogen in place of a carbonyl-group in the aglycone ring, thus creating a 
15-membered ring-structure [133], Figure 1.2.  These structures confer better acid 
stability, greater bioavailability and a longer half-life; 3-5hrs and 40-68hrs 
respectively [133]. 
Figure 1.2: Chemical structure of Erythromycin and derivatives 
 
Reproduced from [134] with permission 
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1.4.2. Evidence of efficacy in other respiratory disease 
1.4.2.1. Diffuse panbronchiolitis 
Diffuse panbronchiolitis [DPB] is characterised by chronic inflammation of the 
respiratory airways and is largely restricted to the Far East.  In 1998 a large 
retrospective study of 498 patients demonstrated clear improvement in lung function 
and survival for patients treated with low dose erythromycin [135].  Macrolides are 
now guideline therapy for DPB with recommendation to commence immediately on 
diagnosis [136].   
1.4.2.2. Cystic fibrosis 
Cystic fibrosis [CF] has clinical and bacteriological similarities to DPB, and following 
the establishment of macrolides in DPB treatment, pilot clinical trials were 
undertaken in CF [137].  A meta-analysis of prolonged-use azithromycin in CF 
confirmed the improvement in lung function [138]. This evidence has led to 
macrolides being a guideline recommendation in CF. 
1.4.2.3. Non-CF bronchiectasis 
Five clinical studies [two randomised] investigated macrolides in non-CF 
bronchiectasis.  The most reproducible finding was decreased sputum volume. This 
appears to be a class-effect with similar improvements following treatment with 
azithromycin [139], clarithromycin [140] and erythromycin [141]. These results were 
used to support recommendations for long-term macrolide treatment for patients 
with bronchiectasis and frequent exacerbations [142].   
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1.4.2.4. Post-transplant obliterative bronchiolitis 
Bronchiolitis obliterans syndrome [BOS] is the leading cause of death following lung 
transplantation, with a progressive decline in FEV1 with mortality rates from 25-50% 
[143].  Open-label studies involving small patient numbers have found improvement 
in FEV1 following treatment with azithromycin; 250 mg for 12-36 weeks [144, 145].  
The mechanism suggested was a reduction in airway neutrophilia and IL-8 [145].   
1.4.2.5. COPD 
Few clinical studies have investigated the efficacy of long-term macrolides in COPD. 
The largest randomised controlled trial in patients with COPD [n=1142] showed that 
250mg daily azithromycin for 1 year reduced the frequency of exacerbations [hazard 
ratio for time to first exacerbation 0.72 [95% CI 0.63 to 0.84, p<0.001]] [146], as well as 
improved quality of life. The number-needed-to-treat was low at 2.86 and the benefit 
was apparent after only 40 days of treatment [146].  Interestingly, current smoking 
abrogated the benefit, and yielded the only positive hazard ratio in the subgroup 
analysis [146]. 
1.4.3. Efficacy in other inflammatory diseases – RA, IBD and skin disorders 
The anti-inflammatory effects of macrolide antibiotics are not just restricted to 
disorders of the respiratory system.  Whilst a significant amount of research has 
focused on respiratory disease, evidence exists that macrolides can have beneficial 
anti-inflammatory effects in other chronic inflammatory diseases such as psoriasis 
and rosacea [147], inflammatory bowel disease [148] and rheumatoid arthritis [148, 
149].  Again, the beneficial effect is not just related to a single antibiotic but is seen 
across the class with both clarithromycin and roxithromycin demonstrating efficacy 
[149, 150]. 
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1.5. Macrolides in asthma 
Anti-inflammatory use of macrolides for asthma was first reported with 
troleandomycin in the 1960’s [151]. Most recent studies have used newer macrolides 
clarithromycin, azithromycin and telithromycin.  
Clarithromycin is the most widely studied macrolide in asthma.  Trials with 
clarithromycin have demonstrated reduced requirement for prednisolone in oral 
corticosteroid dependant asthma [152] but without significant improvements in lung 
function, asthma quality of life or symptom scores [152].  Conversely another 
randomised placebo-controlled study reported improved asthma quality-of-life and 
symptoms scores [153].  A dose dependant improvement in bronchial hyper-
responsiveness [BHR] has also been demonstrated [154].  Improvement in spirometry 
has been more difficult to achieve with only one RCT demonstrating a small rise in 
FEV1.  This occurred in a subgroup of subjects PCR-positive for M. pneumoniae or C. 
pneumoniae.  The improvement in lung function was not found in the PCR negative 
subjects or when both groups were analysed together versus placebo [155].  Another 
clarithromycin study [stratified by PCR-positivity for M. pneumoniae or C. pneumoniae 
in bronchial biopsies] [156] showed no improvements in lung-function or asthma 
control questionnaire scores, however, there was an improvement in BHR in those 
who were PCR-negative or the cohort as a whole; PCR-positive patients did not show 
improvement.  Finally, a recent open label study with clarithromycin administered 
for 3 weeks following an acute exacerbation, with 12 weeks follow up, demonstrated 
an improvement in symptom free days and a reduction in the duration of the 
exacerbation [157].   
There are few clinical studies of azithromycin in asthma, with its advantage of once-
daily dosing.  One of the first pilot studies was terminated early due to treatment 
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failure [158].  Data analysis, from this study suggested that azithromycin was 
unlikely to have had an inhaled corticosteroid-sparing effect [158].  In contrast to this 
conclusion, two other trials using azithromycin showed improvement in BHR [159, 
160], although they were limited in their size and design.  Another azithromycin 
study has demonstrated improvements in symptom scores, and reduction in the use 
of rescue inhalations [161].  More recent reports have suggested a role in attenuating 
mucus hypersecretion [162]; and using azithromycin in non-eosinophilic 
[predominantly neutrophilic asthma] subtypes confers benefits in reducing 
exacerbation frequency [163]. 
The largest macrolide study is the “Telithromycin in Acute Exacerbations of Asthma” 
[TELICAST] study; a multicentre, double-blind, RCT evaluating the efficacy of 
telithromycin in acute exacerbations. Of the two specified outcome measures, there 
was significant reduction in symptom scores in the telithromycin group, but no 
treatment effect on morning PEF [164]. 
Taken together, the results of clinical trials of macrolides in chronic asthma suggest 
that treatment may improve symptoms and non-specific BHR, which may be 
independent of M. pneumoniae or C. pneumoniae, but at present there is little evidence 
of a sustainable beneficial effect on lung function.  A Cochrane review holds the 
opinion that there is currently insufficient evidence to either support or refute the use 
of macrolides as anti-inflammatory therapy in patients with chronic asthma [165]. 
Future studies need to assess macrolide treatment in the management of refractory 
asthma as well as in acute asthma, perhaps in conjunction with assessment of changes 
in the microbial colonisation.  This would control for the anti-inflammatory effects of 
either change in bacterial load or diversity. 
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1.5.1. Macrolides in smokers with asthma 
The previously detailed discussion on the utilisation of macrolides in various clinical 
diseases [1.4.2], suggests that their anti-inflammatory properties may extend beyond 
those described.  At present there are no fully reported studies looking exclusively at 
smokers with asthma being treated with a macrolide antibiotic. 
There are several key factors in the phenotype of smokers with asthma which 
suggests macrolides may be of benefit: 
 Smokers with asthma are commonly steroid insensitive [117]. 
 Smokers with asthma tend to have a non-eosinophilic [neutrophilic] 
phenotype [45, 117, 166]. 
 Neutrophils are recognised to be poorly responsive to corticosteroids [40]. 
Macrolides have been shown to inhibit migration, activation and the oxidative burst 
of neutrophils ex-vivo, in vitro and in experimental models [167] and therefore may be 
therapeutically important in asthma in smokers. Evidence also exists that treatment 
with erythromycin in mouse-smoking models leads to reduction in neutrophil and 
lymphocytes in BAL as well as decreases in TNFα [168]. 
1.5.2. Effect of macrolides on response to corticosteroid 
Macrolides act synergistically with corticosteroids to suppress lymphocyte activation 
[169] with a possible mechanism for this being related to restoration of HDAC 
activity – HDAC activity is reduced in COPD and possibly a similar mechanism may 
exist in smokers with asthma [170].  Erythromycin can increase HDAC2 levels in vitro 
[171] suggesting a possible mechanism by which macrolides therapy may restore 
corticosteroid sensitivity and improve asthma control in smokers with asthma.  
Clarithromycin has no significant effect on prednisolone clearance or mean 
prednisolone plasma concentrations [172].  Although macrolide antibiotics are 
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inhibitors of CYP3A4 and can increase the plasma concentration of CYP3A4 
substrates, which include fluticasone and budesonide [173], this mechanism is 
unlikely to contribute to the localized therapeutic effects of inhaled corticosteroids on 
the airways 
1.5.3. Anti-bacterial effects of macrolides 
The mechanism of anti-microbial function is thought to occur by binding to the 
bacterial 23SrRNA and inhibition of protein synthesis [174]. The bactericidal function 
may provide an additional indirect anti-inflammatory effect by the removal of 
microbes.  The relationship between bacterial colonisation, airway inflammation and 
lung function has been described in COPD in which bacterial load correlated with 
higher sputum IL-8, and with a decline in FEV1; these effects were all associated with 
a greater pack-year history of cigarette smoking [175].  In chronic bronchitis, sputum 
bacterial load correlated with sputum MPO, IL-8, LTB4 levels, and albumin reflecting 
leakage from serum to sputum [176].  There is some limited evidence to suggest 
bronchial infection with atypical bacteria is likely to be associated with increased 
airway inflammation and possible thereby increase asthma severity; 15 out of 19 
studies found an association between C. pneumonia and/or M. pneumonia infection in 
chronic stable asthma [177].  There is preliminary data to suggest that C. pneumonia 
titres may be increased in smokers both with and without asthma compared to non-
smokers [178, 179].  Taken together the anti-bacterial effects of macrolide therapy 
may improve asthma control in smokers with asthma by reducing airway bacterial 
load due to C. pneumonia and M. pneumonia infection.   
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1.5.4. Mechanisms of anti-inflammatory action of macrolide antibiotics 
The mechanism[s] of action of long-term macrolide treatment in chronic respiratory 
diseases is unresolved. Macrolides have anti-inflammatory properties that are 
independent from their antibacterial activity and which may be beneficial in reducing 
airway inflammation. Furthermore macrolides have potential additional beneficial 
properties including anti-viral activity and an ability to restore corticosteroid 
sensitivity. 
A part of macrolide anti-inflammatory activity may be a consequence of the reduction 
in bacterial load afforded by the antibiotic effects [176], in addition to  the anti-
inflammatory activity that is distinct from its anti-bacterial activity [133].  The nature 
and mechanism of the anti-inflammatory activity has been reviewed [55]. The 
diversity of these activities suggests a variety of mechanisms affecting immune and 
tissue-derived cell function including cytokine production.  There is no single 
immunomodulatory-axis through which macrolides exert their effect. 
1.5.4.1. Macrolide effects on inflammatory cells 
1.5.4.1.1. Neutrophils 
Macrolide therapy can reduce neutrophil accumulation in the airway epithelium [145, 
153, 160]. This may be associated with macrolides reducing the local production of 
CXCL-8 [IL-8]; a powerful chemotactic factor for neutrophils, as reported in DPB [145, 
180, 181].  This mechanism was also suggested in a study using clarithromycin and 
azithromycin in refractory asthma leading to reduced airway CXCL-8 and 
neutrophils [153, 160] [Figure 4].  Azithromycin has also been shown to inhibit 
neutrophil accumulation in the airways of mice, possibly by affecting IL-17 
downstream signals [182].  It must be stressed this was in a non-specific inflammatory 
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airways mouse-model, and may not necessarily reflect the inflammatory processes in 
the human [asthmatic] airway. 
1.5.4.1.2. Monocyte and macrophages 
Macrolides have anti-inflammatory effects on monocytes/macrophages.  Classically-
activated macrophage [M1] phenotypes, induced by stimulation with interferon 
[IFN] and bacterial lipopolysaccharide [LPS] are associated with microbicidal and 
cytotoxic function, and pro-inflammatory cytokine production [37].  Alternatively-
activated [M2] phenotypes induced by IL-4/13 are associated with TH2-type, 
immunosuppressive and remodelling responses.  Azithromycin reduced the 
production of pro-inflammatory IL-1, and tumour necrosis factor [TNF] in mouse 
M1 macrophages [183] and polarised cells towards M2, with reduced pro-
inflammatory IL-6 and IL-12, and increased anti-inflammatory IL-10 [184] [Figure 5].  
Ex-vivo human monocytes treated with clarithromycin could effectively and 
significantly reduce LPS stimulated IL-8 production in a dose dependant manner 
[185].  The relevance to lung disease is that, alveolar macrophages become polarised 
during infection towards M1 [186] but their pro-inflammatory activity may be 
attenuated by macrolides e.g. by reduced production of TNFα, IL-1 and IL-8 [183], 
and polarisation towards anti-inflammatory M2 [184] characterised by IL-10 
production and scavenger-receptor expression associated with clearing apoptotic 
cells [187].  Reduced apoptotic bronchial epithelial cells have also been observed in 
COPD patients receiving azithromycin [187]. 
1.5.4.1.3. Macrolide effects on cytokine production  
Azithromycin has many anti-inflammatory effects [188] including down-regulation of 
production of pro-inflammatory mediators e.g. prostaglandin E2, nitric oxide and 
cytokines TNF-α, IL-8, IL-1α, growth-related oncogene [GRO]-α and soluble vascular 
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cell adhesion molecule [sVCAM]-1. Many of these are chemotactic, activation and 
survival factors for neutrophils.  
IL-8 [CXCL8] is a potent chemo-attractant of neutrophils.  A randomised double- 
blind placebo-controlled trial with clarithromycin in refractory asthma demonstrated 
a significant reduction in airway IL-8 levels and neutrophil numbers [153].  Subgroup 
analysis has shown that airway IL-8 protein and gene expression was predominantly 
reduced in the non-eosinophilic asthmatic patients.  Similarly, azithromycin reduced 
airway IL-8 mRNA in patients with post-transplant BOS following 3 months 
treatment [145]. 
IL-1 is sufficient to induce neutrophil accumulation in the lung [189], GM-CSF is a 
neutrophil survival factor [190], and both are derived from macrophage and airway 
epithelial cells and are central to airway infectious inflammation [186]. In a murine 
model of LPS-induced pulmonary neutrophilia, azithromycin or clarithromycin were 
able to reduce airway neutrophilia with striking reductions of IL-1 and GM-CSF 
[191] . 
The effects of azithromycin on cytokine inhibition are not just restricted to the above 
noted cytokines.  More recently azithromycin has been found to inhibit the 
production of IL-5 in ex vivo CD4+ T cells from asthmatic children[192].   
1.5.4.2. Molecular mechanisms of macrolide anti-inflammatory activity 
Defining molecular mechanisms of anti-microbial macrolide function received the 
2009 Nobel prize, yet the mechanisms of anti-inflammatory macrolide function 
remain unresolved, probably reflecting their complexity.  Macrolides accumulate and 
persist inside leukocytes [133] suggesting effects on cell signalling. Azithromycin can 
inhibit mitogen-activated protein [MAP] kinases [193]; which regulate cellular 
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processes, e.g. gene expression, cell growth, proliferation, differentiation and survival 
in response to a variety of extracellular stimuli, especially cytokines including IL-8 
and GM-CSF as mentioned above. Putative mechanisms e.g. with clarithromycin 
suggest altered DNA binding activity of transcription factors NF-kB and AP-1 [185, 
194], and inhibition of synthesis and/or secretion of pro-inflammatory cytokines [55]. 
In summary, different macrolides can cause reductions in pro-inflammatory 
cytokines, suggesting there is a class effect inhibiting airway neutrophilia. Individuals 
with neutrophilic inflammation may therefore derive greatest benefit. 
1.5.4.3. Macrolide effects on mucus production 
Macrolides appear not to affect normal physiological secretion of mucus [55] but can 
reduce hypersecretion [195], possibly by inhibiting production of pro-inflammatory 
cytokines, e.g. TNFα, that stimulate mucin genes MUC5B and MUC5AC in airway 
goblet cells [196]. 
1.5.4.4. Macrolide microbicidal activity as a factor in immuno-
modulation  
Evidence against anti-microbial activity of macrolides accounting for their anti-
inflammatory activity includes effective long-term treatment of DPB at sub-
antibacterial concentrations, and efficacy when colonised with macrolide-resistant P. 
aeruginosa [197]. Mechanisms may include macrolide interference with microbial 
protein synthesis even below minimal antimicrobial concentration [198, 199]. 
1.5.4.5. Macrolide antiviral effects 
Rhinoviruses [RV] cause ~60% of virus-induced asthma exacerbations.  Macrolides 
appear to have inherent anti-viral properties, and induce anti-viral responses. Several 
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studies have demonstrated the beneficial effects of macrolides in experimental RV 
and influenza infections.  The addition of a macrolide led to reduced virus titres, most 
likely as a consequence of inhibition of RV-induced up-regulation of ICAM-1 and also 
inhibition of pro-inflammatory cytokine production; ICAM-1 is the RV receptor on 
airway epithelium [200-202]. 
1.5.4.6. Corticosteroid-sparing effects 
Macrolides may have corticosteroid-sparing effects, first shown with troleandomycin, 
but limited due to adverse effects [203].  Corticosteroid-sparing efficacy is limited to 
case reports [204] and small open-label pilot studies [169], which demonstrate 
improvement in clinical laboratory endpoints – enhanced sensitivity of lymphocytes 
to suppression by dexamethasone. Although macrolide antibiotics are inhibitors of 
CYP3A4 [133] and can increase the plasma concentration of CYP3A4 substrates, 
which include fluticasone and budesonide , this mechanism is unlikely to contribute 
to the localised therapeutic effects of inhaled corticosteroids on the airways of 
patients given macrolides. 
Smokers with COPD have decreased histone deacetylase-2 [HDAC2] activity in 
alveolar macrophages, and this may lead to increased inflammatory gene expression 
and reduced sensitivity to corticosteroids [205] and a similar mechanism may occur in 
smokers with asthma [170]. Erythromycin can increase HDAC2 levels in vitro [171], 
suggesting a mechanism by which macrolides therapy may restore corticosteroid 
sensitivity and improve asthma control in smokers with asthma.  
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1.6. Summary 
Given the preliminary data that macrolides have anti-inflammatory properties both in 
vitro and ex vivo and can improve asthma control in non-smokers with asthma we 
propose that the anti-inflammatory effects of macrolides manifest in these models can 
be achieved also in smokers with asthma, a major subgroup that are currently 
undertreated.  Several large trials are underway to examine the clinical benefits of 
macrolide therapy in asthma.  Presumably to avoid the potential confounding effects 
of cigarette smoking, studies are generally designed to recruit non-smokers [156] or 
predominantly non-smokers [206] and none of the studies have specifically targeted 
smokers with asthma. 
There is now substantial evidence from pre-clinical and clinical studies of the efficacy 
of macrolides and in particular azithromycin.  Smokers with asthma have a 
phenotype which, given laboratory endpoint data would suggest they represent a 
population of individuals who may experience benefit from macrolides.  Macrolides 
are effective therapy in many other respiratory illnesses, but at present there is no 
firm evidence to advocate their use in asthma [165].  Smokers with asthma are an 
under-investigated patient group and bear a significant burden of disease, and stand 
to gain benefit in asthma control and quality of life if new treatments are efficacious. 
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2. Hypothesis 
In a proof-of-concept clinical trial, we tested the hypothesis that macrolides 
[azithromycin] improve asthma control and reduce sputum neutrophil counts of 
smokers with chronic asthma. 
2.1. Primary end-point 
The primary endpoint to test the hypothesis was a change peak expiratory flow 
measurement measured at the study visits.  It was expected that an improvement of 
25L/min would be observed.   
2.2. Secondary end-points 
2.2.1. Clinical 
It is expected that that other clinical indicators of asthma control will also 
demonstrate improvement.  These secondary clinical endpoints will include 
 Average of the last 7 days PEF measurements before each visit [from home 
recordings] 
 Spirometry 
 Airway responsiveness to methacholine 
 Asthma control score 
 Cough score 
 Diary symptom scores 
 Exacerbation rates 
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2.2.2. Inflammatory 
In addition to the above measured endpoints it is expected there will be improvement 
in biomarkers of inflammation.  Measurements will include: 
 Sputum differential cell counts including sputum neutrophil count 
 FENO and Alveolar NO 
 Immunological tests in blood & sputum 
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3. Randomised controlled trial 
Seventy-seven adult asthmatic smokers were recruited to the study.  These subjects 
were recruited from hospital respiratory clinics, general practice database registries 
and from the database of the Asthma and COPD Research Centre, Gartnavel General 
Hospital.  Potential subjects had their records scrutinised for suitability and were then 
contacted by letter from their GP or directly from the Research Centre.  A second site 
was opened at Crosshouse Hospital, Ayrshire and subjects were recruited in the same 
way.  Volunteers were then screened for eligibility, initially by telephone and 
subsequently at the research unit. 
3.1. Regulatory approval 
Clinical trial regulations within the EU require approval from a competent authority 
within the member state in combination with a favourable opinion from an 
appropriate ethics committee.  In the United Kingdom this competent authority is the 
Medicines and Healthcare Regulatory Agency [MHRA].  Before recruitment to the 
trial could be undertaken a clinical trial application was made to the MHRA.  At the 
same time ethical approval was obtained from the West Glasgow Ethics Committee 1.  
All subjects received an information sheet and attended for a discussion of the 
protocol prior to consent and enrolment.   
3.2. Recruitment methods 
Primary care was the main reservoir of patient subjects for recruitment to this clinical 
trial.  Additionally, patients who had attended hospital clinics or had in-patient stays 
were also considered for recruitment.  Finally the research unit had an active 
database of patients willing to take part in clinical trial research.   
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General practitioners were contacted by letter and asked to complete a form agreeing 
to participate in the study.  Research co-ordinators from the Scottish Primary Care 
Research Network then visited the practice and performed a database search for 
prospective patient volunteers.  A list of volunteers was then generated and screened 
by a member of the GP practice to ensure appropriateness for further contact.  Letters 
were then sent from the GP to each individual patient asking them to complete a 
contact form and return in a reply paid envelope.  Once a form was received, 
prospective patients were contacted by telephone and if found suitable, invited to 
attend for a screening visit.   
Case note screening was also undertaken of patients whom had prior attendance at 
either respiratory out-patient clinics or in-patient wards.  These patients were 
contacted directly by telephone.   
The Asthma and COPD Research Centre has an active patient database of prospective 
patients.  This was scrutinised and prospective patient volunteers were contacted 
directly by telephone.   
In this clinical trial over 8000 invitation letters were sent from 80 GP practices in the 
West-of-Scotland.  A summary of patient flow is found below – Figure 5.1: CONSORT 
Flow Diagram. 
3.2.1. Search strategy 
The GP practices in the West-of-Scotland utilise databases provided by “General 
Practice Administration System for Scotland” [GPASS], “In-practice systems Ltd” 
[INPS] “Vision” and more recently “Egton Medical Information Systems” [EMIS].  
Each handles data in a slightly different manner and so searches had to be tailored in 
respect of each individual database.  Each of these systems has its own shortcomings 
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but commonly, the accuracy of the database is dependent on the quality of the data 
entered.  Some patients may not have their data fully updated on a regular basis and 
hence may not be completely accurate. 
In performing searches on any database there is a compromise between capturing 
highly accurate data and excluding inappropriate records without excluding 
potential candidates.  Hence, in the first instance the search aims to capture as broad a 
pool of potential participants as possible. 
Search criteria used were: 
 Age 18-70 
 Diagnosis of asthma 
 Current smoker 
These had to be tailored for each individual database but remained essentially the 
same. 
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3.3. Subjects 
3.3.1. Inclusion criteria 
The main inclusion criteria for the study are detailed in Table 3.1. 
Table 3.1: Main inclusion criteria 
 
Diagnosis of asthma [207]:  
 Typical symptoms [episodic wheezing, chest tightness and/or dyspnoea] 
  And either 
 reversible airflow obstruction [> 12% and 200 ml change in FEV1 with nebulised salbutamol 2.5 
mg] at any study visit prior to randomisation  
  or 
 methacholine airway hyper-responsiveness [20% drop in FEV1 at a concentration of 
methacholine ≤ 8 mg/ml]. 
Age range 18-70 years [subjects above the age of 60 should have had asthma symptoms starting before 
the age of 40] 
Duration of asthma symptoms ≥ 1 year and on stable medication for 4 weeks 
Able to maintain asthma without exacerbations - at BTS step 2 level [beclometasone dose of 400 
mcg/day and salbutamol as required] during the run-in period of the study. 
Able to wean off other asthma medication, other than inhaled corticosteroid and short acting 
bronchodilator in the two weeks prior to the screening visit. 
No other medication for asthma other than the above following the screening visit. 
Symptomatic, defined as an asthma control questionnaire score of ≥ 1.0 [range 0-6] prior to 
randomisation [208]. 
Smokers with asthma will be defined as current cigarette smokers who have a > 5 pack year smoking 
history. Subjects should be smoking at least 5 cigarettes a day. If currently on 2-5 cigarettes a day, a 
previous 10 pack year smoking history would be required. 
If female and able to conceive, willing to utilize medically acceptable forms of contraception. A 
pregnancy test will be performed in urine in all women of child bearing age and able to conceive. 
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3.3.2. Exclusion criteria 
Main exclusion criteria are detailed in Table 3.2. 
Table 3.2: Main exclusion criteria 
 
Ex-smokers or never smokers 
Planning to quit smoking during duration of trial 
Patients with unstable asthma; defined as the presence of 1 or more of the following events in the 
month prior to randomisation [Emergency/’out of hours’ visit of patients to the GP; GP visit to patient 
at home; A & E hospital attendance; hospital admission]. 
Patients with current epilepsy, psychosis or history of significant atrial or ventricular tachyarrhythmia. 
Corrected QT-interval greater than 450msec in women and greater than 430msec in men on baseline 
electrocardiogram [ECG]. 
Low potassium levels [less than normal values for the laboratory]. If low potassium can be corrected, 
screening can continue with confirmation of normal levels prior to taking study medication.  
Liver disease [alanine transaminase and/or aspartate transaminase levels 2 or more times the upper 
limit of normal]. 
Significant renal disease: creatinine or urea levels 2 or more times the upper limit of normal. 
Any previous severe adverse reaction to macrolides. 
Patients who are known to have specific IgE sensitivity or skin test positivity to grass pollen allergen 
and a history of worsening of asthma due to hay fever, will not be recruited from mid May to the end 
of July [grass allergen season in UK]. 
Upper or lower respiratory tract infection in the 4 weeks prior to randomisation. Run-in period can be 
prolonged in this situation to have 4 weeks with no respiratory infection prior to randomisation. 
Weight < 45 kg. 
Frequent asthma exacerbations [> 4] requiring oral corticosteroids in the year prior to randomisation. 
Presence of active lung disease other than asthma, including bronchiectasis and vocal cord 
dysfunction. 
Current or past diagnosis of allergic broncho-pulmonary aspergillosis [ABPA] in the past 
Pregnancy and breast-feeding. 
Mental impairment or language difficulties that makes informed consent not possible 
 
In addition to the above exclusion criteria, consideration was required in patients 
who with medications known to interact with azithromycin – Table 3.3. 
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Table 3.3: Drugs known to interact with azithromycin 
 
antimalarials 
anti-psychotics, including Reboxitine and Quetiapine 
antivirals, including Nelfinavir, Zidovudine, Didanosine  
bromocriptine  
carbergoline 
clozapine 
coumarin-type oral anticoagulants including warfarin 
cyclosporin 
ergot derivatives 
itraconazole 
midazolam 
mizolastine 
moxifloxacin  
rifabutin 
rifamycins  
theophylline 
vinblastine  
Other immunosuppressants or chronic antibiotics e.g. methotrexate, azathioprine, tetracycline. 
 
Certain medications did not exclude subjects from the trial but additional care needed 
to be taken with some of these.  These concomitant medications are detailed in Table 
3.4. 
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Table 3.4: Medications requiring additional consideration/monitoring 
 
Antacids: In patients receiving antacids, azithromycin should be taken at least 1 hour before or 2 hours 
after the antacid. 
Digoxin: Some macrolide antibiotics have been reported to impair the metabolism of digoxin [in the 
gut]. Therefore, in patients receiving concomitant azithromycin and digoxin the possibility of raised 
digoxin levels should be borne in mind and digoxin levels monitored. 
Verapamil 
Amiodarone 
Simvastatin 
 
3.4. Study design  
The study is a 12 week double-blind randomised controlled study [Figure 3.1].  
Subjects who required weaning from high-dose combination inhalers underwent pre-
screening 2 weeks before the screening visit to enable weaning.  Weaning consisted of 
stopping the combination inhaler and providing an equivalent dose of inhaled 
corticosteroid in their now stopped combination inhaler. 
Two weeks after this a screening visit was performed. The dose of inhaled 
corticosteroid was reduced further to a standardised dose [200mcg beclometasone 
equivalent twice daily].  Patients continued on this for a further four weeks.  An 
optional study visit was available at two weeks post screening to ensure safety. 
At 4 weeks post screening patients would undergo a randomisation visit over two 
separate days, up to 5 days apart.  If all of the entrance criteria were achieved and no 
exclusion criteria existed the patient would be randomised to receive either active 
treatment or matched placebo.  Randomisation was undertaken using an automated 
interactive voice response system [IVRS].  Patient visits then continued at 4, 8 and 12 
weeks post randomisation. 
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Figure 3.1: Patient journey in the study 
 
 
3.5. Data management and statistical analysis 
All data for the trial was entered on to specially designed case report forms [CRF’s].  
These were designed in conjunction with the Robertson Centre for Biostatistics [RCB] 
at The University of Glasgow, with appropriate input from the study team.  The CRFs 
were then sent to the RCB for data entry and generation of the research database.  The 
quality of the data entry was assessed by monitors employed by the sponsor.  
Monitoring was performed at the study initiation, midpoint and shortly after 
completion of all patient follow up visits.  Where areas of uncertainty were identified 
either by the monitors or the data managers a data query was generated.  I was 
responsible for clarification of the data where required and corrected any errors 
where appropriate. 
I performed the vast majority of CRF data entry for the study and was solely 
responsible for checking the entries and resolving data queries. 
Visit 0 
•Pre-screening 
•6 weeks to randomisation 
Visit 1 
•Screening 
•4 weeks to randomisation 
Visit 2 
•Randomisation 
•Baseline visit 
Visit 3 
•4 weeks post randomisation 
Visit 4 
•8 weeks post randomisation 
Visit 5 
•12 weeks post randomisation 
•End-of-study 
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3.5.1. Power calculation 
A sample size of 34 in each group will have 80% power to detect a difference in 
means of 25L/min in peak expiratory flow [PEF] change [primary endpoint], 
assuming a standard deviation of changes of 36L/min, using a two sample t-test with 
a 0.050 two-sided significance level [129]. Based on experience in our previous clinical 
studies we intended to recruit a total of at least 80 patients to ensure that 68 patients 
completed the study.   
3.5.2. Analysis sets 
3.5.2.1. Full Analysis Set [FAS] 
The intention-to-treat principle implies that the primary analysis should include all 
randomised subjects.  Compliance of this principle would necessitate complete 
follow-up of all randomised subjects for study outcomes. In practice this ideal may be 
difficult to achieve.  The “full analysis set” is used to describe the analysis set which is 
as complete as possible and as close to the intention-to-treat ideal of including all 
randomised subjects.  Preservation of the initial randomisation in analysis is 
important in preventing bias and in providing a secure foundation for statistical tests. 
There are a limited number of circumstances that might lead to excluding 
randomised subjects from the full analysis set including the failure to satisfy major 
entry criteria [eligibility violations], the failure to take at least one dose of study 
medication and the lack of any data post randomisation.  Violations of the protocol 
that occur after randomisation may have an impact on data and conclusions 
particularly if their occurrence is related to treatment assignment.   
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3.5.2.2. Per Protocol Set [PPS] 
The “per protocol” set of subjects, sometimes described as the “valid cases”, the 
“efficacy” sample or the “evaluable subjects” sample, defines a subset of the subjects 
in the full analysis set whom are more compliant with the protocol, and is 
characterised by criteria such as the following: 
i. The completion of a certain pre-specified minimal exposure to the treatment 
regimen; 
ii. The availability of the measurements of the primary variable[s]; 
iii. The absence of major protocol violations including the violation of entry 
criteria. 
The precise reasons for excluding subjects from the per-protocol set should be fully 
defined and documented before breaking the blind in a manner appropriate to the 
circumstances of the specific trial.  This would be a data set generated by the subset of 
subjects who complied with the protocol sufficiently to ensure that they would be 
likely to exhibit the effects of treatment, according to the underlying scientific model.  
Compliance covers such considerations as exposure to treatment, availability of 
measurements and absence of major protocol violations. 
3.5.2.3. Safety Set 
All randomised subjects who received at least one dose of randomised treatment.  
The primary safety data set will be used to determine the safety of the intervention. 
3.5.2.4. Baseline data 
Baseline characteristics will be summarised for each randomised treatment group 
separately and overall and compared informally for the FAS, and the PPS patients.  
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All baseline data will be obtained from the CRF’s used during the baseline or 
screening/pre-screening visits. 
3.5.3. Endpoints 
3.5.3.1. General principles for statistical analysis 
The treatment period lasted for 12 weeks.  Categorical variables will be summarised 
with the number and proportion of subjects within each category. Continuous 
variables will be summarised using the mean, standard deviation [SD], or median 
and interquartile range; dependent on the distribution [normal or skewed], and 
minimum and maximum values. 
Differences between treatment groups for the primary and secondary outcomes will 
be assessed using appropriate tests. 
Analysis of covariance models, adjusting for the baseline data, will be used to 
compare the treatment groups after 12 weeks for both the primary outcomes and the 
secondary outcomes. 
3.5.3.2. Treatment of ACQ scores [clinic and diary versions] 
The standard version of the ACQ contains seven fields each scored on a seven point 
scale [0=good control, 6=poor control].  The overall score is the arithmetic mean of the 
seven responses.  A copy of the clinic-ACQ can be found in Appendix 1. 
Utilising a daily diary card to derive and ACQ differs from above.  The morning PEF 
data is used as a surrogate of FEV1, and converted to a percent-predicted value which 
is scored like FEV1 on the standard version of the questionnaire.  The parameters are 
the same as the standard ACQ.  Beta2-agonist puffs are totalled for the morning and 
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evening, to calculate the usage over 24hours.  This total is then mapped to the 
relevant field within the standard ACQ to derive a numerical value to be used in the 
final calculation.  Once this is done the mean of the seven fields can be calculated. 
3.5.3.3. Treatment of AQLQ scores 
This study utilised the standardised version of the Asthma Quality of Life 
Questionnaire [12].  This questionnaire allows the clinician to gain an overall measure 
of the problems those adults with asthma experience in their day to day lives.  The 
questionnaire is divided in to 5 generic activities – Table 3.5.  Each question is scored 
on a 7-point Likert scale and is completed independently by the patient with no 
external influence.  Subjects are asked to answer the questions based upon their 
experiences over the past 2 weeks. 
Table 3.5: Five generic activities of the AQLQ 
 
Strenuous activities [such as hurrying, exercising, running up stairs, sports] 
Moderate activities [such as walking, housework, gardening, shopping, climbing stairs] 
Social activities [such as talking, playing with pets/children, visiting friends/relatives] 
Work related activities* [tasks that you have to do at work] 
Sleeping 
*If you are not employed or self-employed, these should be tasks you have to do most days. 
The questionnaire contains 12 items on symptoms, 11 items on activity limitations, 5 
items on emotional functions, and 4 items concerning environmental stimuli.  The 
minimal important difference is determined to be 0.5.  Change of 1.0 represents a 
moderate change and change of >2.0 represents a large change [13, 209].  A copy of 
the AQLQ can be found in Appendix 2. 
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3.5.3.4. Treatment of LCQ scores 
The Leicester Cough Questionnaire is a 19-item self-completed quality-of-life 
measure of chronic cough [210], consisting of 3 domains: physical [8 items], 
psychological [7 items] and social [4 items].  Each item has a response rating from 1 to 
7, with the lowest value indicating the worst response to the question with the 
highest value indicating the best.  Each domain score is an average of the items 
within, and the total score is the sum of each domain’s average.  A domain score will 
range from 1-7 with the total score ranging from 3-21.   
A minimal change in the total score of 2.56 is felt to be significant of change in the 
severity of cough [210].  A copy of the LCQ can be found in Appendix 3. 
3.5.3.5. Treatment of Diary Cards 
The diary cards have space to collect up to five weeks of data.  For the purposes of 
analysis we used the last seven days that were completed prior to each visit.  A card 
was declared null and void if there were no morning peak flow data.  The number of 
completed days in the seven-day period up to and including the last day of data was 
counted.  At least three days of data for each variable had to be available separately 
for that variable to be considered evaluable.  The means of seven days were 
calculated for each of the evaluable variables.  A copy of the diary card can be found 
in Appendix 4. 
As a general observation – the quality of diary entry was variable and despite 
extensive patient education, the completeness of data entry could in some instances 
be poor.  Diary data was scrutinised to ensure accuracy of date and time entry – data 
recorded on the Piko-1 meter was given precedence over the data recorded on paper.  
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An ad-hoc report was generated for manual checking of data.  Manual checking was 
then performed. 
3.5.3.6. Treatment of asthma related events 
The total number of these events [out of hours visits to GP, GP home visits, visits to 
accident and emergency, hospitalisations] was calculated across each of the visits in 
the treatment period [i.e. Weeks 4, 8 and 12]. The totals were also calculated 
separately for each of the four different types of event, and further categorized in 
terms of intensity, relationship with the study medications, treatment required and 
outcome. 
3.5.4. Analysis techniques 
3.5.4.1. Primary efficacy analysis 
Analysis of covariance [ANCOVA] models were used to compare change in the 
primary endpoint [change in Peak Expiratory Flow] from baseline across the 
treatment groups at 12 weeks adjusting for the baseline peak expiratory flow.  The 
treatment difference and corresponding 95% confidence interval will be presented 
and a p-value for the adjusted mean difference [azithromycin-placebo] will be 
reported.  Due to the small number of anticipated missing data for the primary 
outcome at the last visit, the analysis will be run using both complete case analysis 
and analysis using multiple imputation methods. 
3.5.4.2. Secondary efficacy analyses 
The interaction between selected baseline, screening and pre-screening variables and 
treatment efficacy will be tested by adding the relevant main effect and the 
interaction terms to the ANCOVA model above.  The potential interaction of each 
screening or baseline variable will be tested in a separate statistical model.  
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Continuous variables will be dichotomised according to whether the values are either 
lower than, or greater than, or equal to, the mean difference [IMP minus placebo] and 
will be presented alongside its 95% confidence interval; the p-value for the interaction 
term will be reported. 
3.5.4.3. Exploratory analyses 
Exploratory endpoints will be analysed in the same way as the secondary endpoints. 
3.5.5. Software 
All statistical analysis will be performed using SAS version 9.2 or later. 
3.6. Patient safety 
3.6.1. Drug interactions and side effects associated with azithromycin 
Azithromycin is generally a very well tolerated antibiotic and does not have many 
clinically significant interactions.  Whilst caution is advised when administering the 
drug in severe renal impairment, the protocol would exclude such patient.  No dose 
adjustment is necessary in mild to moderate impairment, since azithromycin is 
metabolised in the liver and excreted in the bile 
Side effects in association with azithromycin therapy are generally not serious with 
the commonest being gastro-intestinal [133] upset most likely relating to activity at 
the motilin receptor.  The commonest side effects are diarrhoea; nausea; abdominal 
pain; headache; dizziness; anorexia; visual impairment; deafness; pruritis; rash; 
arthralgia; fatigue; changes in blood lymphocyte [decreased] and eosinophil 
[increased] counts. 
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Patients concurrently taking antacids, digoxin, verapamil, amiodarone and 
simvastatin were closely monitored.  Concomitant use of antacids can lead to a 
reduction in peak serum concentrations, but not overall bioavailability.  If the subject 
was on antacids then they were asked to delay taking these by one hour after 
administration of the IMP to ensure adequate oral absorption.  Digoxin, verapamil, 
and amiodarone are all cardioactive drugs and whilst there is no significant 
pharmacological interaction, there is the theoretical potential for alteration in cardiac-
QTc.  In the majority, these drugs tend to be prescribed for tachyarrhythmias or 
additionally in the case of verapamil, hypertension.  The potential for increased 
toxicity is more applicable to erythromycin and clarithromycin rather than 
azithromycin.  History of atrial or ventricular tachyarrhythmia was an exclusion to 
the study and hence patients on either digoxin or amiodarone were generally 
excluded for another reason.  Azithromycin is not known to interact with any of the 
statins but there is well documented interaction between simvastatin and 
erythromycin/clarithromycin and so it was felt prudent to also include this drug as 
one for special consideration. 
3.6.2. Unused medication 
Unused medication was returned to our local pharmacy where each pack’s contents 
were first counted, logged then destroyed.  Regulatory requirements ensure that a log 
is kept of all returned and destroyed investigational medicinal products. 
3.6.3. Current anti-asthma medication 
During the study patients required to be on standardised treatment containing a 
maximum of 200mcg beclometasone equivalent twice daily.  Our protocol required 
each participant to be on either budesonide 200mcg, 1 inhalation twice daily, or 
Symbicort® 200/6, 1 inhalation twice daily.  All other asthma medication was 
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discontinued in the run-in phase and patients were not allowed to restart any 
additional asthma medications during the study or increase the dose of inhaled 
therapy either. 
Upon completion of the study, participants were either placed back on their usual 
medication if there was no perceived benefit from the study inhaler, or if evidence of 
ongoing symptoms were present a letter was written to their GP advising an 
escalation of therapy to the next appropriate step. 
3.6.4. Adverse events [AE’s] 
An adverse event [AE] is defined by the UK Medicines for Human Use [Clinical 
Trials] Regulations 2004 [SI 2004/1031] as: 
An exacerbation, or unexpected increase in the frequency or intensity of a pre-
existing condition [other than asthma], including intermittent or episodic conditions.  
This could be significant or unexpected worsening or exacerbation of asthma, a 
suspected drug interaction or any clinically significant laboratory abnormality. 
Adverse events are graded according to their severity as follows: 
 Mild: Awareness of signs or symptoms, but easily tolerated. There is no loss of 
time from normal activities. Symptoms resolve easily with no medical 
treatment [other than short-acting bronchodilators]. Signs and symptoms are 
transient. 
 Moderate: Discomfort severe enough to cause interference with the patient’s 
usual activities. Symptomatic treatment is possible. 
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 Severe: Incapacitating with inability to do work or usual activities, signs and 
symptoms may be of a systemic or require medical intervention and/or 
treatment.  Hospitalisation may be required. 
A reasonably related event is one that is in the opinion of the investigator, possibly, 
probably or is definitely related to the study product. 
3.6.4.1. Serious Adverse Events [SAE’s] 
A serious adverse event is defined as any adverse event or adverse reaction that: 
 Results in death 
 Is life threatening 
 Requires hospitalisation or prolongation of existing hospitalisation 
 Results in persistent or significant disability or incapacity 
 Consists of a congenital anomaly or birth defect 
For the purposes of the study the following events, although not classified as SAE’s 
would also require reporting. 
 Important adverse events/reactions that are not immediately life threatening or 
do not result in death or hospitalisation but may jeopardise the subject or may 
require intervention to prevent one of the other outcomes listed in the 
definition above 
 Pregnancy 
3.6.4.2. Serious Adverse Reaction 
Any adverse reaction that is classed in nature as serious and which is not consistent 
with the information about the medicinal product in question, as set out in the 
summary of product characteristics [SmPC] or the Investigator’s Brochure [IB] 
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3.6.4.3. Suspected Unexpected Serious Adverse Reaction [SUSAR’s] 
SUSAR’s are serious adverse reactions related to an investigational medicinal product 
that are both serious and unexpected.   
 
3.6.4.4. Method for reporting of Adverse Events 
All adverse events [AE’s] must be recorded, notified, assessed, reported, analysed 
and managed in accordance with the Medicines for Human Use [Clinical Trials] 
regulations 2004 [as amended].  All adverse events must be assessed for seriousness, 
causality, expectedness and severity.  This assessment is the responsibility of the 
Chief Investigator.  The Chief Investigator is required to inform the sponsor 
immediately [within 24hrs].  For all SAE’s, SAR’s and SUSAR’s a generic [Robertson 
Centre of Biostatistics] Serious Adverse Event form was completed and a copy 
forwarded to the Pharmaco-vigilance Officer in the Research & Development 
Department, Greater Glasgow & Clyde Health Board. 
Serious Adverse Events: were collected in the CRF, an SAE form completed for each 
one, and sent to the pharmaco-vigilance office as above.  Copies were then held in the 
site file and formed part of the Annual Safety Report which was sent to the MHRA, 
Ethics and the sponsor. 
Serious Adverse Reactions [SAR’s]: are reactions judged by the chief investigator to 
be related to the study drug, although listed in the protocol as expected drug 
reactions. These were collected in the CRF, an SAE form completed for each one, and 
sent to the pharmaco-vigilance office as above. All SAR’s were held in the site file and 
formed part of the Annual Safety Report sent out as above. 
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Suspected Unexpected Serious Adverse Reactions: are reactions judged by the chief 
investigator to be related to the study drug, and are unexpected study drug reactions 
according to the protocol. If they occur, they are collected in the CRF and an SAE 
form completed for each one.  SUSARs should be sent to the MHRA, ethics committee 
and the sponsor within 7 days for all fatal or life-threatening SUSARs and 15 days for 
all others. 
SAE’s that occur at any time after the inclusion of the subject in the study [defined as 
the time when the subject signs the informed consent] up to 30 days after the subject 
competed or discontinued the study will be reported. 
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Is event serious? 
 
No Yes 
This is an Adverse 
Event. (AE) 
Record in CRF and 
report as per 
protocol. 
 
This is a Serious 
Adverse Event 
(SAE) 
 
Does the SAE have a 
“reasonable causal 
 relationship” with trial 
medication? 
 
Yes 
Record the SAE in 
CRF. 
Assess for severity. 
Complete SAE form. 
Report to Sponsor 
within 24 hours. 
 
This is a Serious 
Adverse Reaction (SAR) 
Record the SAE in CRF. 
Assess for severity. 
Complete SAE form. 
Report to Sponsor within 
24 hours. 
(Will be reported in 
Annual Safety Report) 
 
Is the event expected? 
(i.e. is it included in 
SmPC?) 
Yes 
No 
This is a  
Suspected 
Unexpected 
Serious Adverse 
Reaction 
(SUSAR) 
 
Record in CRF 
Assess for severity 
Complete SAE/SUSAR 
form. Report to Sponsor 
within 24 hrs. 
Is the SUSAR life 
threatening or fatal? 
 
Yes No 
To be reported to 
MHRA/REC within 7 days 
with follow- up within 8 
days 
 
To be reported to 
MHRA/REC within 
15days 
No 
Adverse Event reported to Trial Staff 
 
Figure 3.2: Safety Flow Chart 
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3.6.5. Clinical trial obligations 
In 2004, the introduction of EU directive 2001/20/EC [SI1031] meant that in order to 
conduct a clinical trial of a medicinal product, the following must be obtained: 
3.6.5.1. Sponsorship 
A sponsor is an individual, company, institution or organisation which takes 
responsibility for the initiation, management or financing of a clinical trial.  The 
University of Glasgow and NHS Greater Glasgow & Clyde operate a joint Research & 
Development department.  For the purposes of this clinical trial U.o.G. and NHS 
GG&C acted as co-sponsors. 
3.6.5.2. Ethical approval 
Ethical approval for clinical research is now centralised under the auspices of the 
National Research Ethics Service [NRES], part of the National Patient Safety Agency.  
The purpose of NRES is twofold: 
 to protect the rights, safety, dignity and well being of research participants and 
 to facilitate and promote ethical research that is of potential benefit to 
participants, science and society 
Application is made using an electronic form and subsequent to this accompanying 
documents are submitted to an ethics committee for consideration.  An ethics 
committee is an independent body consisting of health-care professionals and lay 
members.  Their function is to provide an opinion about whether a trial clinical trial is 
ethically responsible.  This opinion is offered before a clinical trial commences based 
on the following information which they should be provided with:  
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 Summary of the study and principal research question 
 Study design and type of medicinal trial 
 Scientific justification for the research 
 Risks and ethical issues including patient selection and interventions 
 Recruitment methods and confidentiality of subjects 
 Research sponsor and other regulatory oversight 
3.6.5.3. MHRA approval 
Application to the MHRA is fully electronic.  For the purposes of this clinical trial we 
were required to provide copies of the following documents in PDF format for 
review: 
 Clinical trial application form with accompanying data in XML format 
 Confirmation of EudraCT number 
 Copy of favourable ethics opinion 
 Copy of letter of authorisation from the sponsor 
 Current version of clinical trial protocol 
 Simplified investigation medicinal product dossier [Simplified-IMPD] for 
Azithromycin 250mg capsules 
 Copy of the manufacturing authorization from Bilcare [GCS] Europe Limited 
ML[IMP]10284 – GMP documents 
 Example of the IMP label in the national language 
Formal application to the MHRA was made on the 23rd of March with clinical trial 
being authorised on the 24th April 2009 
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3.6.5.4. Amendments 
Several amendments were made during the trial.  Amendments can be classified as 
either substantial or non-substantial.  Examples of changes require application for a 
substantial amendment would be: 
i. change of the main objective of the clinical trial; 
ii. change of primary or secondary endpoint 
iii. changes to inclusion/exclusion criteria 
iv. addition of a new site 
This list is not exhaustive. 
Examples of changes that are typically non-substantial 
i. the addition/deletion of tertiary/exploratory endpoints 
ii. minor clarifications of the protocol 
iii. correction of typographical errors 
This list is not exhaustive 
3.6.5.5. Annual Safety Reports 
Annual safety reports are compiled by the sponsor based upon the SAE’s reported 
during the period of the trial.  Copies of the annual safety report are circulated to the 
ethics committee, MHRA and the study team. 
3.6.5.6. Other obligations 
3.6.5.6.1. Trial registration 
Clinical trial registration is a voluntary undertaking.  However, the International 
Committee of Medical Journal Editors member journals now require, as a 
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consideration for publication, registration in a public trials registry.  This policy 
applied to all clinical trials after 1st July 2005, and trial registration must be 
undertaken before the first patient is recruited.  Clinical trial registration reduces the 
likelihood of selective reporting, more of a concern in commercially funded trials.  
The clinical trial discussed in this thesis commenced as a non-commercial study and 
latterly some of the secondary exploratory endpoints were only measured through 
some commercial funding.   
There are various clinical trial registries.  The macrolides in asthma study was 
registered at clinicaltrials.gov, an American based but international registry of clinical 
trials operated by the United States National Institutes of Health, National Library of 
Medicine. 
The macrolides in asthma study was registered on the 26th February 2009 and was 
given registration number: 
NCT00852579. 
3.6.5.6.2. Confidentiality 
Patient confidentiality is ensured by statute – Data protection act [1998] and all trial 
investigators had a responsibility to adhere to this act and ensure patient 
confidentiality was maintained throughout the study and thereafter during the 
archiving of data.  Confidentiality is also covered by the Clinical Trials Directive 
2001/20/EC “Good Clinical Practice” [GCP] guidelines. 
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3.6.5.6.3. Monitoring of the study 
Monitoring of the study is the responsibility of the sponsor.  An initiation visit was 
performed shortly after the first patient was screened, thereafter a mid-point visit and 
finally a close-out visit once the study has closed.  Monitors from Research & 
Development attended the unit performing a 10% sample check of all CRF data 
entered and verified adherence to the protocol.  The Principal Investigator and 
research team  
3.7. Location of work 
The clinical visits for this study were performed at two sites.  The main site was The 
Asthma and COPD Research Centre, Gartnavel General Hospital, Glasgow with the 
secondary site being the pulmonary function lab at Crosshouse Hospital, Kilmarnock.  
Sputum and blood analysis were performed in the Graham Davies Building, 
University of Glasgow.  Statistical analysis was performed in association with the 
Robertson Centre for Biostatistics, University of Glasgow.   
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4. Methods 
4.1. Asthma control and quality of life 
4.1.1. Assessment of asthma control 
4.1.1.1. Asthma Control Questionnaire [ACQ] 
The Junipers Asthma Control Questionnaire is a simple, reproducible, and sensitive 
questionnaire that was developed to allow a rapid assessment of asthma control in all 
severities of asthma and will demonstrate the impact of asthma treatment in 
interventions [208]. 
The score derived by the questionnaire is based on a series of seven questions.  The 
first six questions cover symptoms the respondent has experienced in the past week.  
These include: night time wakening; limitation of normal daily activities; early 
morning wakening; dyspnoea and wheeze; and frequency of use of inhaled β2 
agonist.  Each question is answered by the respondent selecting one choice from six.  
The severity of choices ranges from responses which signal no symptoms or none to a 
maximum severity for that particular symptom.  The final question is completed by 
the clinic staff using the respondent’s FEV1 result from spirometry performed on the 
day of the assessment.  A copy of this can be found in Appendix 1.   
The ACQ is performed at each visit from the screening visit onwards.  It was not 
performed if the subject underwent a pre-screening visit or optional safety visit 
during the run-in phase. 
The respondents score is calculated by deriving the arithmetic mean of the 7 fields, 
with a score of 0 resulting if maximum asthma control is achieved and 6 if completely 
uncontrolled.  Recent research suggests that a minimally significant difference of 0.5 
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[10] is clinically significant for altered control.  A score of less than 0.75 is indicative of 
good asthma control, with a score above 1.5 indicating inadequate asthma control 
[211].  A copy of the ACQ can be found in Appendix 1. 
4.1.1.2. Asthma Quality of Life Score [AQLQ] 
Quality of life measurement was performed using the Juniper Asthma Quality of Life 
Questionnaire [12].  The AQLQ was recorded before and after treatment [baseline and 
12 weeks respectively].  A copy of this is in Appendix 2. 
4.1.1.3. Leicester Cough Questionnaire [LCQ] 
Cough is not just a symptom exclusively related to asthma.  The LCQ can be used 
generically to measure the response to treatment of any condition which might 
generate cough as a clinical symptom.  The Leicester Cough Questionnaire is a self-
completed, health related quality of life measure of chronic cough.  It has a 19 items 
which are sub-divided in to 3 domains: physical; psychological and social.  The 
minimally important clinical difference for the total score is 1.3, with each domain 
having an MICD of 0.2, physical; 0.2 social; and 0.8, psychological [212].   
4.1.2. Diary card recordings 
A validated diary card [213] was used to measure asthma symptoms, PEF recordings 
and inhaled beta2-agonist use.  PEF measurements were undertaken by patients at 
home using a PIKO-1 electronic peak flow meter [nSpire Health, Hertford UK].  The 
Piko-1 meter has been demonstrated to be comparable to the pneumotachograph 
[214].  On return visits the electronic diary was downloaded and analysed for 
exacerbations and measurement compliance [215].  The best of three measurements 
was recorded in the diary twice daily [am/pm] prior to treatment with salbutamol.  A 
copy of the diary can be found in Appendix 4. 
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Home monitoring of peak flow in clinical trials is frequently undertaken for a variety 
of reasons.  The most important of these is to alert the subject to the possibility of an 
exacerbation having developed.  This is particularly useful if the subject’s baseline 
inhaled therapy is being altered.  In addition, it gives a more realistic view of the 
patient’s clinical status than a single isolated measure of either FEV1 or PEF in the 
clinic setting.  This too is not without its caveats, as frequently patient effort can be 
reduced in the private setting of their home than when they are being prompted to 
perform maximal efforts by a member of the study team.  Nonetheless, daily peak 
flow measurement provides a better impression of the diurnal variation in airway 
calibre and hence evidence of day-to-day fluctuation in the patient’s clinical status 
[216]. 
4.2. Assessment of airway inflammation 
4.2.1. Non-Invasive investigation 
4.2.1.1. Induced sputum 
Sputum induction was performed using a widely accepted method [64], and was 
performed following pre-treatment with 2.5mg nebulised salbutamol.  Subjects were 
initially asked to inhale nebulised 3% saline [Stockport Pharmaceuticals, Stockport] 
using an ultrasonic handheld nebuliser [Sonix 2000, Medic Ltd, Harlow, Essex, UK].  
Inhalation continued for a total of 7 minutes with the opportunity during this period 
for the subject to expectorate into a polypropylene container.  After completion of this 
phase, time was allowed for further expectoration and spirometry checks.  If lung 
function remained within safety parameters, further concentrations of 4 and 5% saline 
were administered, each for 7 minutes and with spirometry monitoring between 
doses. 
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The test was not performed if FEV1 was less than 1L.  If FEV1 fell by 10-19% from 
post-salbutamol the concentration of saline was not increased.  If FEV1 fell by >20% or 
the patient felt unable to continue [e.g. due to nausea] the test was discontinued. 
The sample was stored on ice until laboratory processing for cell counts and 
centrifugation to harvest the soluble phase could be performed.  For optimum 
cytology this was always done within 2 hours [217].  Cell counts were performed and 
in addition sputum supernatant fluid was analysed for leukotriene [LT]B4 and 
myeloperoxidase [MPO] using EIA [LTB4 from R&D Systems, Abingdon, UK, MPO 
from Cambridge Bioscience, Cambridge, UK] and interleukin [IL]-1β, 2, 4, 5, 6, 8, 10, 
tumour necrosis factor [TNF]-α, granulocyte-macrophage colony stimulating factor 
[GM-CSF] and interferon [IFN]-γ using a Luminex microbead fluorescence kit 
[Biosource, Invitrogen, Paisley, UK]. 
4.2.1.2. Sputum sample preparation 
Induced sputum samples were processed using a sputum-plug-selection method as 
previously described [218].  Mucus plugs within the expectorate were selected using 
forceps and placed in a pre-weighed tube and then re-weighed to estimate volume.  
Sputum plugs were then dispersed by addition of a 1:10 dilution dithiothreitol [DTT, 
Calbiochem, Merck Biosciences Ltd, Beeston] in phosphate-buffered saline [PBS, 
VWR International Ltd, Poole], the amount of DTT being 4x the weight of sputum.  
The volume was increased again by the addition of PBS, at 4x the original weight of 
sputum.  The sample is then filtered through a nylon [nitex] mesh to remove clumps.  
After centrifucation at 1200rpm for 5 minutes the pellet is resuspended in 1ml of 
culture medium and a 20μl aliquot is removed and diluted 1:1 with 0.1% Trypan blue 
[Sigma-Aldrich, Gillingham].  A manual total cell count and a viability count were 
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then performed using a haemocytometer.  Samples were assessed against quality 
indicators and were excluded if they failed to meet these – Table 4.1. 
Table 4.1: Sputum quality indicators 
 
Parameter Threshold for exclusion 
Cell viability <40% 
Total cells to be counted <400 
Proportion of squamous cells >80% 
 
4.2.1.2.1. Quality control for sputum cytokine analysis 
The validity of sputum cytokine analysis is assessed using technique known as 
“spiking” [86].  This is a form of quality control where a known amount of mediator 
to unprocessed sputum, processing the sputum as usuaul and then measuring 
recovery by immunoassay.  Unspiked sputum is simultaneously processed and 
assayed so that percentage recovery can be calculated.  This is an expensive technique 
and hence is not possible to run spiking experiments for all the mediators in this 
study.  We have done this work previously and have shown good levels of recovery 
[Appendix 7: Cytokine analysis quality control consistent with those described in 
other centres [86] 
4.2.1.3. Differential Cell Counting 
The cell pellet was resuspended at a concentration of 0.6 x106/ml in culture medium 
which was kept on ice.  75μl was pipette in to each cyto-funnel to obtain 7 x 104/ml 
and inserted in to a cytospin holder.  2 slides [VWR International Ltd, Poole] were 
prepared for cytospins using filter cards, funnels and cytoclips [Thermo Electron 
Corporation, Basingstoke] as per manufacturer’s instructions.  These were 
centrifuged at 450 rpm for 6 minutes [Shandon Cytospin 4 Centrifuge, Thermo 
Electron Corp.], and then air dried for 1-2 hours.  Samples were then fixed in 
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methanol for 10 minutes.  Fixed slides were then stained using Romanowsky staining 
– Rapi Diff II Stain Pack [Triangle Biomedical Sciences Ltd, Skelmersdale]. 
A differential cell count of greater than 400 inflammatory cells was performed.  
Squamous epithelial cells were counted in addition to this in order to estimate 
contamination from saliva.   
4.2.1.4. Measurement of exhaled Nitric Oxide [eNO] 
In this study FENO was measured using a Niox Flexflow Analyser [Aerocrine AB, 
Sundbybergsvagen 9, SE-171 73 Solna, Sweden].  This analyser meets joint ATS/ERS 
criteria for the measurement of on-line FENO [219].  FENO present in exhaled air is 
measured using a chemiluminescence technique where ozone generated within the 
analyser reacts with NO to produce NO2.  This reaction leads to a change in the 
energy state of the electrons from low energy to higher energy.  The movement of the 
electrons between different orbitals [from high to low as the energy is released] emits 
electromagnetic radiation between the wavelengths of 600 and 3000nm.  A linear 
relationship exists between Nitric Oxide present and the amount of light emitted and 
so once passed through a photomultiplier a derived value can be obtained for the 
FENO [220]. 
Measurements were performed to include extended flow rates [30, 50, 100, 150, 200, 
250 & 300ml sec-1].  The Niox-Flex has a published measuring range of 0-200 ppb, a 
detection limit of 1 ppb, a sampling frequency of 20Hz, a response time of <1.5 
seconds and an accuracy of +/- 2.5 ppb for levels < 50 ppb and +/- 5% of values >50 
ppb. Calibration was carried out every two weeks or as required when the machine 
instructed the user to do so. 
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Adherence to strict measurement techniques can prevent contamination of the 
exhaled air from the lungs.  Nose clips should not be worn as these can affect closure 
of the soft palate.  FENO is also best measured before other airways tests as repeated 
spirometric manoeuvres can lower the NO [221, 222].  Subjects received instruction 
on how to perform the test by the study doctor or nurse.  Tests were then preformed 
following consensus guidelines [219].  Subjects are required to take a deep inhalation 
through the mouthpiece of the machine which is connected to a filter [scrubber] to 
ensure removal of any ambient nitric oxide.  Exhalation continues without removal of 
the mouthpiece and the Niox-Flex will begin the measurement.  A visual feedback 
mechanism is employed by the machine to inform the subject and aid provision of a 
constant flow rate and provide sufficient pressure above that required for closure of 
the velum, reducing nasal contamination of the exhaled breath.  The Niox-Flex 
automatically calculates nitric oxide output [VNO] and exhaled nitric oxide 
concentration, discarding measurements inconsistent with previous results at that 
flow rate and which did not demonstrate a plateau. 
4.3. Asthma specific measurements 
4.3.1. Spirometry [FEV1, FVC and reversibility testing] 
Baseline pre-bronchodilator spirometry was performed using a dry wedge spirometer 
[Vitalograph, Buckingham, UK], with the best of three measurements being recorded.  
All tests were performed following the appropriate recommendations in consensus 
guidelines [223].  Measurements were deemed acceptable if they were reproducible to 
within 5% or 0.15L.  Spirometric measurements were performed before and after 
nebulised salbutamol [2.5mg].  Salbutamol was delivered via a compressed air 
nebuliser [Pari Boy, PARI, VA, USA] for 5 minutes, following suitable baseline 
recordings.  Subjects then performed spirometry from 15mins post completion of the 
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salbutamol inhalation.  Measurements were performed as before to the same 
standards and following consensus guidelines [223].  Reversible airflow obstruction 
was defined as an improvement in FEV1 of ≤12% [and greater than 200ml in absolute 
volume] and was calculated using the formula: 
                 [
                      
          
]      
4.3.2. Asthma severity 
4.3.2.1. GINA Severity Classification 
Conventional assessments of asthma severity have combined assessments of 
symptoms, amounts of β2-agonist used to treat symptoms and lung function [224].  
Asthma classification based on severity criteria can aid decision making about 
management at the initial assessment of the patient.  This is because asthma therapy 
involves a stepwise approach in which the level of therapy is increased as the severity 
of the asthma increases.   
In this study, asthma severity was based not only on the classifications of GINA but 
also in combination with the level of treatment the patient was receiving at the time 
of screening.  The subject was first questioned about their current asthma therapy.   
Therapy was categorised as follows 
 Intermittent – salbutamol alone 
 Mild [low ICS or theophylline or LTA] 
 Moderate [low/med ICS+LABA or high dose ICS or med ICS + theo/LTA/oral 
salbutamol] 
 Severe [high ICS+LABA ± other tablets] 
 105 
 
 
Following this, the level of symptoms the patient experience whilst receiving this 
treatment was explored.  Categorising symptoms was based on sub-divisions in Table 
4.2. 
Table 4.2: Classification of Asthma Severity by Clinical Features 
 
Step 1: Intermittent 
Symptoms less than once a week 
Brief exacerbations 
Nocturnal symptoms not more than twice a month 
 FEV1 or PEF ≥ 80 % predicted 
 PEF or FEV1 variability < 20 % 
Step 2: Mild persistent 
Symptoms more than once a week but less than once a day 
Exacerbations may affect activity and sleep 
Nocturnal symptoms more than twice a month 
 FEV1 or PEF ≥ 80 % predicted 
 FEV1 or PEF variability 20-30% 
Step 3: Moderate persistent 
Symptoms daily 
Exacerbations may affect activity and sleep 
Nocturnal symptoms more than once a week 
Daily use of inhaled short-acting β2-agonist 
 FEV1 or PEF 60-80% predicted 
 PEF or FEV1 variability >30% 
Step 4: Severe persistent 
Symptoms daily 
Frequent exacerbations 
Frequent nocturnal asthma symptoms 
 FEV1 or PEF ≤60% predicted 
 PEF or FEV1 variability >30% 
 
If the patient’s symptoms were controlled on their current therapy they remained 
within the symptom category in Table 4.2, above.  If however their symptoms 
persisted despite their current treatment they would be moved up a category.  
Subjects already in the severe persistent group would remain in that group.  A copy 
of the questionnaire can be found in Appendix 5.  The GINA severity classification is 
now only recommended for research purposes [224].   
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4.3.2.2. GINA Asthma Control 
There is the understanding that asthma severity involves not only the severity of the 
underlying disease but also its responsiveness to treatment, and that severity can be a 
variable feature of an individual patient’s asthma but may change over time.  GINA 
have developed a system for categorizing asthma control, although this is based on 
current opinion and has not been formally validated [224]. 
Table 4.3: Global Initiative for Asthma [GINA] definitions of asthma control 
 
Characteristic Controlled Partly controlled Uncontrolled 
Daytime symptoms None [twice or 
less/week] 
More than twice per 
week 
Three or more features 
of partly controlled 
asthma present in any 
week 
Limitations of activities None Any 
Nocturnal 
symptoms/awakenings 
None Any 
Need for reliever/rescue 
treatment 
None [twice of less per 
week] 
More than twice per 
week 
Lung function PEF or 
FEV1 
Normal <80% predicted or 
personal best [if known] 
Exacerbations None One or more per year One in any week 
[224] 
4.3.3. Exacerbations of asthma and Adverse Events 
Asthma is a heterogeneous disease and as a consequence asthma exacerbations can be 
heterogeneous in nature.  The difficulty in providing an accurate and encompassing 
definition for asthma is mirrored in the difficulty that has arisen in providing an 
acceptable definition of exacerbation that has relevance for every patient.  A joint 
ATS/ERS Task Force attempted to clarify this, and noted the difficulty in doing so [9].  
It was observed that for severe exacerbations no two studies had the same definition 
[9].  Most studies regard severe exacerbation as those requiring either systemic 
corticosteroid or hospitalisation [including emergency department admission] [9] and 
moderate exacerbations as those leading to increasing clinical symptoms from 
baseline for 2 consecutive days [9].  Classification of moderate exacerbation is 
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unfortunately not based on any validated criteria.  Monitoring PEFR is an important 
safety aspect for clinical studies and is generally a requirement for ethics.  A PEFR 
drop of >30% is a useful measure for subjects to monitor and seems reasonable based 
on the Task Force guidance [9].  A mild exacerbation is even more difficult to define 
as this could simply be normal variation in the patient’s symptoms and 
representative of loss of control as opposed to the development of an exacerbation 
episode.  For the purposes of the study, exacerbations of asthma were defined by the 
criteria outlined in Table 4.4.   
Table 4.4: Criteria for reporting asthma exacerbation 
 
Severity Criteria 
Severe Oral steroid use for at least 3 days [course separated by 1 week or more should be 
treated as separate exacerbations 
 Hospitalisation because of asthma requiring oral steroids 
 Emergency department visit because of asthma requiring oral steroids 
Moderate One or more of the following for 2 consecutive days 
 Drop in peak flow>30% baseline value,    or 
 Night awakening due to asthma [more than the individual considers normal] 
Mild Increased asthma symptoms 
 Drop in peak flow >20% baseline value 
Table derived from [225] 
 
4.3.4. Airways responsiveness – Methacholine hyper-reactivity 
Airway responsiveness is an objective, well standardised measure of variable airflow 
limitation and is accepted as diagnostic of the condition.  For patients with symptoms 
consistent with asthma but normal lung function a positive challenge test to 
methacholine may help establish the diagnosis with reasonable certainty [2, 226].  
Methacholine PC20 is frequent employed within clinical trials as an endpoint.  
Broncho-provocation testing is performed using a calibrated nebuliser [Airlife® 
Sidestream high efficiency nebuliser] to supply an output of 0.13ml/min of solution 
per minute in serial doubling doses using the tidal breathing method in 2 minute 
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intervals.  As a safety aspect, patients undergoing broncho-provocation testing were 
required to have a baseline FEV1 >60% predicted.  Patients were also required to 
abstain from using their normal asthma medication, anti-histamines and caffeine 
containing drinks as per recommendations [5] and Table 4.5.  Female subjects were 
required to have a pregnancy test and methacholine broncho-provocation was only 
performed if not pregnant.  Methacholine was provided by the Western Infirmary & 
Gartnavel General Hospital Sterile Production Unit and Stockport Pharmaceuticals, 
Stockport Hospital NHS trust. 
Table 4.5: Factors that decrease bronchial responsiveness 
 
Medication Duration of withdrawal 
Short acting β2 agonist 8 hours 
Long acting β2 agonist 48 hours 
Anti-histamines 72 hours 
Caffeine containing food/drinks 
[chocolate/tea/coffee/soft drinks] 
Day of study 
Adapted from [5] 
 
Baseline spirometry was performed on all subjects before receiving any form of 
bronchial challenge.  Nebulised saline was then delivered for 2 minutes followed by 
measurement of FEV1 at 30, 90 and 180 seconds.  The highest post-saline FEV1 is used 
to calculate the target drop of 20%.  The subject begins by inhalation of 0.03125mg/ml 
of methacholine for 2 minutes [3ml of solution placed in nebuliser] followed by 
sequential measurement of FEV1 as outlined.  If the FEV1 stays within 20% of baseline 
[highest post-saline], the test is continued by administering a sequence of doubling 
concentrations of methacholine – 0.0625mg/ml, 0.125mg/ml, 0.25mg/ml to 16mg/ml at 
which point the test is discontinued.  The target drop is identified when the FEV1 has 
dropped beneath the target on two measurements within a single phase.  If the target 
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drop occurs before all concentrations have been administered the test is stopped.  At 
this point the patient is nebulised with 2.5mg of salbutamol. 
The provocation concentration of methacholine required to produce a drop in FEV1 of 
20% [PC20] for each subject was calculated by interpolation. 
Figure 4.1: Methacholine calculation 
 
            [      
(           )(     )
     
] 
C1 = second to last methacholine concentration; C2 = last methacholine calculation; R1 = %age fall in 
FEV1 after C1; R2 = %age fall in FEV1 after C2 [227] 
 
A provocation concentration of <8mg/ml in the context of the appropriate clinical 
history and good quality spirometric efforts was considered to confirm the diagnosis 
of asthma and eligibility for the clinical trial.   
4.4. Measurement of atopy 
Serum samples were taken from each patient and analysed.  Total IgE was measured 
and in addition specific IgE for house dust mite, cat dander, grass pollen, aspergillus 
and specific IgG for aspergillus.  Atopy was defined as having IgE antibody against 
any of the common inhalant allergens, house dust mite, cat dander or grass pollen.  
The assay is an automated fluorescent immunoassay [UniCAP 100, Pharmacia UK 
Ltd, Milton Keynes, UK].  Total IgE >120 kilo-International Units/L [kIU/L], and 
specific IgE>0.35 kA[arbitrary]U/L were considered positive.  Grass pollen serology 
was reported as either positive or negative with no specific value reported.   
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Specific IgE antibodies within the subject’s serum binds to the allergen or antigen of 
interest, which in turn is bound to a flexible cellulose matrix.  This is then washed to 
remove any unbound antibody and a second detection antibody that recognises 
bound human IgE ie anti-IgE antibody-beta-galactosidase conjugate is then added.  If 
the subject has specific IgE remaining this antibody conjugate will then bind.  The 
activity of the bound enzyme is then measured by the addition of a colourless 
substrate which is metabolised to a fluorescent product [umbelliferone] and thus can 
be measured.  The fluorescence is produced is directly proportional to the presence of 
IgE and can be quantified to a standard curve.  The assay has a working range of 0.35 
– 100 arbitrary units [kU/L].   
4.5. Blood lymphocyte proliferative response in vitro 
Peripheral blood mononuclear cells are readily separated by centrifugation [1800 rpm 
for 20min] on a Ficol gradient [lymphoprep, specific gravity SG1.088].  The 
mononuclear cell fraction which collects between the plasma ficol interface is 
harvested, washed with HBSS and cultured at 106cells/ml in-vitro in complete RMPI 
media, 10% autologous plasma, L-glutamine and with antibiotic [penicillin, 
streptomycin] cover for 3 days with various additives in a humidified 5% CO2 
atmosphere for 3 days.   
To test a functional proliferation response the lymphocytes were cultured with the 
mitogen phytohaemagglutinin PHA at 8mg/ml.  The lectin non-specifically binds and 
cross-links CD3 T-cell receptor thus activating the cell.  This activation was measured 
by the incorporation of tritiated thymidine added 16 hours before harvesting 
automatically by washing on glass fibre filters then counting in a beta counter.  The 
purpose of the assay was to assess the immune-competence in response to mitogen 
[as a surrogate for antigen] and to test if azithromycin had altered this response.   
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One important purpose of this assay is its potential value as an in-vitro means of 
exploring the mechanisms of glucocorticoid refractory immune responses.  This was 
done by adding varying concentrations of the immune-suppressive dexamethasone 
to determine if there was any alteration in response to this exogenous steroid by 
azithromycin.  Appropriate controls were included in all assays.   
4.6. Other immunological tests in blood 
Serum was analysed for C-Reactive Protein [CRP] using a high sensitivity [hs]-CRP 
assay by enzyme immune-assay [EIA] [R&D Systems] and IL-1β, 2, 4, 5, 6, 8, 10, TNF-
α and GM-CSF [using a multiplex fluorescence bead kit, Biosource] and a Luminex 
platform [Biorad]. 
4.7. Measurement of renal and liver safety biomarkers in blood 
Blood was taken to measure serum markers of renal and liver function at baseline, 8 
and 12 weeks.  Subjects with significantly abnormal renal function [urea or creatinine 
>2 times ULN] or abnormal liver function [ALT or AST >2 times ULN] at baseline 
were excluded from the study.  Abnormal results during the study [8 weeks] led to 
repeat specimens being sent urgently in the first instance and if confirmed, a decision 
was made on continuance of the subject within the trial.  Subjects with abnormal 
results at 12 weeks had these repeated in the first instance.  In all cases clinical 
assessment would be made to define a cause and appropriate onward referrals 
carried out if necessary.   
4.8. Virological analysis of induced sputum and blood 
Virological analysis of the sputum was done using a panel of primers for upper 
airway viruses as well as for M. pneumonia [Superscript III Platinum One Step 
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Quantitative RT-PCR System, Invitrogen, with appropriate primer and probe 
mix[228, 229]] and C. pneumonia [Platinum Quantitative PCR Supermix, Invitrogen, 
with CP primer[230]].  Serological analysis was also performed for evidence of 
antibody response to each organism [CP, Medac GmbH, Hamburg, Germany; MP, 
Sekisui Virotech GmbH, Russelsheim, Germany].   
Subjects would be categorised as carriers of C pneumonia if both IgA [IgA antibodies 
appear early in infection and then persist] and IgG [IgG antibodies develop within 2 
to 3 weeks of infection] were positive.  Confirmation of the presence of M pneumonia 
is dependent upon there being the development of IgM antibodies.  Serological 
results would be supported by PCR. 
4.9. Bacteriological analysis of induced sputum 
Simple quantitative bacteriology is a crude and convenient method that is regarded 
as an acceptable technique and results from it are regularly published following peer-
review [176, 231-234].  The technique does not guarantee to collect a sample free of 
contamination from elsewhere in the upper airway – the samples must traverse the 
oropharynx during expectoration and so there is the possibility of contamination with 
the flora or the oropharyngeal mucosa.  There is no certainty that any growth truly 
reflects the bacterial burden as individual isolates of bacteria may not grow 
particularly well in culture.  Identification of individual bacteria is not always 
possible as there could be overgrowth from non-pathogenic organisms leading to 
crowding on the plate.  The count can sometimes only be estimated, with results 
reported within a range estimate.  Finally it can be difficult to identify some 
organisms e.g. S. pneumoniae particularly if this is in low numbers given its similarity 
colonies of commensal α-streptococci. 
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0.2ml of homogenised sputum was delivered to the routine service bacteriology, 
Yorkhill Royal Hospital for Sick Children, Glasgow, in a sterile container.  10l of the 
homogenate was inoculated onto blood agar+optochin disc, chocolate agar, CLED 
agar and Sabouraud agar and spread with a loop for discrete colonies.  100l of the 
homogenate was then added to 5ml sterile saline and mixed, making a 1:100 dilution.  
50l of the 1:100 dilution was then added to 5ml sterile saline, giving a final dilution 
of 10-4.  A 20l loop of the 10-4 dilution was inoculated onto a blood and chocolate 
agar and spread over the entire surface with the loop.  This was followed by 
incubation of the blood and chocolate agars at 37C in 5% CO2, the CLED and 
Sabouraud agars at 37C. 
The number of colony forming units per gram of sputum was enumerated from the 
total number of colonies obtained and the dilution [10-4] to give the total bacterial 
count for each sample expressed in colony forming units [cfu]/ml. 
Table 4.6: Interpretation of the 10-4 dilution cultures 
 
Number of colonies Count per ml 
0-2 106  cfu/ml 
2-20 107  cfu/ml 
20-200 108  cfu/ml 
>200 109  cfu/ml 
 
Only significant pathogens were to be counted and followed up with the appropriate 
identification and sensitivity. Normal respiratory flora was recorded as normal. 
  
 114 
 
 
4.10. Equivalent steroid dose 
Beclometasone dipropionate [BDP] and budesonide are approximately 
therapeutically equivalent in clinical practice, although there may be variations with 
different devices.  Mometasone and fluticasone appear to provide equal clinical 
activity to BDP and budesonide at half the dosage [1, 2].  Subjects who screened, and 
were on high dose ICS or combination ICS/LABA, required weaning to the standard 
run-in dose of 200mcg budesonide±LABA.  Relative potency of ICS compared to 
BDP/beclometasone can be found in Table 4.7 
Table 4.7: Relative potency of inhaled corticosteroids 
 
Inhaled corticosteroid Relative potency 
Budesonide 1 
Beclometasone dipropionate 1 
Fluticasone 2 
QVAR® 2 
Mometasone 2 
 
4.11. Pre-specified and post-hoc analysis 
All of the aforementioned outcome measures were included in the original protocol 
and analysed as a pre-specified outcome measure.  Any additional measurement and 
analysis not included above was performed as a post-hoc analysis. 
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5. Clinical results 
5.1. Introduction 
A total of 80 GP practices were visited over the 2 year period from commencement of 
the study.  8398 approach letters were generated and mailed to prospective 
participants.  715 positive responses were received, in the form of a returned 
acceptance slip or a telephone call leading to 705 being further assessed for eligibility.  
Prospective participants were “pre-screened” at the point of invitation to attend for a 
screening appointment, with 347 not meeting the entrance criteria.  23 people were 
unwilling to take part following explanation of the study and 101 did-not-attend for 
their initial screening appointment.   
5.2. Flow of participants 
Of the 715 replies received, screening visits were arranged for 234 and 77 were 
randomised.  Baseline demographic data and clinical characteristics of the patients 
are shown in Table 5.2, and the participant flow can be found in Figure 5.1.   
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Figure 5.1: CONSORT Flow Diagram 
  
Assessed for eligibility [n=234] 
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Not meeting inclusion criteria [n=148] 
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Analysed [n=39] 
 
Excluded from analysis [n=0] 
Lost to follow-up [n=1] 
 
Discontinued intervention [n=2] 
Allocated to Azithromycin [n=39] 
 
Received allocated intervention [n=39] 
 
Did not receive allocated intervention [n=0] 
Lost to follow-up [n=3] 
 
Discontinued intervention [n=0] 
Allocated to placebo [n=38] 
 
Received allocated intervention [n=38] 
 
Did not receive allocated intervention [n=0] 
Analysed [n=38] 
 
Excluded from analysis [n=0] 
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Analysis 
Follow-up 
Randomized [n=77] 
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A complete breakdown of the reasons for screening failure can be found in Table 5.1: 
Breakdown of exclusions of screened patients from the study. 
Table 5.1: Breakdown of exclusions of screened patients from the study 
 
Reason for exclusion Number of participants 
Exacerbation of asthma 56 
Did not attend for randomisation visit 37 
ACQ<1 11 
Withdrew consent 10 
Prolonged QTc 7 
No reversibility & methacholine negative 7 
Unable to wean inhaler 4 
Abnormal blood indices 4 
Other 12 
Total 148 
 
5.3. Baseline characteristics 
5.3.1. Demographics 
Baseline demographic characteristics of the 77 subjects who underwent 
randomisation were similar between the two groups and are displayed in Table 5.2. 
The mean ages were similar between the two groups.  There were slight differences in 
men and women between the two groups; 21 females in the placebo group and 19 in 
the azithromycin group.  There were 3 fewer men in the placebo group. 
The duration of asthma was 24.6 years in the placebo group and 18.8 years in the 
azithromycin group.  There was a slight difference in the mean number of pack years 
between the two groups with the azithromycin group having a greater number 
although the mean number of cigarettes was almost the same.  The difference was not 
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of importance and was well over the minimum pack exposure [5 years] required for 
inclusion in the study. 
For each of the specific measurements there were no significant differences in the 
baseline outcomes.   
Table 5.2: Baseline demographics and subject characteristics 
 
Variable Placebo 
[n=39]† 
Azithromycin 
[n=38]† 
Age, years 42.84 [8.8] 46.44 [8.8] 
Male sex, n [%] 17 [44.7%] 20 [51.3%] 
Smoking history [pack years] 23.6 [15.8] 28.6 [16.4] 
Duration of asthma symptoms, years 24.6 [12.6] 18.8 [12.5] 
Atopic, n [%] 23 [60.1] 27 [69.2] 
Total IgE [IU/ml] [Median [Q1, Q3] 103 [38, 291] 265 [48, 254] 
Use of inhaled corticosteroid at screening, n [%] 31 [81.6%] 35 [89.7%] 
Equivalent beclometasone dose at screening, µg 709 [564] 603 [457] 
Use of LABA at randomisation, n [%] 18 [47.4%] 15 [38.5%] 
Pre-bronchodilator FEV1 [L] 2.54 [0.77] 2.43 [0.72] 
Pre-bronchodilator FEV1 % predicted 81 [16.8] 78.3 [16.4] 
Post-bronchodilator FEV1 % predicted 89.0 [15.1] 86.8 [15.2] 
FEV1 % reversibility 11.3 [9.8] 12.3 [10] 
Geometric mean [range] PC20 methacholine [mg/ml] 1.06 [4.10] 1.07 [3.13] 
Mean [SD] unless stated.  †Number of randomized subjects with at least one post-baseline 
assessment of peak expiratory flow [PEF]. 
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5.4. Clinical endpoint results 
5.4.1. Primary outcome peak expiratory flow [PEF] 
Baseline measurements between the two groups were well matched, the mean [SD] 
peak expiratory flow for all the randomised patients was 400.7 L/min [119.1] and 
when separated for the placebo group was 411.1 L/min [124.3] and the azithromycin 
group was 390.5 L/min [114.5]. 
The primary outcome was clinic visit PEF at 12 weeks.  At 12 weeks, the mean 
difference in clinic visit PEF for azithromycin compared with placebo was not 
statistically different [mean difference -10.4 L/min 95% CI -47.1 to 26.4, p=0.58].  A 
detailed breakdown of these results can be found in Table 5.3.  This table 
demonstrates there was no substantial difference between the azithromycin and 
placebo group at baseline and 12 weeks for the primary endpoint.  The primary 
outcome results in Table 5.3 are presented graphically in Figure 5.2 
Table 5.3: Change from baseline to 12 weeks in clinic visit PEF [L/min] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 400.7 119.1 38 411.1 124.3 39 390.5 114.5 
Visit 5 71 405.3 140.2 35 416.7 122.7 36 394.7 156.3 
Δ baseline 
to Visit 5 
 6.6 76.6  11.8 64.7  1.4 87.2 
Mean 
Difference 
[95% CI] 
 
-10.3  [-47.1 , 26.4],  p=0.58 
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Figure 5.2: Box-whisker plot clinic visit PEF [L/min] by visit  
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No significant difference is seen between the treatment groups at 4 [p=0.75], 8 [p=0.94] or 12 weeks 
[p=0.58] Mean denoted by crossed-circle and outliers with asterisk. 
The data collected at the final visit is displayed in an enlarged, more detailed form in 
Figure 5.3. 
Figure 5.3: Box-whisker plot of clinic PEF [L/min] at 12 weeks by treatment group. 
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No significant difference is seen between the treatment groups [p=0.58] 
Mean denoted by crossed-circle and outliers with asterisk. 
 121 
 
 
5.4.1.1. FEV1 
FEV1 [pre and post-salbutamol] did not show any statistically significant difference 
after 12 weeks treatment with azithromycin.  Pre-salbutamol FEV1 treatment 
difference 0.03L [95%CI -0.08 to 0.14], p=0.62, with post-salbutamol FEV1 treatment 
difference 0.04L [95%CI -0.08 to 0.17]. p=0.50.  The baseline means [SD] for both pre 
and post-salbutamol FEV1 measurements are displayed in Table 5.4, Table 5.5 and 
graphically in Figure 5.4. 
Table 5.4: Pre-salbutamol FEV1 [L] at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 2.48 0.74 38 2.54 0.77 39 2.43 0.72 
Visit 5 71 2.43 0.76 35 2.46 0.75 36 2.41 0.77 
Δ baseline 
to Visit 5 
 -0.04   0.23  -0.06  0.24  -0.03 0.23 
Mean 
Difference 
[95% CI] 
 
0.03  [-0.08 , 0.14], p=0.62 
 
Table 5.5: Post-salbutamol FEV1 [L] at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 2.74 0.76 38 2.8 0.8 39 2.68 0.73 
Visit 5 71 2.66 0.73 35 2.73 0.72 36 2.59 0.74 
Δ baseline 
to Visit 5 
 -0.07 0.26  -0.09 0.28  -0.04 0.25 
Mean 
Difference 
[95% CI] 
 
0.04  [-0.08 , 0.17], p=0.50 
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Figure 5.4: Box-whisker plot of FEV1 [L], [pre & post-salbutamol] at 12 weeks 
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No significant difference is seen between the treatment groups: Pre-salbutamol p=0.62; Post-
salbutamol p=0.50.  Mean denoted by crossed-circle and outliers with asterisk. 
5.4.1.2. FVC 
No effect was seen in either mean [SD] FVC either pre or post salbutamol following 
12 weeks treatment with azithromycin.  The mean difference in pre-salbutamol FVC 
was 0.01L [95%CI -0.13 to 0.15], p=0.89 with mean difference post-salbutamol FVC of 
0.06L [95%CI -0.04 to 0.16], p=0.27.   The details of these measurements are displayed 
in Table 5.6 and Table 5.7, with a graphical summary of the datasets in Figure 5.5. 
Table 5.6: Pre-salbutamol FVC [L] at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 3.65 1.06 38 3.72 1.16 39 3.58 0.97 
Visit 5 71 3.64 1.12 35 3.68 1.26 36 3.6 0.98 
Δ baseline 
to Visit 5 
 -0.02 0.29  -0.02 0.33  -0.02 0.24 
Mean 
Difference 
[95% CI] 
 
0.01  [-0.13 , 0.15], p=0.89 
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Table 5.7: Post-salbutamol FVC [L] at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 3.92 1.09 38 3.99 1.22 39 3.84 0.96 
Visit 5 71 3.92 1.12 35 3.94 1.26 36 3.9 0.99 
Δ baseline 
to Visit 5 
 -0.01 0.22  -0.04 0.25  0.02 0.18 
Mean 
Difference 
[95% CI] 
 
0.06  [-0.04 , 0.16], p=0.27 
 
Figure 5.5: Box-whisker plot of FVC [L], [pre & post-salbutamol] at 12 weeks 
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No significant difference is seen between the treatment groups: Pre-salbutamol, p=0.89; Post-
salbutamol p=0.27.  Mean denoted by crossed-circle and outliers with asterisk. 
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5.4.1.3. FEF25-75 
No effect was seen in either mean [SD] FEF25-75 either pre or post salbutamol following 
12 weeks treatment with azithromycin.  The mean difference in pre-salbutamol FEF25-
75 was 0.08L/sec [95%CI -0.07 to 0.24], p=0.28 with mean difference post-salbutamol 
FEF25-75 of -0.04L/sec [95%CI -0.21 to 0.12], p=0.60.   The details of these measurements 
are displayed in Table 5.8 and Table 5.9, with a graphical summary of the datasets in 
Figure 5.6. 
Table 5.8: Pre-salbutamol FEF25-75 [L/sec] at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 1.71 0.72 38 1.81 0.77 39 1.63 0.68 
Visit 5 71 1.62 0.69 35 1.65 0.68 36 1.6 0.7 
Δ baseline 
to Visit 5 
 -0.07 0.33  -0.11 0.36  -0.02 0.29 
Mean 
Difference 
[95% CI] 
 
0.08  [-0.07 , 0.24], p=0.28 
 
Table 5.9: Post-salbutamol FEF25-75 [L/sec] at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 2.05 0.86 38 2.12 0.86 39 1.98 0.86 
Visit 5 71 1.93 0.82 35 2.00 0.86 36 1.86 0.78 
Δ baseline 
to Visit 5 
 -0.08 0.35  -0.06 0.44  -0.1 0.25 
Mean 
Difference 
[95% CI] 
 
-0.04  [-0.21 , 0.12], p=0.60 
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Figure 5.6: Box-whisker of FEF25-75 [L/sec], [pre & post-salbutamol] at 12 weeks 
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No significant difference is seen between the treatment groups: Pre-salbutamol, p=0.28; Post-
salbutamol p=0.60.  Mean denoted by crossed-circle and outliers with asterisk. 
5.4.1.4. FEV1/FVC ratio 
No effect was seen in either mean [SD] FEV1/FVC ratio either pre or post salbutamol 
following 12 weeks treatment with azithromycin.  The mean difference in pre-
salbutamol FEV1/FVC ratio was -0.2% [95%CI -2.0 to 1.6], p=0.84 with mean 
difference post-salbutamol FEV1/FVC ratio of -0.1% [95%CI -1.6 to 1.4], p=0.86.  The 
details of these measurements are displayed in Table 5.10 and Table 5.11, with a 
graphical summary of the datasets in Figure 5.7. 
Table 5.10: Pre-salbutamol FEV1/FVC ratio [%] at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 68.4 8.5 38 69.2 8.5 39 67.6 8.5 
Visit 5 71 67.2 8.4 35 68.1 8.2 36 66.4 8.7 
Δ baseline 
to Visit 5 
 -0.9 3.8  -0.8 4.0  -0.9 3.6 
Mean 
Difference 
[95% CI] 
 
-0.2  [-2.0 , 1.6], p=0.84 
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Table 5.11: Post-salbutamol FEV1/FVC ratio [%] at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 70.5 8.6 38 71.1 8.6 39 69.9 8.7 
Visit 5 71 68.9 8.6 35 69.6 8.5 36 68.1 8.8 
Δ baseline 
to Visit 5 
 -1.3 3.1  -1.2 3.6  -1.3 2.6 
Mean 
Difference 
[95% CI] 
 
-0.1  [-1.6 , 1.4], p=0.86 
 
Figure 5.7: Box-whisker of FEV1/FVC ratio [%], [pre & post-salbutamol] at 12 weeks 
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No significant difference is seen between the treatment groups: Pre-salbutamol, p=0.84; Post-
salbutamol p=0.86.  Mean denoted by crossed-circle and outliers with asterisk. 
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5.4.2. Methacholine responsiveness 
No effect was seen on mean [SD] methacholine-PC20 following 12 weeks treatment 
with azithromycin.  The mean difference was 0.08mg/ml [95%CI -1.8 to 1.97], p=0.93.  
The details of these measurements are displayed in Table 5.12, with a graphical 
summary of the dataset in Figure 5.8. 
Table 5.12: Methacholine responsiveness PC20 [mg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 2.22 3.05 34 1.88 1.94 35 2.55 3.84 
Visit 5 61 3.11 4.58 30 2.73 4.12 31 3.47 5.03 
Δ baseline 
to Visit 5 
 0.87 3.6  0.86 3.63  0.87 3.63 
Mean 
Difference 
[95% CI] 
 
0.08  [-1.8 , 1.97], p=0.93 
 
Figure 5.8: Box-whisker plot of methacholine PC20 [mg/ml] responsiveness 
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No significant difference is seen between the treatment groups [p=0.93] 
Mean denoted by crossed-circle and outliers with asterisk. 
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The geometric mean was calculated on the log transformed methacholine data in 
addition to the raw data, due to its distribution.  This can be found in Table 5.13, but 
has not been represented graphically.  Even with log-transformation there was no 
statistically significant difference [p=0.93], between the two groups.   
Table 5.13: Log transformed methacholine responsiveness PC20 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 0.06 1.28 34 0.07 1.14 35 0.06 1.41 
Visit 5 61 0.19 1.4 30 0.19 1.29 31 0.2 1.52 
Δ baseline 
to Visit 5 
 0.16 0.93  0.17 1.04  0.14 0.82 
Mean 
Difference 
[95% CI] 
 
-0.02  [-0.49 , 0.45], p=0.93 
 
5.4.3. GINA Asthma Severity 
Asthma severity was measured at baseline only using the GINA severity 
classification.  This was similar across both groups.  The majority of patients in both 
groups were classified in category 4 – Severe Persistent Asthma and overall the 
population was positively skewed.  The results are detailed in Table 5.14 and 
graphically in Figure 5.9. 
Table 5.14: GINA asthma severity category 
 
Category All subjects n=77 Placebo n=38 Azithromycin 
n=39 
Intermittent Asthma 1  [1.3%] 1  [2.63%] 0  [0%] 
Mild Persistent Asthma 14  [18.18%] 6  [15.79%] 8  [20.51%] 
Moderate Persistent Asthma 26  [33.77%] 12  [31.58%] 14  [35.9%] 
Severe Persistent Asthma 36  [46.75%] 19  [50%] 17  [43.59%] 
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Figure 5.9: Baseline GINA severity category divided by treatment group 
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Score: 1 – Intermittent; 2 – Mild persistent; 3 – Moderate persistent; 4 – Severe persistent. 
5.4.4. Asthma control score [ACQ] 
No effect was seen on mean [SD] ACQ following 12 weeks treatment with 
azithromycin.  The mean difference was 0.21 [95%CI -0.11 to 0.53], p=0.20.  The details 
of these measurements are displayed in Table 5.15, with a graphical summary of the 
dataset in Figure 5.10.   
Table 5.15: ACQ total score at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 1.74 0.81 38 1.76 0.88 39 1.73 0.74 
Visit 5 71 1.67 0.89 35 1.58 0.96 36 1.75 0.83 
Δ baseline 
to Visit 5 
 -0.09 0.72  -0.21 0.81  0.02 0.61 
Mean 
Difference 
[95% CI] 
 
0.21  [-0.11 , 0.53], p=0.20 
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Figure 5.10: Box-whisker plot of ACQ score by visit 
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No significant difference is seen between the treatment groups at 4 weeks [p=0.43], 8 weeks [p=0.23] 
and 12 weeks [p=0.20].  Mean denoted by crossed-circle and outliers with asterisk. 
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5.4.5. Asthma quality of life [AQLQ] 
AQLQ was measured at baseline and 12 weeks.  No effect was seen on mean [SD] 
AQLQ following 12 weeks treatment with azithromycin.  The mean difference was -
0.31 [95%CI -0.69 to 0.07], p=0.11.  The details of these measurements are displayed in 
Table 5.16, with a graphical summary of the dataset in Figure 5.11. 
Table 5.16: AQLQ total score at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 5.17 1.09 38 5.09 0.99 39 5.25 1.18 
Visit 5 71 5.31 1.19 35 5.42 1.31 36 5.2 1.06 
Δ baseline 
to Visit 5 
 0.2 0.83  0.37 0.97  0.04 0.65 
Mean 
Difference 
[95% CI] 
 
-0.31  [-0.69 , 0.07], p=0.11 
 
Figure 5.11: Box-whisker plot of AQLQ score 
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No significant difference is seen between the treatment groups [p=0.11] 
Mean denoted by crossed-circle and outliers with asterisk. 
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5.4.5.1. AQLQ Individual domain scores 
Subdivision of the AQLQ in to its component domains did not demonstrate any 
difference between azithromycin and placebo following 12 weeks of treatment. 
 AQLQ-symptoms domain had a mean difference -0.32 [95%CI -0.75 to 0.11], 
p=0.14 
 AQLQ-activity limitation domain, mean difference -0.17 [95%CI -0.53 to 0.19] 
p=0.35 
 AQLQ-emotional function domain almost reached a statistically significant 
difference but was in direction suggesting deterioration, mean difference -0.44 
[95%CI -0.9 to 0.02] p=0.06 
 AQLQ-environmental stimuli domain, mean difference -0.38 [95%CI -0.87 to 
0.11], p=0.13.   
These results are tabulated in Table 5.17, with the summary statistics being 
represented graphically in Figure 5.12. 
Table 5.17: AQLQ by domain following 12 weeks 
 
AQLQ domain Placebo Azithromycin Treatment 
difference 
95% 
CI 
p 
value 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
   
Symptoms 
35 5.26 1.37 36 5.01 1.08 -0.32 
-0.75, 
0.11 
0.14 
Activity 
limitation 
35 5.64 1.27 36 5.48 1.21 -0.17 
-0.53, 
0.19 
0.35 
Emotional 
function 
35 5.51 1.56 36 5.23 1.19 -0.44 
-0.9, 
0.02 
0.06 
Environmental 
stimuli 
35 5.2 1.49 36 5.01 1.28 -0.38 
-0.87 , 
0.11 
0.13 
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Figure 5.12: AQLQ individual domain scores at baseline and 12 weeks 
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No significant difference is seen between the treatment groups: Symptoms, p=0.14; Activity, p=0.35; 
Emotional function, p=0.06; Environmental Stimuli, p=0.13.  Mean denoted by crossed-circle and 
outliers with asterisk. 
5.4.6. Leicester cough questionnaire [LCQ] 
LCQ was measured at baseline and 12 weeks.  No effect was seen on mean [SD] LCQ 
following 12 weeks treatment with azithromycin.  The mean difference was -1.06 
[95%CI -2.16 to 0.05], p=0.06.  The details of these measurements are displayed in 
Table 5.18, with a graphical summary of the dataset in Figure 5.13. 
Table 5.18: LCQ total score at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 16.60 3.50 38 16.90 3.49 39 16.31 3.53 
Visit 5 71 16.75 3.36 35 17.51 3.55 36 16.01 3.02 
Δ baseline 
to Visit 5 
 0.38 2.61  0.81 2.16  -0.03 2.96 
Mean 
Difference 
[95% CI] 
 
-1.06  [-2.16 , 0.05], p=0.06 
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Figure 5.13: LCQ score at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.06] 
Mean denoted by crossed-circle and outliers with asterisk. 
 
5.4.6.1. LCQ Individual domain scores 
Subdivision of the LCQ in to its component domains did not demonstrate any 
difference between azithromycin and placebo following 12 weeks of treatment.   
 LCQ-physical domain almost reached statistical significance with a mean 
difference -0.33 [95%CI -0.67 to 0.02], p=0.07 
 LCQ-psychological domain did reach statistical significance, mean difference -
0.46 [95%CI -0.9 to 0.02] p=0.04 
 LCQ-social domain mean difference -0.29 [95%CI -0.73 to 0.15] p=0.19 
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These results are tabulated in Table 5.19, with the summary statistics being 
represented graphically in Figure 5.14. 
Table 5.19: LCQ individual domain scores 
 
LCQ domain Placebo Azithromycin Treatment 
difference 
95% 
CI 
p-
value 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
   
Physical 35 5.58 1.21 36 5.16 0.89 -0.33 
-0.67 , 
0.02 
0.07 
Psychological 35 6.03 1.24 36 5.38 1.18 -0.46 
-0.9 , -
0.02 
0.04 
Social 35 5.89 1.25 36 5.47 1.26 -0.29 
-0.73 , 
0.15 
0.19 
 
Figure 5.14: LCQ individual domain scores divided by visit 
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No significant difference is seen between the treatment groups: Physical, p=0.07; Psychological, 
p=0.04; Social, p=0.19.  Mean denoted by crossed-circle and outliers with asterisk. 
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5.5. Home diary card recordings 
5.5.1. Evening PEF recordings 
Daily PEF was performed in the evening by the study subjects and recorded 
electronically by the Piko-1 meter.  This was downloaded at each study visit with the 
data for the previous seven days [minimum of three useable] recordings being 
analysed.  There was no difference between the azithromycin or placebo group in 
either the evening PEF [L/min] at 4, 8 or 12 weeks [mean difference, 12 weeks, -4.5, 
95%CI -36.3 to 27.4, p=0.78].  Details of the daily PEF recordings are summarised in 
Table 5.20. 
Table 5.20: Evening PEF [L/min] recordings at baseline, 4, 8, and 12 weeks 
 
Variable Placebo 
PEF Baseline Week 4 Week 8 Week 12 
 n Mean SD n Mean SD n Mean SD n Mean SD 
Evening 38 378.3 120.9 34 388.0 115.0 31 392.6 118.2 34 386.8 117.6 
 Azithromycin 
 Baseline Week 4 Week 8 Week 12 
 n Mean SD n Mean SD n Mean SD n Mean SD 
Evening 39 363.7 120.0 34 366.4 140.9 32 367.7 145.4 36 373.3 155.9 
 Treatment difference 
  Week 4 Week 8 Week 12 
    Δ 95%CI p Δ 95%CI p Δ 95%CI p 
    -1.0 
-27.1, 
25.2 
0.94 -7.2 
-36.41 , 
22.03 
0.62 -4.5 
-36.3, 
27.4 
0.78 
 
5.5.2. Symptom scores 
Diary card symptom scores were assessed at each visit comprising: frequency of 
asthma symptoms; annoyance of asthma symptoms; activity and activity limitation.  
No effect was found at 4, 8 or 12 weeks treatment with azithromycin in any of these 
parameters.  The results are summarised for all the questions at 12 weeks in Table 
5.21.  In the interests of clarity only 12 week endpoint data is shown.   
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Table 5.21: Diary card questions at 12 weeks 
 
Diary card 
question 
Placebo Azithromycin Treatment 
difference 
95% CI p 
value 
 n Mean SD n Mean SD    
Early morning 
wakening 
30 0.23 0.65 31 0.21 0.33 0.07 -0.09, 0.23 0.38 
Frequency of 
asthma 
symptoms 
30 1.33 1.32 31 1.24 1.03 -0.11 -0.51, 0.29 0.58 
Annoyance of 
asthma 
symptoms 
32 1.2 1.3 31 1.21 1.13 0.04 -0.36, 0.44 0.85 
Activity 31 2.07 1.33 31 1.85 1.37 -0.22 -0.65, 0.22 0.33 
Activity 
limitation 
31 1.2 1.34 31 1.22 1.32 0.01 -0.36, 0.38 0.96 
 
5.5.3. Reliever inhaler use 
Reliever inhaler use was recorded in the daily diary card.  No effect was found at 4, 8 
or 12 weeks treatment with azithromycin when compared to placebo.  Mean 
difference at 4 weeks, -0.1 puffs per 24 hours, 95%CI -0.8 to 0.6, p=0.78; 8 weeks, 0.3 
puffs per 24 hours, 95%CI -0.5 to 1.0, p=0.50 and 12 weeks -0.3 puffs per 24 hours, 
95%CI -1.3 to 0.7, p=0.55.  The results for the 12 week endpoint are displayed in Table 
5.22. 
Table 5.22: Reliever inhaler use [puffs per 24hours], [diary card] at 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 66 2.9 3.8 30 2.8 2.9 36 2.9 4.4 
Visit 5 58 2.9 3.4 26 2.7 2.5 32 3.0 4.0 
Δ baseline 
to Visit 5 
 0.1 2.0  0.3 1.2  -0.1 2.4 
Mean 
Difference 
[95% CI] 
 
-0.3 [-1.3 , 0.7], p=0.55 
 
 138 
 
 
5.5.4. Clinical results:  Summary 
Changes in clinical outcomes after treatment with oral azithromycin are listed in 
Table 5.3 to Table 5.18 and Figure 5.2 to Figure 5.11.  At 12 weeks the change in mean 
morning PEF [primary outcome], as compared with baseline, did not differ 
substantially between the azithromycin and placebo treatment groups [mean 
difference -10.3 L/min, 95% CI -47.1 to 26.4, p=0.58.  Secondary outcome measures of 
mean morning PEF at 4 and 8 weeks were also not substantially different from their 
baseline between the azithromycin and placebo groups [mean difference at 4 weeks -
4.2 L/min, 95% CI -30.6 to 22.2; 8 weeks 1.2 L/min 95% CI -28.1 to 30.5].  There were 
no improvements in any of the health-related quality-of-life-outcomes.  The 7 point 
ACQ score did not differ substantially from baseline between the azithromycin and 
placebo groups at 12 weeks [0.21, 95% CI -0.11 to 0.53, p=0.20].  There was no 
substantial difference at either 4 or 8 weeks.  AQLQ score did not differ substantially 
from baseline between the azithromycin and placebo groups at 12 weeks [mean 
difference -0.31 95% CI -0.69 to 0.07].  In addition when addressing each domain of 
the AQLQ separately, there were no substantial differences between the two groups 
[Table 5.17].  The LCQ score did not differ substantially from baseline between the 
azithromycin and placebo groups at 12 weeks [mean difference -1.06, 95% CI -2.16 to 
0.05, p=0.06].  When addressing each of the domains separately both the social and 
physical domains had non-significant differences but the LCQ-psychological domain 
did, with a mean difference between the two groups of -0.46, 95% CI -0.9 to -0.02, 
p=0.04.  The minimal clinically important difference for the psychological domain is 
0.8 [212], and whilst there is statistical significance in this domain, this might not 
reflect true clinical improvement across the groups and so needs to be interpreted 
with caution.  There was no difference in either pre- or post-salbutamol FEV1 at 4, 8 or 
12 weeks between the two groups.  The PC20 of methacholine was measured at 
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baseline and 12 weeks with no differences observed between the azithromycin or 
placebo groups 0.08mg/ml, 95% CI -1.8 to 1.97, p=0.93. 
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6. Laboratory endpoint results 
6.1. Induced sputum analysis 
Sputum induction was performed at baseline and 12 weeks following standard 
operating procedure.  Safety aspects precluded some subjects from performing this 
test and some subjects were unable to expectorate.  In addition, some subjects were 
able to produce a sample at baseline only.  Subjects who did not produce a sample at 
baseline were not asked to do so at the 12 week visit. 
6.1.1.1. Sputum quality indicators 
Median total filtrate volume was 33.5ml [IQR 15.4, 66.5] at baseline and 37.6ml [IQR 
13.1, 57.7] at 12 weeks.  This was similar between the two groups.  Additionally, 
indicators of sputum quality such as total cells recovered and viability were also 
similar across the groups.  These results are detailed in Table 6.1. 
Table 6.1: Sputum quality indicators at baseline [Visit 2] and 12 weeks [Visit 5] 
 
Variable Visit Total Placebo Azithromycin 
  n Median IQR n Median IQR n Median IQR 
Filtrate 
Vol. [ml] 
2 71 33.5 15.4, 66.5 34 24.6 14.4, 57.6 37 45.5 17.1, 78.9 
5 65 37.6 13.1, 57.7 32 36.3 12.3, 55.1 33 38.2 16.2, 63.2 
Absolute 
number of 
cells per 
slide 
2 69 559 486, 743 33 565 492, 753 36 540 480, 724 
5 59 624 520, 760 29 585 509, 767 30 628 524, 745 
Total cell 
count 
[x106/ml] 
2 69 0.76 0.40, 1.45 33 0.56 0.34, 1.25 36 0.92 0.52, 1.66 
5 61 0.77 0.50, 0.97 29 0.73 0.56, 0.97 32 0.8 0.37, 1.03 
Total 
viable cells 
[x106/ml] 
2 69 0.39 0.20, 0.81 33 0.24 0.17, 0.65 36 0.46 0.24, 0.96 
5 61 0.38 0.19, 0.61 29 0.42 0.20, 0.62 32 0.37 0.18, 0.62 
Viability 
[%] 
2 69 53.0 44.5, 64.5 33 51.0 43.0, 63.0 36 56.5 46.5, 64.8 
5 61 55.0 40.0, 60.0 29 55.0 36.0, 67.0 32 54.5 42.0, 64.8 
The lower number of samples between visits represents samples discarded due to inadequate 
quality.   
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6.1.2. Sputum cell differential 
6.1.2.1. Neutrophils 
No significant difference was seen in either total neutrophil cell count [mean 
difference 19.2 x104 cells 95% CI -24.2 to 62.6, p=0.38] or the proportion of neutrophils 
[mean difference 3.0% 95% CI -5.9 to 11.8, p=0.50] within the sample when the 
azithromycin group was compared to the placebo group at 12 weeks.  These results 
are detailed in Table 6.2 and Table 6.3 and displayed graphically in Figure 6.1 and 
Figure 6.2. 
Table 6.2: Absolute neutrophil cell count [x104 cells] at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 161.7 113.0 33 149.9 123.3 36 172.5 103.3 
Visit 5 59 151.5 96.1 29 140.7 95.7 30 161.8 96.9 
Δ baseline 
to Visit 5 
 -4.6 98.9  -9.3 93.6  -0.1 105.2 
Mean 
Difference 
[95% CI] 
 
19.2 [-24.2 , 62.6], p=0.38 
 
Table 6.3: Proportion neutrophils [%] at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 36.2 23.4 33 33.1 24.3 36 39.0 22.5 
Visit 5 59 32.7 19.1 29 31.0 19.9 30 34.4 18.6 
Δ baseline 
to Visit 5 
57 -2.4 20.9 28 -2.6 20.0 29 -2.2 22.1 
Mean 
Difference 
[95% CI] 
 
3.0  [-5.9 , 11.8], p=0.50 
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Figure 6.1: Absolute neutrophil count [x104 cells] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.38] 
Mean denoted by crossed-circle and outliers with asterisk. 
 
Figure 6.2: Proportion neutrophils [%] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.50] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.1.2.2. Eosinophils 
No significant difference was seen in either total eosinophil cell count [mean 
difference 1.0 x104 cells 95% CI -0.5 to 2.0, p=0.89] or the proportion of eosinophils 
[mean difference -0.4% 95% CI -1.7 to 1.0, p=0.50] within the sample when the 
azithromycin group was compared to the placebo group at 12 weeks.  These results 
are detailed in Table 6.4 and Table 6.5 and graphically in Figure 6.3 and Figure 6.4. 
Table 6.4: Absolute eosinophil cell count [x104 cells] at baseline and 12 weeks 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 6.0 8.1 33 4.9 6.4 36 6.9 9.3 
Visit 5 59 8.6 17.3 29 6.8 13.9 30 10.3 20.1 
Δ baseline 
to Visit 5 
 3.11 16.5  2.1 12.0  4.1 20.0 
Mean 
Difference 
[95% CI] 
 
1.0 [0.5 , 2.0], p=0.89 
 
Table 6.5: Proportion eosinophils [%] at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 1.4 1.9 33 1.1 1.5 36 1.6 2.3 
Visit 5 59 1.6 3.0 29 1.5 3.1 30 1.6 3.0 
Δ baseline 
to Visit 5 
57 0.3 2.5 28 0.5 2.6 29 0.1 2.4 
Mean 
Difference 
[95% CI] 
 
-0.4  [-1.7 , 1.0], p=0.55 
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Figure 6.3: Absolute eosinophil count [x104 cells] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.89] 
Mean denoted by crossed-circle and outliers with asterisk. 
 
Figure 6.4: Proportion eosinophils [%] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.55] 
Mean denoted by crossed-circle and outliers with asterisk. 
 
 145 
 
 
6.1.2.3. Macrophages 
No significant difference was seen in either total macrophage cell count [mean 
difference -1.2 x104 cells 95%CI -41.2 to 38.8, p =0.95] or the proportion of 
macrophages [mean difference 0.8% 95% CI -7.3 to 9.0, p=0.84] within the sample 
when the azithromycin group was compared to the placebo group at 12 weeks. These 
results are detailed in Table 6.6 and Table 6.7 and displayed graphically in Figure 6.5 
and Figure 6.6. 
Table 6.6: Absolute macrophage cell [x104 cells] count at baseline and 12 weeks 
 
 
Table 6.7: Proportion macrophages [%] at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 47.1 21.5 33 49.7 22.9 36 44.7 20.2 
Visit 5 59 45.6 17.0 29 45.3 18.7 30 45.8 15.5 
Δ baseline 
to Visit 5 
57 -2.0 19.5 28 -3.5 19.8 29 -0.7 19.4 
Mean 
Difference 
[95% CI] 
 
0.8  [-7.3 , 9.0], p=0.84 
 
 
  
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 204.3 94.5 33 211.4 99.6 36 197.7 90.5 
Visit 5 59 196.1 87.2 29 197.1 92.5 30 195 83.3 
Δ baseline 
to Visit 5 
 -11.3 85.1  -13.0 98.0  -9.7 72.1 
Mean 
Difference 
[95% CI] 
 
-1.2 [-41.1 , 38.8], p=0.95 
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Figure 6.5: Absolute macrophage count [x104 cells] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.95] 
Mean denoted by crossed-circle and outliers with asterisk. 
 
Figure 6.6: Proportion macrophages [%] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.84] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.1.2.4. Lymphocytes 
No significant difference was seen in either total lymphocyte cell count [p=1.00] or the 
proportion of lymphocyte [mean difference -0.4% 95% CI -1.8 to 1.0, p=0.55] within 
the sample when the azithromycin group was compared to the placebo group at 12 
weeks.  These results are detailed in Table 6.8 and Table 6.9 and graphically in Figure 
6.7.  The total lymphocyte count was analysed using a non-parametric test of 
association due to the low absolute counts and minimal observed differences.  The 
proportion of percentage lymphocytes has not been displayed graphically due to the 
influence of outliers [compressing the boxplot].  The absolute lymphocyte count is 
displayed in Figure 6.7. 
 
Table 6.8: Absolute lymphocyte count [x104 cells] at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 0.6 0.7 33 0.5 0.4 36 0.7 0.9 
Visit 5 59 0.9 1.0 29 0.9 1.1 30 1.0 1.0 
Δ baseline 
to Visit 5 
 0.3 1.2  0.4 1.1  0.2 1.4 
Mean 
Difference 
[95% CI] 
 
p=1.00 
 
Table 6.9: Proportion lymphocytes [%] at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 1.4 1.9 33 1.1 1.5 36 1.6 2.3 
Visit 5 59 1.6 3 29 1.5 3.1 30 1.6 3.0 
Δ baseline 
to Visit 5 
57 0.3 2.5 28 0.5 2.6 29 0.1 2.4 
Mean 
Difference 
[95% CI] 
 
-0.4  [-1.7 , 1.0], p=0.55 
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Figure 6.7: Absolute lymphocyte count [x104 cells] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=1.00] 
Mean denoted by crossed-circle and outliers with asterisk. 
 
6.1.2.5. Bronchial epithelial cells [BEC’s] 
No significant difference was seen in either total broncho-epithelial cell count [mean 
difference 1.0 x104 cells 95% CI -0.6 to 1.7, p=0.97] or the proportion of broncho-
epithelial cells [BEC’s] [mean difference -8.1% 95% CI -25.5 to 9.3, p=0.35] within the 
sample when the azithromycin group was compared to the placebo group at 12 
weeks.  These results are detailed in Table 6.10 and Table 6.11 and graphically in 
Figure 6.8 and Figure 6.9. 
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Table 6.10: Absolute bronchial epithelial cell count [x104 cells] at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 66.9 65.7 33 67.4 64.4 36 66.4 67.7 
Visit 5 59 85.0 80.9 29 89.3 81.4 30 80.9 81.6 
Δ baseline 
to Visit 5 
 15.6 66.4  20.8 65.4  10.6 68.1 
Mean 
Difference 
[95% CI] 
 
1.0  [0.6 , 1.7], p=0.97 
 
Table 6.11: Proportion bronchial epithelial cells [%] at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 69 15.0 13.8 33 16.2 15.9 36 13.9 11.6 
Visit 5 59 23.4 36.1 29 28.7 47.9 30 18.3 18.5 
Δ baseline 
to Visit 5 
57 8.0 32.4 28 12.3 42.3 29 3.7 18.4 
Mean 
Difference 
[95% CI] 
 
-8.1  [-25.5 , 9.3], p=0.35 
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Figure 6.8: Absolute bronchial epithelial cell count [x104 cells] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.97] 
Mean denoted by crossed-circle and outliers with asterisk. 
Figure 6.9: Proportion bronchial epithelial cells [%] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.35] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.2. Plasma cytokines 
6.2.1. IL-1β 
There was no significant difference in plasma IL-1β in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.49 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in Table 6.12. 
Table 6.12: Change from baseline to 12 weeks in plasma IL-1β [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 9.7 24.4 20 13.7 34.5 20 5.6 0 
Visit 5 40 9.1 21.3 20 12.6 30.1 20 5.6 0 
Δ baseline 
to Visit 5 
39 -0.6 3.2 20 -1.1 4.4 19 0 0 
Test of 
association 
 
p=0.49 
 
6.2.2. IL-2 
There was no significant difference in plasma IL-2 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.16 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in Table 6.13 and graphically in Figure 
6.10. 
Table 6.13: Change from baseline to 12 weeks in plasma IL-2 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 5.3 13.2 20 7.4 18.6 20 3.2 0.8 
Visit 5 40 4.7 9.6 20 6.2 13.5 20 3.3 0.9 
Δ baseline 
to Visit 5 
39 -0.6 3.7 20 -1.2 5.1 19 0.1 0.8 
Test of 
association 
 
p=0.16 
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Figure 6.10: IL-2 [pg/ml] at baseline and 12 weeks 
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Outliers not shown: Baseline Placebo Group 86.10; V5 Placebo Group 63.11 
No significant difference is seen between the treatment groups [p=0.16] 
Mean denoted by crossed-circle. 
6.2.3. IL-4 
There was no significant difference in plasma IL-4 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.39 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in Table 6.14. 
Table 6.14: Change from baseline to 12 weeks in plasma IL-4 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 17.0 54.5 20 25.8 77.1 20 8.2 1.2 
Visit 5 40 15.0 42.1 20 21.7 59.5 20 8.4 1.1 
Δ baseline 
to Visit 5 
39 -2.0 12.6 20 -4.1 17.5 19 0.2 1.4 
Test of 
association 
 
p=0.39 
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6.2.4. IL-5 
There was no significant difference in plasma IL-5 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=1.00 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in Table 6.15 and graphically in Figure 
6.11. 
Table 6.15: Change from baseline to 12 weeks in plasma IL-5 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 0.4 0.7 20 0.5 1.0 20 0.2 0.1 
Visit 5 40 0.3 0.5 20 0.4 0.7 20 0.2 0.1 
Δ baseline 
to Visit 5 
 -0.1 0.4  -0.1 0.5  0.0 0.1 
Test of 
association 
 
p=1.00 
 
Figure 6.11: IL-5 [pg/ml] at baseline and 12 weeks 
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Outliers not shown: Baseline Placebo Group 3.54; 3.07; V5 Placebo Group 1.21 
No significant difference is seen between the treatment groups [p=1.00] 
Mean denoted by crossed-circle. 
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6.2.5. IL-6 
There was no significant difference in plasma IL-6 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.14 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in Table 6.16. 
Table 6.16: Change from baseline to 12 weeks in plasma IL-6 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 22.5 131.6 20 43.0 186.1 20 1.9 3.6 
Visit 5 40 7.1 36.2 20 13.1 51.1 20 1.0 2.1 
Δ baseline 
to Visit 5 
39 -15.9 96.7 20 -29.9 135.1 19 -1.3 4.1 
Test of 
association 
 
p=0.14 
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6.2.6. IL-8 
There was no significant difference in plasma IL-8 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.35 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in Table 6.17 and graphically in Figure 
6.12. 
Table 6.17: Change from baseline to 12 weeks in plasma IL-8 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 39 142.3 403.6 20 213.1 543.8 19 67.7 142.6 
Visit 5 40 151.5 439.7 20 204.7 581.1 20 98.3 230.5 
Δ baseline 
to Visit 5 
 12.5 633.5  -8.4 837.7  35.7 296.6 
Mean 
Difference 
[95% CI] 
 
p=0.35 
 
Figure 6.12: IL-8 [pg/ml] at baseline and 12 weeks 
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Outliers not shown: Baseline Azithromycin – 616; 243; Baseline Placebo – 2162;1314; 328; V5 
Azithromycin – 933; 562; V5 Placebo – 2437; 1138 
No significant difference is seen between the treatment groups [p=0.35] 
Mean denoted by crossed-circle. 
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6.2.7. IL-10 
There was no significant difference in plasma IL-10 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.16 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in Table 6.18 and graphically in Figure 
6.13. 
Table 6.18: Change from baseline to 12 weeks in plasma IL-10 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 38 0.5 0.7 20 0.3 0.2 18 0.6 1.0 
Visit 5 40 0.5 0.4 20 0.4 0.2 20 0.5 0.5 
Δ baseline 
to Visit 5 
37 0.0 0.6 20 0.1 0.1 17 -0.1 0.8 
Test of 
association 
 
p=0.16 
 
Figure 6.13: IL-10 [pg/ml] at baseline and 12 weeks 
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Outliers not shown: Baseline Azithromycin 1.43; 1.03; 0.77; Baseline Placebo 0.77; V5 Azithromycin 
1.03; 1.99; 1.16; 0.9; V5 Placebo 0.90; 0.77; 0.77 
No significant difference is seen between the treatment groups [p=0.16] 
Mean denoted by crossed-circle. 
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6.2.8. TNFα 
There was no significant difference in plasma TNFα in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was non-significant p=0.39 [Pearson’s Chi-
squared test].  Mean [SD] for each and mean change is displayed in Table 6.19 and 
graphically in Figure 6.14. 
Table 6.19: Change from baseline to 12 weeks in plasma TNFα [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 9.1 35.5 20 14.7 50.2 20 3.5 1.1 
Visit 5 40 8.2 29.9 20 12.9 42.3 20 3.5 1.0 
Δ baseline 
to Visit 5 
39 -0.9 5.7 20 -1.8 7.9 19 0.1 0.8 
Test of 
association 
 
p=0.39 
 
Figure 6.14: TNFα [pg/ml]at baseline and 12 weeks 
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Outliers not shown: Baseline Placebo 228.01; 7.12 V5 placebo 192.52 
No significant difference is seen between the treatment groups [p=0.39] 
Mean denoted by crossed-circle. 
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6.2.9. IFNγ 
There was no significant difference in plasma IFNγ in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.25 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in Table 6.20 and graphically in Figure 
6.15. 
Table 6.20: Change from baseline to 12 weeks in plasma IFNγ [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 39 2.0 1.5 20 1.8 0.7 19 2.1 2.0 
Visit 5 40 2.0 1.6 20 1.8 0.5 20 2.3 2.2 
Δ baseline 
to Visit 5 
38 0.0 0.4 20 -0.1 0.4 18 0.1 0.3 
Test of 
association 
 
p=0.25 
 
Figure 6.15: IFNγ [pg/ml] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.25] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.2.10. GM-CSF 
There was no significant difference in plasma GM-CSF in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was non-significant p=0.79 [Fisher’s exact 
test].  Mean [SD] for each and mean change is displayed in Table 6.21.  When outliers 
were removed and the data looked at in detail, the vast majority measures were 1.4 
pg/ml.  Hence, there was little value in showing this graphically.  
Table 6.21: Change from baseline to 12 weeks in plasma GM-CSF [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 39 4.2 11.5 20 2.0 2.7 19 6.5 16.1 
Visit 5 40 1.5 0.3 20 1.5 0.3 20 1.5 0.3 
Δ baseline 
to Visit 5 
38 -2.8 11.7 20 -0.5 2.8 18 -5.3 16.6 
Test of 
association 
 
p=0.79 
 
 
. 
6.2.11. C-reactive protein 
There was no significant difference in plasma CRP in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.08 [Fisher’s exact test].  In 
this instance there was sufficient change to allow for calculation of a mean difference, 
-35.2 ng/ml 95%CI -84.5 to 14.2, p=0.16.  Both statistical methods support this 
difference as not significant.  Mean [SD] for each and mean change is displayed in 
Table 6.22 and graphically in Figure 6.16. 
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Table 6.22: Change from baseline to 12 weeks in plasma CRP [ng/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 148.8 140.4 20 108.3 102.2 20 189.4 163.0 
Visit 5 40 105.0 99.2 20 99.9 90.8 20 110.1 109.2 
Δ baseline 
to Visit 5 
39 -50.0 119.2 20 -8.4 58.5 19 -93.7 149.9 
Mean 
Difference 
[95% CI] 
 
-35.2  [-84.5 , 14.2], p=0.16 
 
 
Figure 6.16: CRP [ng/ml] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.16] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.2.12. MPO 
There was no significant difference in plasma MPO in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.52 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in Table 6.23 and graphically in Figure 
6.17 
Table 6.23: Change from baseline to 12 weeks in plasma MPO [ng/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 1267.0 933.3 20 1178.7 836.0 20 1355.3 1035.7 
Visit 5 40 1379.4 1031.1 20 1464.1 1260.0 20 1294.8 761.3 
Δ baseline 
to Visit 5 
 124 1009.5  285.4 824.23  -46.0 1743.8 
Test of 
association 
 
p=0.52 
 
Figure 6.17: Plasma MPO [ng/ml] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.3. Sputum Cytokines 
6.3.1. IL-1Rα 
There was no significant difference in plasma IL-1Rα in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was non-significant p=0.75 [Fisher’s exact 
test].  Mean [SD] for each and mean change is displayed in Table 6.24 and graphically 
in Figure 6.18. 
Table 6.24: Change from baseline to 12 weeks in sputum supernatant IL-1Rα [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 9466.66 9268.4 21 11479.9 10811.9 19 7241.5 6803.2 
Visit 5 40 8371.1 8964.7 21 9921.7 9814.8 19 6657.2 7822.3 
Δ baseline 
to Visit 5 
 -1095.6 7277.8  -1558.2 8944.0  -584.3 5035.0 
Test of 
association 
 
p=0.75 
 
Figure 6.18: Sputum IL-1Rα [pg/ml] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.75] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.3.2. IL-1β 
There was no significant difference in sputum IL-1β in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was not possible because there were too 
few patients with a change value between visits to allow for formal testing.  Mean 
[SD] for each and mean change is displayed in Table 6.25 but the test of association 
has not been done.  We would therefore regard this assay as having no change as a 
result of the azithromycin. 
Table 6.25: Change from baseline to 12 weeks in sputum supernatant IL-1β [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 1.6 0.7 21 1.7 1.0 19 1.5 0 
Visit 5 40 2.0 2.3 21 2.5 3.2 19 1.5 0 
Δ baseline 
to Visit 5 
40 0.4 1.7 21 0.8 2.3 19 0 0 
Test of 
association 
 
N/D 
 
6.3.3. IL-2 
There was no significant difference in sputum IL-2 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was not possible because there were too few patients 
with a change value between visits to allow for formal testing.  Mean [SD] for each 
and mean change is displayed in Table 6.26 but the test of association has not been 
done.  We would therefore regard this assay as having no change as a result of the 
azithromycin. 
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Table 6.26: Change from baseline to 12 weeks in sputum supernatant IL-2 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 5.9 0 21 5.9 0 19 5.9 0 
Visit 5 40 5.9 0 21 5.9 0 19 5.9 0 
Δ baseline 
to Visit 5 
40 0 0 21 0 0 19 0 0 
Test of 
association 
 
N/D 
 
6.3.4. IL-4 
There was no significant difference in sputum IL-4 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was not possible because there were too few patients 
with a change value between visits to allow for formal testing.  Mean [SD] for each 
and mean change is displayed in Table 6.27 but the test of association has not been 
done.  We would therefore regard this assay as having no change as a result of the 
azithromycin. 
Table 6.27: Change from baseline to 12 weeks in sputum supernatant IL-4 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 19.3 0 21 19.3 0 19 19.3 0 
Visit 5 40 19.3 0 21 19.3 0 19 19.3 0 
Δ baseline 
to Visit 5 
40 0 0 21 0 0 19 0 0 
Test of 
association 
 
N/D 
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6.3.5. IL-5 
There was no significant difference in sputum IL-5 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.62 [Pearson’s Chi-Squared 
Test].  Mean [SD] for each and mean change is displayed in Table 6.28 and 
graphically in Figure 6.19. 
Table 6.28: Change from baseline to 12 weeks in sputum supernatant IL-5 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 0.3 0.2 21 0.3 0.3 19 0.3 0.1 
Visit 5 40 0.3 0.3 21 0.4 0.5 19 0.2 0.1 
Δ baseline 
to Visit 5 
40 0.0 0.4 21 0.1 0.5 19 0.0 0.1 
Test of 
association 
 
p=0.62 
 
Figure 6.19: Sputum supernatant IL-5 [pg/ml] at baseline and 12 weeks. 
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Outliers not shown: Baseline Azithromycin 0.62; Baseline Placebo 1.33; V5 Azithromycin 0.34; 0.45; 
V5 Placebo 2.34; 0.70; 0.43 
No significant difference is seen between the treatment groups [p=0.62] 
Mean denoted by crossed-circle. 
 166 
 
 
6.3.6. IL-6 
There was no significant difference in sputum IL-6 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.14 [Fisher’s exact test].  In 
this instance there was sufficient change to allow for calculation of a mean difference, 
-40.1 95%CI -90.6 to 10.4, p=0.12.  Both statistical methods support this difference as 
not significant.  Mean [SD] for each and mean change is displayed in Table 6.29 and 
graphically in Figure 6.20. 
Table 6.29: Change from baseline to 12 weeks in sputum supernatant IL-6 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 140.9 171.8 21 151.5 220.0 19 129.0 99.6 
Visit 5 40 125.8 131.3 21 151.3 161.0 19 97.7 83.6 
Δ baseline 
to Visit 5 
40 -15.0 103.7 21 -0.3 118.6 19 -31.4 84.3 
Mean 
Difference 
[95% CI] 
 
-40.1  [-90.6 , 10.4], p=0.12 
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Figure 6.20: Sputum supernatant IL-6 [pg/ml] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.12] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.3.7. IL-8 
There was no significant difference in sputum IL- in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.34 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in and graphically in Table 6.30 and 
graphically in Figure 6.21. 
Table 6.30: Change from baseline to 12 weeks in sputum supernatant IL-8 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 18481.9 42434.4 21 24491.5 56067.3 19 11839.7 17886.9 
Visit 5 40 32474.1 72387.6 21 46795.1 85443.2 19 16645.7 52324.3 
Δ baseline 
to Visit 5 
 13992.2 62861.2  22303.6 71555.0  4806.0 51989.9 
Test of 
association 
 
p=0.34 
 
Figure 6.21: Sputum supernatant IL-8 [pg/ml] at baseline and 12 weeks 
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Outliers not shown: Baseline Azithromycin 14441; Baseline Placebo 154800; 232200; V5 
Azithromycin 232200; V5 Placebo 232200; 232200;154800; 77145 
No significant difference is seen between the treatment groups [p=0.34] 
Mean denoted by crossed-circle. 
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6.3.8. IL-10 
There was no significant difference in sputum IL-10 in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was non-significant p=0.92 [Fisher’s exact 
test].  Mean [SD] for each and mean change is displayed in Table 6.31 and graphically 
in Figure 6.22. 
Table 6.31: Change from baseline to 12 weeks in sputum supernatant IL-10 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 1.1 1.8 21 1.3 2.4 19 0.8 0.6 
Visit 5 40 1.4 4.7 21 0.7 0.4 19 2.2 6.9 
Δ baseline 
to Visit 5 
40 0.4 5.0 21 -0.5 2.2 19 1.4 6.9 
Test of 
association 
 
p=0.92 
 
Figure 6.22: Sputum supernatant IL-10 [pg/ml] at baseline and 12 weeks 
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Outliers not shown: Baseline Azithromycin 2.59; Baseline Placebo 11.31; 3.17; V5 Azithromycin 
30.51; V5 Placebo 1.82; 1.53; 1.47; 1.14 
No significant difference is seen between the treatment groups [p=0.92] 
Mean denoted by crossed-circle. 
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6.3.9. TNFα 
There was no significant difference in sputum TNFα in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was not possible because there were too 
few patients with a change value between visits to allow for formal testing.  Mean 
[SD] for each and mean change is displayed in Table 6.32 and graphically in Figure 
6.23 but the test of association has not been done.  We would therefore regard this 
assay as having no change as a result of the azithromycin. 
Table 6.32: Change from baseline to 12 weeks in sputum supernatant TNFα [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 1.3 2.7 21 1.4 3.0 19 1.2 2.3 
Visit 5 40 0.7 1.3 21 1.0 1.8 19 0.4 0.4 
Δ baseline 
to Visit 5 
40 -0.6 2.8 21 -0.4 3.3 19 -0.7 2.3 
Test of 
association 
 
N/D 
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Figure 6.23: Sputum supernatant TNFα [pg/ml] at baseline and 12 weeks 
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Outliers not shown: Baseline Azithromycin 8.92; 5.77; 1.18; 1.18; Baseline Placebo 13.92; 3.84; 2.99; V5 
Azithromycin 2.11; 0.51; 0.51; 0.51; V5 Placebo 8.40; 2.40; 1.80; 1.18 
No significant difference is seen between the treatment groups [p=N/D] 
Mean denoted by crossed-circle. 
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6.3.10. IFNγ 
There was no significant difference in sputum IFNγ in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was non-significant p=0.72 [Pearson’s Chi-
Squared].  Mean [SD] for each and mean change is displayed in Table 6.33 and 
graphically in Figure 6.24. 
Table 6.33: Change from baseline to 12 weeks in sputum supernatant IFNγ [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 0.7 0.9 21 0.8 1.1 19 0.7 0.5 
Visit 5 40 0.7 0.8 21 0.7 1.0 19 0.7 0.5 
Δ baseline 
to Visit 5 
40 0 0.7 21 0.0 0.7 19 0.0 0.6 
Test of 
association 
 
p=0.72 
 
Figure 6.24: Sputum supernatant IFNγ [pg/ml] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.72] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.3.11. GM-CSF 
There was no significant difference in sputum GM-CSF in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was not possible because there were too 
few patients with a change value between visits to allow for formal testing.  Mean 
[SD] for each and mean change is displayed in Table 6.34 but the test of association 
has not been done.  We would therefore regard this assay as having no change as a 
result of the azithromycin. 
Table 6.34: Change from baseline to 12 weeks in sputum supernatant GM-CSF [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 0.2 0.6 21 0.3 0.8 19 0.1 0.1 
Visit 5 40 0.1 0.0 21 0.1 0.0 19 0.1 0.0 
Δ baseline 
to Visit 5 
40 -0.1 0.6 21 -0.2 0.8 19 0.0 0.1 
Test of 
association 
 
N/D 
 
6.3.12. MPO 
There was no significant difference in sputum MPO in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was non-significant p=0.76 [Fisher’s exact 
test].  In this instance there was sufficient change to allow for calculation of a mean 
difference, -255.3 95%CI -2812.3 to 2301.8, p=0.84.  Both statistical methods support 
this difference as not significant.  Mean [SD] for each and mean change is displayed 
in Table 6.35 and graphically in Figure 6.25. 
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Table 6.35: Change from baseline to 12 weeks in sputum supernatant MPO [ng/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 5772.5 4655.7 21 6367.5 5658.1 19 5114.9 3243.9 
Visit 5 40 5276.5 4629.8 21 5724.5 5529.6 19 4781.3 3460.7 
Δ baseline 
to Visit 5 
40 -496.0 4375.1 21 -643.1 5363.3 19 -333.5 3075.6 
Test of 
association 
 
-255.3  [-2812.3 , 2301.8], p=0.84 
 
Figure 6.25: Sputum supernatant MPO [ng/ml] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.84] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.3.13. LTB4 
There was no significant difference in sputum LTB4 in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was non-significant p=0.84 [Fisher’s exact test].  Mean 
[SD] for each and mean change is displayed in Table 6.36 and graphically in Figure 
6.26. 
Table 6.36: Change from baseline to 12 weeks in sputum supernatant LTB4 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 88.0 134.8 21 90.0 132.4 19 85.9 141.1 
Visit 5 40 187.7 883.6 21 322.6 1214.1 19 38.6 95.1 
Δ baseline 
to Visit 5 
40 99.7 846.1 21 232.6 1155.8 19 -47.2 153.3 
Test of 
association 
 
p=0.84 
 
Figure 6.26: Sputum supernatant LTB4 [pg/ml] at baseline and 12 weeks 
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Outliers not shown: V5 Azithromycin 410.72; 116.65; V5 Placebo 5596.66; 445.16; 308.73; 196.65 
No significant difference is seen between the treatment groups [p=0.84] 
Mean denoted by crossed-circle. 
 176 
 
 
6.3.14. ECP 
There was no significant difference in sputum ECP in the azithromycin treated group 
after 12 weeks when compared to placebo.  The test of association between treatment 
group and the selected variable was not possible because there were too few patients 
with a change value between visits to allow for formal testing.  Mean [SD] for each 
and mean change is displayed in Table 6.37 and graphically Figure 6.27 in but the test 
of association has not been done.  We would therefore regard this assay as having no 
change as a result of the azithromycin. 
Table 6.37: Change from baseline to 12 weeks in sputum supernatant ECP [ng/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 334.9 538.7 21 327.2 528.4 19 343.4 564.3 
Visit 5 40 768.0 3532.4 21 1323.1 4849.8 19 154.5 380.3 
Δ baseline 
to Visit 5 
40 433.1 3380.0 21 995.9 4608.6 19 -188.9 613.1 
Test of 
association 
 
N/D 
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Figure 6.27: Sputum supernatant ECP [ng/ml] at baseline and 12 weeks 
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Outliers not shown: Baseline Placebo 1706.20; V5 Azithromycin 1642.90; 507.30; V5 Placebo 22386.00; 
1780.60 
No significant difference is seen between the treatment groups [p=N/D] 
Mean denoted by crossed-circle and. 
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6.3.15. MMP-9 
There was no significant difference in sputum MMP-9 in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was non-significant p=0.75 [Fisher’s exact 
test].  Mean [SD] for each and mean change is displayed in Table 6.38 and graphically 
in Figure 6.28. 
Table 6.38: Change from baseline to 12 weeks in sputum supernatant MMP-9 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 20194.5 6159.3 21 21481.1 6767.6 19 18772.4 5219.5 
Visit 5 40 19156.9 7552.4 21 19617.2 7910.0 19 18648.1 7317.3 
Δ baseline 
to Visit 5 
 -1037.6 7347.4  -1863.8 7351.8  -124.3 7431.9 
Test of 
association 
 
p=0.75 
 
Figure 6.28: Sputum supernatant MMP-9 [pg/ml] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.3.16. MMP-12 
There was no significant difference in sputum MMP-12 in the azithromycin treated 
group after 12 weeks when compared to placebo.  The test of association between 
treatment group and the selected variable was non-significant p=0.52 [Fisher’s exact 
test].  Mean [SD] for each and mean change is displayed in Table 6.39 and graphically 
in Figure 6.29. 
Table 6.39: Change from baseline to 12 weeks in sputum supernatant MMP-12 [pg/ml] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 40 1227.1 459.1 21 1332.1 477.9 19 1111.1 419.3 
Visit 5 40 1124.7 483.5 21 1210.9 565.6 19 1029.5 364.5 
Δ baseline 
to Visit 5 
 -102.4 424.0  -121.2 517.9  -81.6 301.0 
Test of 
association] 
 
p=0.52 
 
Figure 6.29: Sputum supernatant MMP-12 [pg/ml] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.52] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.4. Monocyte response to LPS stimulation 
Blood monocytes from each treatment group were stimulated with LPS, either alone 
or in combination with varying concentrations of dexamethasone [10-6, 10-8 and 10-10 
mmol/L].  Appropriate controls were used.  Cell culture supernatant was then 
collected and assayed for a panel of cytokines.  This was intended not only to 
determine if there was any change in behaviour of these cells but to further examine 
if azithromycin had altered the cells to be respond differently to corticosteroid.  
Samples of each treatment group were assayed similar to above [n=20, each group].  
The full panel of cytokines measured is detailed in Table 6.40. 
Table 6.40: Cytokines measured during monocyte response to LPS 
 
IL-1β 
IL-2 
IL-5 
IL-6 
IL-8 
IL-10 
TNFα 
GM-CSF 
 
Following the assays detailed above there was no evidence of any change in the 
behaviour of the monocytes to stimulation when the two groups were compared.  
Statistical tests of association were performed and no p values were found to be 
below or near 0.05, in any of the test conditions.  The data is extensive, consistently 
negative and was felt of little value to include in any further detail. 
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6.5. Lymphocyte proliferation 
No significant difference was seen in lymphocyte proliferation between baseline and 
12 weeks following treatment with azithromycin.  Lymphocyte proliferation assays 
were carried out with PHA mitogen, and PHA with varying concentrations of 
dexamethasone [10-6, 10-8 and 10-10 mmol/L].  Appropriate controls were used.  This 
would also help in determining if any sensitisation to corticosteroid had developed 
following treatment with azithromycin.  Only the proliferation assays for the control 
group [no stimulation] and PHA alone have been displayed – Table 6.41 and Table 
6.42.  In the control group there was no significant difference in proliferation as 
measured by counts/min/cell of incorporated radioactive tracer [Fishers exact test, 
p=1.00] when the azithromycin group was compared to the placebo group at 12 
weeks.  Similarly there was no change in proliferation between the treatment and 
placebo groups when the cells were stimulated with PHA [Fishers exact test, p=1.00]. 
Table 6.41: Change from baseline to 12 weeks in proliferation [cpm/cell] – control 
 
Variable Total Placebo Azithromycin 
Control n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 14 77.7 35.5 7 67.6 31.3 7 87.9 38.8 
Visit 5 14 77.0 48.8 7 78.4 52.5 7 75.6 48.9 
Δ baseline 
to Visit 5 
 -0.7 69.1  10.8 59.1  -12.3 80.8 
Test of 
association 
 
p=1.00 
Counts/min/cell 
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Table 6.42: Change from baseline to 12 weeks in proliferation [cpm/cell] - PHA alone 
 
Variable Total Placebo Azithromycin 
PHA alone n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 14 6978.2 7956.0 7 10769.7 7898.0 7 3186.7 6420.7 
Visit 5 14 6714.5 12103.7 7 9480.5 16435.2 7 3948.5 5426.8 
Δ baseline 
to Visit 5 
 -263.7 13597.2  -1289.2 17381.0  761.8 9799.4 
Test of 
association 
 
p=1.00 
Counts/min/cell 
In order to assess if there was any influence of the azithromycin in the steroid 
response during stimulation of lymphocytes, an interaction analysis was performed.  
This did not demonstrate any evidence of sensitisation of the lymphocytes by the 
azithromycin and hence there was no measureable change in responsiveness to 
mitogen.  Details of the statistical analysis can be found in Table 6.43. 
Table 6.43: Interaction analysis 
Change from baseline to 12 weeks in lymphocyte proliferation [cpm/cell] with dexamethasone 
concentration 
 
Dose Estimate and 95% CI p-value 
Nothing [control] - 0.52 
Dexamethasone 10-10 7850 [-5880, 21580] 0.25 
Dexamethasone 10-8 7075 [-7006, 21155] 0.31 
Dexamethasone 10-6 821 [-13267, 14908] 0.91 
 
6.6. Exhaled gases 
6.6.1. FENO50 
At 12 weeks, the mean difference in FENO50 for azithromycin compared with placebo 
was statistically no different [mean difference -0.9ppb  95%CI -5.3 to 3.4, p=0.67].  A 
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detailed breakdown of these results can be found in Table 6.44.  Mean [SD] for each 
and mean change is displayed in and graphically in  
Table 6.44: Change from baseline to 12 weeks in Exhaled Nitric Oxide at 50ml/s flow rate [ppb] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 13.5 16.2 38 15.6 21.2 39 11.5 8.9 
Visit 5 71 13.6 15.3 35 16.2 20.1 36 11 7.9 
Δ baseline 
to Visit 5 
71 0.3 9.1 35 0.8 9.4 36 -0.2 9 
Mean 
Difference 
[95% CI] 
 
-0.9  [-5.3 , 3.4], p=0.67 
 
6.6.2. Alveolar Nitric Oxide 
Alveolar nitric oxide concentrations can be derived using multiple methods[235], 
utilising both linear and non-linear methods, both providing slightly differing results.  
No normal ranges are currently available for smokers with asthma and no consensus 
yet exists on which derivation method should be used as both have their advantages.  
For the purposes of our study, we have provided an analysis using both methods.  
The concentration alveolar NO [Calv] increased by a statistically significant amount in 
the azithromycin group when compared to the placebo group, mean difference 
1.3ppb 95% CI 0.3 to 2.3, p=0.01.  This statistical difference was not observed when 
utilising then non-linear method, mean difference 0.7ppb 95% CI -0.86 to 2.26, p=0.38.  
These results are detailed in Table 6.45 and Table 6.46.   
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Table 6.45: Change from baseline to 12 weeks in Alveolar Nitric Oxide [ppb], [linear regression 
method]  
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 62 1.9 1.4 31 2.1 1.6 31 1.7 1.1 
Visit 5 62 2.2 1.4 31 1.7 1.6 31 2.6 1.1 
Δ baseline 
to Visit 5 
53 0.4 1.9 28 -0.2 1.8 25 1.1 1.7 
Mean 
Difference 
[95% CI] 
 
1.3  [0.3 , 2.3], p=0.01 
 
Table 6.46: Change from baseline to 12 weeks in Alveolar Nitric Oxide [ppb], [non-linear regression 
method] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 1.7 2.9 38 1.9 3.0 39 1.5 2.8 
Visit 5 70 1.3 1.4 34 1.2 1.5 36 1.4 1.2 
Δ baseline 
to Visit 5 
70 -0.4 3.3 34 -0.7 3.4 36 -0.1 3.1 
Mean 
Difference 
[95% CI] 
 
0.7  [-0.9 , 2.3], p=0.38 
 
6.6.3. Flux of nitric oxide 
Flux of nitric oxide concentrations can also be derived using multiple methods [235, 
236], utilising both linear [+/- correction] and non-linear methods, all providing 
slightly differing results.  No normal ranges are currently available for smokers with 
asthma and no consensus yet exists on which derivation method should be used.  For 
the purposes of our study, we have provided an analysed using the linear regression 
method with and without correction.  The flux of NO [J’aw] decreased with a tendency 
towards statistical significance when the azithromycin group was compared to the 
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placebo group, mean difference -304.6 pl/s 95% CI -622.1 to 12.8, p=0.06, detailed in 
Table 6.47.  When the analysis was performed using the correction method, the p 
value tended further from significance [p=0.09].  The detailed results have not been 
tabulated as they do not add anything beyond the data in Table 6.47.   
Table 6.47: Change from baseline to 12 weeks in Flux of Nitric Oxide [pl/s], [linear regression 
method] 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 74 714.1 880.8 36 822.9 1159.7 38 611.0 485.8 
Visit 5 66 656.3 895.1 32 855.2 1158.1 34 469.1 493.7 
Δ baseline 
to Visit 5 
 5.04 652.9  164.4 721.9  -140.3 554.5 
Mean 
Difference 
[95% CI] 
 
-304.6 [-622.1 , 12.8], p=0.06 
 
6.7. Inflammatory markers results – summary 
In summary, there was no substantial difference in every measure of inflammation 
measured in sputum and plasma, and whilst there was a measured difference in 
alveolar NO when this was analysed using a separate method, significance was not 
found.  Overall, it is reasonable to say that there was no consistent improvement in 
measures of inflammation following 12 weeks treatment with azithromycin when 
compared to placebo.  It is difficult to account for the changes observed in alveolar 
NO, but having no other supporting improvements leaves this finding isolated and 
difficult to interpret with any certainty. 
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6.8. Correlations 
6.8.1. ACQ, AQLQ and LCQ 
There was no correlation between efficacy on the primary outcome and effect of 
treatment on the change in ACQ, AQLQ or LCQ, Table 6.48.  None of the individual 
AQLQ or individual LCQ domains demonstrated any correlation [data not shown].  
p-values were not calculated but confidence intervals have been provided. 
Table 6.48: Pearson's correlation coefficient for relationship between efficacy on the primary 
outcome and effect of treatment on ACQ, AQLQ and LCQ 
 
Variable 
Number of 
observations 
Pearson’s r Approximate 95% CI 
ACQ 71 -0.14 -0.37, 0.1 
AQLQ 71 -0.01 -0.24, 0.23 
LCQ 71 -0.01 -0.25, 0.23 
 
6.8.2. Methacholine PC20 
There was no correlation between efficacy on the primary outcome and effect of 
treatment on the change in methacholine PC20, Table 6.49.  As before, p-values were 
not calculated but confidence intervals have been provided. 
 
Table 6.49: Pearson's correlation coefficient for relationship between efficacy on the primary 
outcome and effect of treatment on Methacholine PC20 [mg/ml] 
 
Variable 
Number of 
observations 
Pearson’s r Approximate 95% CI 
Methacholine PC20 61 -0.15 -0.39, 0.11 
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6.8.3. Percentage Cell Counts 
There was no correlation between efficacy on the primary outcome and effect of 
treatment on the change in percentage neutrophils, eosinophils and macrophages, 
Table 6.50.  As before, p-values were not calculated but confidence intervals have 
been provided. 
Table 6.50: Pearson's correlation coefficient for relationship between efficacy on the primary 
outcome and effect of treatment on percentage cell counts 
 
Variable 
Number of 
observations 
Pearson’s r Approximate 95% CI 
Change in % 
Neutrophils 
57 0.03 -0.2 
Change in % 
Eosinophils 
57 -0.06 -0.3, 0.2 
Change in % 
Macrophages 
57 -0.08 -0.3, 0.2 
 
6.9. Correlations summary 
No correlation was seen between the primary endpoint and various indices of asthma 
control and markers of airway inflammation.  Multiple other comparisons were 
derived but none of these were found to have any correlation, data not shown.  In the 
interests of brevity only a selection of relevant measures were detailed.   
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6.10. Bacteriology & Virology 
6.10.1. Bacterial Colony Counts 
Bacterial culture and colony counts were performed on every subject who provided 
sputum plugs with sufficient volume.  Culture and colony counts were performed on 
a total of 55 subjects at baseline [placebo n=26; azithromycin n=29] and 52 subjects at 
12 weeks [placebo n=24; azithromycin n=28].  Only subjects with results before and 
after treatment could be analysed for comparison and this is detailed in Table 6.51.  
There were very few positive cultures and colony counts provided data that changed 
very little from baseline to 12 weeks between the two groups.  Therefore Fisher’s 
exact test of association was performed and found to be non-significant, p=0.33.  This 
suggests that treatment was not associated with any change in bacterial colony 
counts. 
Table 6.51: Changes in bacterial colony counts from baseline to 12 weeks 
 
Variable n Decreasing No change Increasing 
Placebo 22 7 [31.8%] 11 [50%] 4 [18.2%] 
Azithromycin 25 9 [36%] 14 [56%] 2 [8%] 
Fishers exact test of association   p=0.33 
 
6.10.2. Serological measurements 
6.10.2.1. Mycoplasma antibody status 
Of the 71 subjects who completed the study all had serum tested at baseline and 12 
weeks for the presence of antibodies to M pneumonia.  All subjects [n=77, 100%] tested 
negative for these antibodies at baseline.  Of the subjects who completed the study 
[n=71] none tested positive.  Two subjects [one in each group] had equivocal results.  
This was not significant [p=0.98].  The results are summarised in Table 6.52.  In 
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support of these findings, no subject tested positive for M pneumonia by PCR of 
sputum. 
Table 6.52: Mycoplasma antibody status at baseline and 12 weeks 
 
Parameter Total[n=71] Placebo[n=35] Oral Azithromycin [n=36] 
Negative to Positive 0  [0%] 0  [0%] 0  [0%] 
Equivocal to Positive 0  [0%] 0  [0%] 0  [0%] 
Negative to Equivocal 2  [2.8%] 1  [2.9%] 1  [2.8%] 
No change 69  [97.2%] 34  [97.1%] 35  [97.2%] 
Equivocal to Negative 0  [0%] 0  [0%] 0  [0%] 
Positive to Equivocal 0  [0%] 0  [0%] 0  [0%] 
Positive to Negative 0  [0%] 0  [0%] 0  [0%] 
Treatment effect estimate for Oral Azithromycin – 
Placebo [95%CI] 1.0  [0.1 , 16.2] p=0.98 
 
6.10.2.2. Chlamydia antibody status 
In chlamydial infection the subject first develops mucosal IgA and then subsequently 
IgG.  Infection is confirmed if both are present when tested or when IgG is present in 
high concentrations.  At baseline none of the 77 randomised subjects were positive for 
either IgG.  Three subjects tested positive for IgA but by 12 weeks, none of the 71 
subjects who completed the study tested positive for IgG and the same number tested 
positive to IgA.  IgG testing is detailed in Table 6.53. This was deemed non-significant 
[p=0.96] for C. pneumonia IgG.  Formal assessment of C. pneumonia IgA could not be 
undertaken as there were too few change values, Table 6.54.  This result should be 
regarded as non-significant. Sputum PCR testing was also performed and was 
negative amongst all subjects at baseline and 12 weeks.   
  
 190 
 
 
Table 6.53: Chlamydia pneumoniae antibody status [IgG] at baseline and 12 weeks 
 
Parameter Total [n=61] Placebo [n=30] Oral Azithromycin [n=31] 
Negative to Positive 0  [0%] 0  [0%] 0  [0%] 
Equivocal to Positive 0  [0%] 0  [0%] 0  [0%] 
Negative to Equivocal 2  [3.3%] 1  [3.5%] 1  [3.2%] 
No change 56  [93.3%] 27  [93.1%] 29  [93.6%] 
Equivocal to Negative 2  [3.3%] 1  [3.5%] 1  [3.2%] 
Positive to Equivocal 0  [0%] 0  [0%] 0  [0%] 
Positive to Negative 0  [0%] 0  [0%] 0  [0%] 
Treatment effect estimate for Oral Azithromycin – 
Placebo [95%CI] 0.9  [0.1 , 15.6] p=0.96 
 
Table 6.54: Chlamydia pneumoniae antibody status [IgA] at baseline and 12 weeks 
 
Parameter Total [n=71] Placebo [n=35] Oral Azithromycin [n=36] 
Negative to Positive 0  [0%] 0  [0%] 0  [0%] 
Equivocal to Positive 0  [0%] 0  [0%] 0  [0%] 
Negative to Equivocal 2  [2.8%] 0  [0%] 2  [5.6%] 
No change 68  [95.8%] 34  [97.1%] 34  [94.4%] 
Equivocal to Negative 1  [1.4%] 1  [2.9%] 0  [0%] 
Positive to Equivocal 0  [0%] 0  [0%] 0  [0%] 
Positive to Negative 0  [0%] 0  [0%] 0  [0%] 
Treatment effect estimate for Oral Azithromycin – 
Placebo  N/D 
 
6.10.2.3. Virological PCR status 
No formal analysis was undertaken for these results due to the very low numbers of 
positivity found during the study.  PCR was performed on a panel of upper airway 
respiratory viruses and also M. pneumoniae.  The panel of viruses tested can be found 
in Table 6.55. 
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Table 6.55: Panel for upper airway respiratory PCR analysis 
 
Influenza A and B 
Adenovirus 
Respiratory Syncytial Virus 
Parainfluenza 1, 2, 3 and 4 
Rhinovirus 
Metapneumovirus 
C pneumoniae 
M pneumoniae 
 
Of the 77 randomised patients only 5 subjects produced a positive result.  All of these 
results were for rhinovirus, and only one patient produced a positive result at both 
baseline and 12 weeks [both rhinovirus].   
6.10.3. Summary of bacteriology and virology results. 
Bacterial colony counts did not demonstrate any treatment difference between the 
placebo and azithromycin groups.  Whilst unique organisms could be cultured in 
some individual subjects, resistance assays were not undertaken.  PCR for M. 
pneumoniae and C. pneumoniae were all negative at both baseline and 12 weeks.  This 
was supported by there being no substantial difference in serological positivity for 
both these organisms as measured by IgA and IgG for C. pneumonia, and IgM, M. 
pneumonia.  The only positive result from viral screening was for rhinovirus, which 
was found in 6 sputum samples across 5 subjects, 1 subject was positive at baseline 
and 12 weeks. 
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6.11. Haematological outcomes  
6.11.1. Haemoglobin concentration 
Unexpectedly, following 12 weeks of treatment there was found to be a reduction in 
the mean haemoglobin concentration in the treatment group, by a small but 
statistically significant amount, mean difference -0.4g/dl 95%CI -0.8 to -0.1, p=0.02. 
Detailed results are displayed in Table 6.56 and are displayed graphically in Figure 
6.30.  This still falls within the normal range expected for an adult of male is 13 to 18 
and adult female 11.5 to 16.5. 
Table 6.56: Haemoglobin concentration [g/dl] at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 14.6 1.3 38 14.6 1.3 39 14.5 1.3 
Visit 5 71 14.5 1.3 35 14.7 1.3 36 14.3 1.3 
Δ baseline 
to Visit 5 
 0.0 0.8  0.2 0.7  -0.2 0.9 
Mean 
Difference 
[95% CI] 
 
-0.4  [-0.8 , -0.1], p=0.02 
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Figure 6.30: Haemoglobin concentration [g/dl] at 12 weeks 
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No significant difference is seen between the treatment groups [p=0.02] 
Mean denoted by crossed-circle and outliers with asterisk. 
6.11.2. Platelet count 
No effect was seen in either mean [SD] platelet count following 12 weeks treatment 
with azithromycin.  The mean difference in was -6.06 x109/L [95%CI -19.88 to 7.77], 
p=0.38.  The details of these measurements are displayed in Table 6.57, with a 
graphical summary of the datasets in Figure 6.31.  The normal range for platelet 
concentration is 150 to 400 x109/L 
Table 6.57: Platelet count [x109/L ]at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 266.9 57.8 38 261.7 55.3 39 271.9 60.4 
Visit 5 71 267.0 58.6 35 267.7 51.9 36 266.3 65.2 
Δ baseline 
to Visit 5 
 -3.0 29.7  0.3 27.1  -6.3 32.0 
Mean 
Difference 
[95% CI] 
 
-6.1  [-19.9 , 7.8], p=0.39 
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Figure 6.31: Platelet concentration [x109/L] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.39] 
Mean denoted by crossed-circle and outliers with asterisk. 
 
6.11.3. White cell count 
No effect was seen in either mean [SD] platelet count following 12 weeks treatment 
with azithromycin.  The mean difference in was 0.15 x109/L [95%CI -0.66 to 0.96], 
p=0.71.  The details of these measurements are displayed in Table 6.58, with a 
graphical summary of the datasets in Figure 6.32.  The normal range for total white 
cell count is 4 to 11 x109/L. 
Table 6.58: Total white cell count [x109/L] at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 9.1 2.4 38 9.0 2.2 39 9.2 2.5 
Visit 5 71 8.2 2.0 35 8.1 1.9 36 8.3 2.2 
Δ baseline 
to Visit 5 
 -0.96 2.1  -1.0 2.1  -0.9 2.2 
Mean 
Difference 
[95% CI] 
 
0.2  [-0.7 , 1.0], p=0.71 
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Figure 6.32: Total WCC [x109/L] at baseline and 12 weeks 
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6.11.4. Biochemical outcomes 
6.11.5. Electrolytes and Creatinine 
Serum electrolytes were measured at baseline and 12 weeks with none of them 
demonstrating any substantial difference when the azithromycin was compared to 
placebo.  In the interests of succinctness only the mean differences have been 
summarised and can be found in Table 6.59. 
Table 6.59: Summary mean differences for serum biochemistry following 12 weeks treatment 
 
Parameter Mean difference 95% CI Significance 
Sodium 0.2 -0.6 , 1.0 p=0.59 
Potassium 0.0 -0.1 , 0.2 p=0.70 
Chloride -0.2 -1.2 , 0.8 p=0.68 
Creatinine -0.5 -3.5 , 2.6 p=0.76 
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6.11.6. Liver function tests 
6.11.6.1. Aspartate aminotransferase 
There was no substantial difference in the level of serum aspartate aminotransferase 
following 12 weeks treatment with azithromycin when compared to placebo.  The 
mean difference was 2.2 U/L 95%CI -1.9 to 6.3, p=0.28.  The normal range was 
anything below 40 U/L.  Detailed results can be found in Table 6.60 with a graphical 
representation of the data set displayed in Figure 6.33. 
Table 6.60: Serum AST [U/L] concentration at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 21.3 6.5 38 21.8 5.9 39 20.7 7.1 
Visit 5 69 21.3 10.3 34 20.2 8.2 35 22.4 12.0 
Δ baseline 
to Visit 5 
 -0.4 8.5  -1.6 6.6  0.7 10.0 
Mean 
Difference 
[95% CI] 
 
2.2  [-1.9 , 6.3], p=0.28 
 
Figure 6.33: Serum AST [U/L] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.28] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.11.6.2. Alanine aminotransferase 
There was no substantial difference in the level of serum alanine aminotransferase 
following 12 weeks treatment with azithromycin when compared to placebo.  The 
mean difference was 1.39 U/L 95%CI -2.67 to 5.45, p=0.50.  The normal range was 
anything below 50 U/L.  Detailed results can be found in Table 6.61 with a graphical 
representation of the data set displayed in Figure 6.34. 
Table 6.61: Serum ALT [U/L] concentration at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 23.3 11.61 38 24.87 11.46 39 21.77 11.71 
Visit 5 70 23.53 12.38 35 23.51 12.65 35 23.54 12.28 
Δ baseline 
to Visit 5 
 -0.61 8.74  -1.49 10.75  0.26 6.16 
Mean 
Difference 
[95% CI] 
 
1.39  [-2.67 , 5.45], p=0.50 
 
Figure 6.34: Serum ALT [U/L] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.50] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.11.6.3. Serum Alkaline phosphatase 
There was no substantial difference in the level of serum alkaline phosphatase 
following 12 weeks treatment with azithromycin when compared to placebo.  The 
mean difference was 2.68 U/L 95%CI -2.46 to 7.83, p=0.30.  The normal range was 
anything below 40 to 150U/L.  Detailed results can be found in Table 6.62 with a 
graphical representation of the data set displayed in Figure 6.35. 
Table 6.62: Serum Alkaline Phosphatase [U/L] concentration at baseline and 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 77.36 24.82 38 78.11 23.35 39 76.64 26.46 
Visit 5 70 77.64 21.22 35 76.97 20.21 35 78.31 22.47 
Δ baseline 
to Visit 5 
 -1.27 12.65  -2.86 8.58  0.31 15.67 
Mean 
Difference 
[95% CI] 
 
2.68  [-2.46 , 7.83], p=0.30 
 
Figure 6.35: Serum Alkaline Phosphatase [U/L] at baseline and 12 weeks 
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No significant difference is seen between the treatment groups [p=0.30] 
Mean denoted by crossed-circle and outliers with asterisk. 
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6.11.7. Electrocardiography 
An electrocardiogram was recorded at baseline then again at the final study visit.  
Subjects were screen failed if the corrected-QT-interval was greater than 430ms in 
men or 450ms in women.  There was no substantial change in the mean corrected-QT-
interval between the azithromycin and placebo group following 12 weeks of 
treatment.  The mean difference was 2.8ms 95%CI -5.08 to 10.68, p=0.48.  The results 
are detailed in Table 6.63, and depicted graphically in Figure 6.36. 
Table 6.63: Change in QTc interval [ms] from baseline to 12 weeks 
 
Variable Total Placebo Azithromycin 
 n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
n Mean Standard 
Deviation 
Baseline 77 417.01 15.09 38 415.95 14.75 39 418.05 15.55 
Visit 5 69 420.72 18.86 34 419.12 18.3 35 422.29 19.53 
Δ baseline 
to Visit 5 
 3.38 17.05  2.06 19.65  4.66 14.25 
Mean 
Difference 
[95% CI] 
 
2.8 [-5.08 , 10.68], p=0.48 
 
Figure 6.36: QTc Interval [ms] measured at baseline and 12 weeks  
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No significant difference is seen between the treatment groups [p=0.48] 
Mean denoted by crossed-circle and outliers with asterisk. 
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When the raw data is reviewed a total of 5 patients had prolongation of QTc, 4 in the 
azithromycin group and 1 in the placebo.  In the treatment group 3 of these subjects 
had only slight prolongation of the QTc of <10ms above the upper limit of normal 
[ULN].  One subject in each group had QTc prolongation of >20ms above ULN.  Only 
3 people had QTc intervals above 450ms [all were female]. 
7. Regulatory reporting 
7.1. Patients who did not complete the trial 
7.1.1. Loss to follow up 
Four patients were lost to follow-up after randomisation.  Two subjects did not attend 
any further visits following randomisation with another subject attending only at the 
four week visit and the remaining subject attending at 8 weeks before non-
attendance.  Contact was attempted by telephone in all cases and messages left on 
several occasions to encourage attendance.  One subject did re-contact the unit but 
this was out-with the timeframe for completion of all their study visits and they could 
not be incorporated back in to the trial.  When made aware of this they informed the 
study team that they would not re-attend for a safety visit and returned all of the 
study materials by mail.   
7.1.2. Patient withdrawals 
Only one patient withdrew consent following randomisation.  This was due in part to 
a relapse of alcohol abuse [reported as an SAE] and the patient deciding that 
treatment of the addiction took precedence and they could no longer commit to daily 
PEF monitoring, compliance with medication or attendance for study visits.   
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One patient was withdrawn due to an unrelated ailment requiring the prescription of 
a long-term antibiotic.  This was an exclusion criterion for the study and it was felt 
treatment of the condition [hidradenitis suppurativa] should not be deferred.   
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7.2. Adverse events 
No suspected unexpected serious adverse events [SUSARS] occurred during the 
reporting period of the study.  There were more adverse events in the azithromycin 
group [52 events occurring in 34 subjects] than the placebo group [events in 23 
subjects], and hence a single subject may account for multiple AE’s.  The breakdown 
of adverse events, [excluding asthma related and SAE’s can be found in Table 7.1].  
Four serious adverse events occurred – 3 during the study and 1 three weeks after the 
final visit.  All 4 were in the azithromycin group.  One was constipation, the second 
angina, and the third a relapse of alcoholism.  The fatal SAE was recorded as 
myocardial infarction and occurred in a patient with known coronary artery disease, 
several cardiovascular risk factors and under regular cardiology follow-up.  The 
event occurred three weeks after completion of the trial medication.  The study team 
were not made aware of this until several months had passed and they were 
informed by a family member attending the unit for a different study.  Despite the 
delay in the study team becoming aware of the death, an SAE was reported within 
the regulatory timeframe.  The study protocol stated that AE’s and SAE’s required 
reporting up to 4 weeks following completion of study medication.  Hence this event 
was reported as an SAE.  There was no evidence to suggest this was an asthma 
related death or a death related to any adverse drug effect. 
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Table 7.1: Unique adverse events excluding asthma related and serious adverse events 
 
Event type Placebo Azithromycin 
Alcohol related 0 2 
Ankle swelling 0 1 
Assault 0 1 
Back pain 6 2 
Cellulitis 1 3 
Common cold 1 5 
Conjunctivitis 0 1 
Constipation 0 1 
Cough 1 1 
Dental related 2 0 
Dermatitis 2 1 
Diarrhoea 3 4 
Dyspepsia 1 1 
Epistaxis 0 1 
Gastroenteritis 0 7 
Haemorrhoids 2 0 
Headache 1 2 
Hypothyroidism 1 0 
Increasing breathlessness 0 1 
Knee pain 0 2 
Leg cramps 0 1 
Malaise 2 1 
Non-specific viral illness 2 0 
Oral candidiasis 1 1 
Otitis/vertigo 7 0 
Psychiatric related 2 4 
Recurrence of herpes virus 0 1 
Respiratory tract infection 5 5 
Sinus infection 2 0 
Urinary Tract Infection 1 0 
Vomiting 0 2 
Total number of adverse events 42 52 
 
QTc was recorded in every patient as an entrance criterion and again at 8 and 12 
weeks as a safety measure.  There was no significant difference between the two 
groups at 12 weeks and in particular was not abnormally prolonged in the subject 
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who died.  Of the 3 adverse events during the study only one [relapse of alcoholism] 
led to withdrawal from the study.  Gastrointestinal upset was uncommon with only 7 
reported events, 5 in the azithromycin group and 2 in the placebo. Only 2 subjects 
reported diarrhoea in the azithromycin group. 
7.2.1. Exacerbations rates 
Recording the frequency of exacerbation in the randomised patients helps provide us 
with a crude impression of any difference between the treatment groups.  In this 
study we recorded exacerbation severity as mild, moderate or severe based on the 
criteria discussed in section 4.3.3, Table 4.4, p107.  Across both groups there were 
exacerbations throughout the study, reassuringly none were severe.  There were an 
apparent higher number of exacerbations in the azithromycin group 12 [30.8%] 
subjects vs. 3 [7.9%] subjects in the placebo group.  The study was not powered to 
assess differences in exacerbation frequency, but when the available data is analysed 
using Fisher’s exact test there is no difference between the two groups or their 
severity of exacerbations, p=1.00].  The results for exacerbations can be found in Table 
7.2. 
Table 7.2: Severity of asthma exacerbations by treatment group 
 
Asthma exacerbation 
category 
Total [n=77] Placebo [n=38] Azithromycin [n=39] 
Mild 10 [13.0%] 2 [5.3%] 8 [20.5%] 
Moderate 5 [6.5%] 1 [2.6%] 4 [10.3%] 
Severe Nil Nil Nil 
Total for all categories 15 [19.5%] 3 [7.9%] 12 [30.8%] 
 
7.2.2. Asthma related adverse events 
In addition to the recording of exacerbation frequency, other asthma related adverse 
events were also captured at each study visit.  These included GP attendance 
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[unscheduled or home visit], A&E visit or hospital admission and treatment with oral 
steroids.  There were only 3 asthma related events in total, all in the azithromycin 
group.  Although this was never formally tested, it probably did not represent any 
statistically significant difference between the two groups.  The results can be found 
in Table 7.3. 
Table 7.3: Asthma related adverse events 
 
 Total [n=77] Placebo [n=38] Azithromycin [n=39] 
Oral steroid treatment 0 0 0 
Unscheduled GP 
appointment 
3 [3.9%] 0 3 [7.7%] 
GP home visit 0 0 0 
A&E visit 0 0 0 
Hospital admission 0 0 0 
Total asthma related 
adverse events 
3 [3.9%] 0 3 [7.7%] 
 
7.2.3. Possible drug related adverse events 
The frequency of possible drug related adverse events were low with a total of 3 
[7.9%] in the placebo group and 6 [15.4%] in the azithromycin group.  The summary 
product characteristics of azithromycin report GI related side effects as the most 
common side effect found in approximately 1:10 patient treatments, this would 
include diarrhoea.  Constipation is expected less frequently and is rarely seen, 
although there were 2 reports of this in the treatment group.  The details of the 
reported possible drug related adverse effects can be found in Table 7.4. 
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Table 7.4: Possible adverse drug reactions 
 
Event Placebo n=38 
Number of events [% total] 
Azithromycin n=39 
Number of events [%total] 
Any adverse event 3 [7.9%] 6 [15.4%] 
Constipation 0 2 [5.1%] 
Diarrhoea 0 2 [5.1%] 
Oral candidiasis  1 [2.6%] 
Fatigue 1 [2.6%] 0 
Back pain 1 [2.6%] 0 
Cough 0 1 [2.6%] 
Sore throat 1 [2.6%] 0 
 
7.2.3.1. Haemoglobin concentration 
Unexpectedly the haemoglobin concentration was found to have dropped in the 
treatment group.  The cause for this was not clear.  Azithromycin is not a drug 
recognised to cause alterations in the haemoglobin concentration.  Three factors need 
to be considered in the interpretation of this drop. 
Firstly, the drop was very small, only 0.4g/dl.  Most automated analysers have will 
measure with a standard deviation of 0.4, which could considerably influence this 
result and hence it may not have fallen to a level that would be considered 
statistically significant.  It could be argued therefore that the result is within the 
laboratory error of the assay and is not clinically significant. 
Secondly, the drop as well as being small is still well within the normal range for both 
men and women and so would cause no physical symptoms in the study subjects. 
Finally, in a study such as this, the result could simply be due to multiple testing. 
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Overall, whilst a statistically significant result was detected this is irrelevant due to 
the possibility of the confounding factors detailed above and hence the finding 
should be dismissed. 
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8. Discussion 
8.1. Principal findings 
This randomised controlled study examined the effects on lung function asthma 
control, airway inflammation and bacterial colonisation of azithromycin 250mg daily 
with matched placebo in adult smokers with asthma.  The hypothesis was that 
azithromycin improves lung function, asthma control and airway inflammation in 
smokers with asthma.  We found that azithromycin has no effect after 12 weeks 
treatment in a range of clinical indices, markers of inflammation or bacterial 
colonisation in smokers with chronic asthma.  Immunological investigation did not 
demonstrate any changes which could be satisfactorily attributable to treatment with 
azithromycin.   
8.1.1. Clinical effects 
The lack of any clinical benefits of azithromycin in smokers with asthma cannot be 
compared with any other study.  This was the first study utilising azithromycin, or 
any macrolide antibiotic, in smokers with asthma.  It provides clear evidence that 12 
weeks of azithromycin provides no benefit in smokers with asthma.  Our study 
extends the findings by Albert et al [146] in COPD where current smokers did not 
derive any benefit in exacerbation frequency [primary outcome] when given 
azithromycin daily for one year.   
8.1.1.1. Effects on lung function 
The study presented here clearly demonstrates that 12 weeks treatment with 250mg 
azithromycin makes no difference to any of the lung function parameters measured 
in our patient group.  There was no statistical difference in the primary outcome 
measure; PEF or any of the secondary outcomes of FEV1 or FVC.  In addition, all of 
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the derived measures e.g. % predicted or response to nebulised salbutamol was 
unchanged.  Multiple studies of macrolides in asthma have been performed, and to 
date only one of these has demonstrated improvement in lung function[154].  Whilst 
this improvement was deemed statistically significant it was interpreted that the 
improvement of 3% had no clinical significance.  Therefore our study remained 
consistent with the published literature.  
Airways responsiveness measured by methacholine PC20 was unchanged in this 
study.  This is different from many of the previously published findings in non-
smoking asthmatics which demonstrate consistent evidence that macrolides, when 
given to non-smoking asthmatics have beneficial effects on bronchial hyper-
responsiveness [156, 159, 160, 237].  No clear explanation can be given to account for 
the lack of response to treatment in our study and this is explored further in section 
8.6.1. 
8.1.1.2. Effects on symptom scores 
Symptom scores were recorded in the patient diary and at clinic visits.  The validated 
diary card recorded a modified ACQ.  At each clinic visit the ACQ was recorded 
separately and at visits 2 and 5 two quality of life questionnaires, the LCQ and AQLQ 
were also recorded.  Following the 12 week treatment period, none of the recorded 
questionnaires demonstrated any improvement.  When the AQLQ and LCQ were 
broken down in to their individual domains, it was only the LCQ-psychological 
domain that demonstrated any change of statistical significance.  This was an adverse 
change, with the true relevance unlikely to reflect any possibility that treating 
patients with azithromycin caused any deterioration in this measure.  It could simply 
be explained by multiple testing leading to a significant result.   
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Only one study with azithromycin has demonstrated an improvement in AQLQ 
[238], but this was in non-smokers with asthma and required 6 months treatment.  
Other measures such as ACQ and EuroQOL 5D did not demonstrate any 
improvements[238] and so it is difficult to draw any firm conclusions of improvement 
following treatment.  The published literature of clinical studies utilising other 
macrolides has failed to demonstrate any consistent improvements in patient 
reported symptom or quality of life scores.  There is only one recent study by 
Koutsoubari et al [157] where there was clear evidence of improved symptom scores.  
The criticism of this study is that it was open-label and hence open to bias.   
8.1.2. Effects on inflammatory outcomes 
8.1.2.1. Serum measurements 
8.1.2.1.1. Serum cytokine measurement 
A wide-ranging panel of serum biomarkers were measured at baseline and 12 weeks.  
None of these demonstrated any statistically significant difference following 12 weeks 
treatment with azithromycin.  We were uncertain if any serum biomarker response 
would be observed but from previous in-vitro work we would have expected to see 
some response in cytokine production[239].  There are a number of reports of 
macrolides affecting in-vitro analysis of cytokine production; one demonstrating up-
regulation of IL-10 when dendritic cells are stimulated with LPS following pre-
incubation with azithromycin [240], and another demonstrating reduced production 
of the pro-inflammatory cytokines IL-1β and TNFα by macrophages, following pre-
incubation with azithromycin and subsequent stimulation with LPS [183].  In ex-vivo 
studies of CD4+ T-helper cells, [from asthmatic children] incubation of the cells with 
azithromycin led to a decreased production of IL-5 following stimulation [192].  The 
only study looking directly at serum levels ex-vivo following treatment with 
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azithromycin was in normal volunteers demonstrated a reduction in serum IL-6 [188].  
Taken together, we might have expected to find minor some changes in cytokine 
concentration; at least in IL-6 in the current study.  This was not the case, but the 
current study differs from those above.  We obtained serum samples directly from 
subjects treated with azithromycin, and hence our samples give a more representative 
illustration of the response to treatment.  We measured in-vivo production and 
response of cytokines in relation to treatment with oral azithromycin.  There was no 
signal response, and this was consistent with the lack of any other clinical effects. 
The hs-CRP measurement demonstrated a reduction of 93.7 ng/ml [SD 149.9] in the 
treatment group with the placebo group only having a reduction of 8.4 ng/ml [SD 
58.5].  The mean difference and subsequent statistical analysis found this change to 
have a p=0.16.  This is approaching statistical significance.  Using this as pilot data, a 
power calculation can be performed [using G Power 3.1.7, Franz Faul, Universität 
Kiel, Germany].  A sample size of 33 in each group will have 80% power to detect a 
difference-in-means of 35.2 ng/ml in the C-reactive protein concentration [CRP], 
assuming a standard deviation of changes of 120 pg/ml, using a two sample t-test 
with a 0.050 two-sided significance level.  More than 33 subjects in each group 
completed the trial.  Resource implications prevented the purchase of kits to analyse 
all the serum specimens, and it is possible this result may have reached statistical 
significance.  CRP is a non-specific marker of inflammation and is frequently elevated 
in bacterial infection.  It is entirely possible that this was a real finding related to the 
anti-microbial activity of azithromycin.  The low sample size means this result needs 
to be interpreted with caution. 
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8.1.2.1.2. Blood differential cell counts 
There was no published literature [pre-study] to suggest an alteration in blood 
differential cell counts following treatment with azithromycin.  Only the data for the 
total white cell and platelet count were presented, with no other differential cell 
absolute counts or relative proportions demonstrating any change following 12 weeks 
treatment. 
8.1.2.2. Sputum measurements 
8.1.2.2.1. Cellular response 
There is much evidence to support the likelihood of changes to sputum differential 
cell count following treatment with azithromycin based on studies in murine models 
[182, 191, 241, 242].  These demonstrated a reduction in a number of inflammatory 
cell types, and non-asthma inflammation models [145, 243] demonstrating consistent 
evidence of a reduction in BAL fluid neutrophilia.  This was also observed in 
experimental asthma models [160].  We expected therefore to see some alterations in 
the inflammatory cell differential counts from induced sputum, but this was not 
observed.  We had a dataset comprising 59 of the 77 randomised subjects providing 
sputum specimens at baseline and at trial completion.  The study was not powered 
for changes in induced sputum cell counts but with these numbers, there was 
convincing statistical evidence that azithromycin does not alter the inflammatory cell 
profile of induced sputum in smokers with asthma following 12 weeks treatment.  
The apparent lack of response could be accounted for by the potent inflammatory 
stimulus introduced by active cigarette smoking.  The study controlled for evidence 
of active infection – either viral or bacterial and there was no evidence of any change 
in this at baseline or 12 weeks.  There were no obvious external factors accounting for 
the lack of sputum cytology response. 
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8.1.2.2.2. Sputum mediator response 
A similar panel of sputum mediators [cf serum] were assayed taking in to account 
previous experience of mediators expected to be below detection threshold in sputum 
fluid.  Again there is a sufficient evidence from animal work [182, 191, 240, 241], other 
airways disease [145, 244] and in asthma related studies [192]  to expect changes in 
concentration of soluble mediators when azithromycin is administered.  Sputum 
mediator profiles and concentrations, in particular chemokines will indirectly reflect 
the overall inflammatory cell infiltrate, for example sputum fluid IL-8 was found to 
correlate with sputum neutrophilia [145].  In keeping with the lack of change 
observed in induced sputum differential cell counts, the administration of 
azithromycin was not associated with any significant change in concentrations of any 
of the sputum mediators measured.  This lack of cytokine response to azithromycin 
appears similar to that detailed above for sputum inflammatory cells.  There were a 
few minor limiting factors. Firstly, only 20 of the available samples in each treatment 
group were assayed as a pilot study, and although the data was statistically 
convincing it was still possible that measuring all the samples may have changed the 
statistical analysis.  This number of sputum fluids were analysed due to funding 
constraints for the purchase of assay kits.  Secondly, the mediator analysis was a 
secondary endpoint and the study was not powered for changes in sputum cytokine 
levels.   
8.2. Summary of background to study 
Macrolides have anti-inflammatory properties both in vitro [185], in experimental 
animal models [241] and in non-smokers with asthma, that demonstrate they can 
restore corticosteroid sensitivity in vitro and ex vivo [192] and can improve asthma 
control in non-smokers with asthma [154, 159, 160].  We proposed that the anti-
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inflammatory effects of macrolides demonstrated in these models could also be 
achieved in smokers with asthma, a major subgroup that are currently undertreated.  
Several licensed drugs and new drugs under development might be of benefit for 
these patients [117], but none have yet been evaluated specifically in smokers with 
asthma. This group of patients is often excluded from clinical trials, especially studies 
involving new therapies. The clinical trial presented here was to determine whether 
macrolide treatment can improve asthma control of smokers with asthma. The long-
term goal of this research was to improve the quality of life of smokers with asthma.  
8.3. Comparison with other clinical studies of macrolides in asthma 
Comparing the findings from this current study with the literature is difficult.  Other 
studies with azithromycin have demonstrated no or mixed responses.  Our study 
supports the findings of Strunk et al [158] where no benefit was found.  Other 
investigators have demonstrated improvements in symptom scores [161] or other 
measures of asthma control such as bronchial hyper-responsiveness [159, 160].  
Whilst the above studies have statistically significant outcomes, the clinical evidence 
is weak – the study by Hahn et al [161] did not find any improvement in AQLQ and 
the reported positive outcome used was in an unvalidated symptom score.  The 
studies by Ekici [159] and Piacientini [160] were both in small studies n=11 and n=16 
respectively.  Our study was of a longer duration than the above three studies and 
used a daily dose of azithromycin [250mg], giving a greater accumulated treatment 
dose, and to a larger group of participants [n=71].  A recent study [n=109] with 
azithromycin [250mg thrice weekly] given for 6 months to never or ex-smokers with 
frequent exacerbations of asthma did not demonstrate any statistically significant 
differences in the primary endpoint – exacerbation frequency [163].  A subgroup 
analysis was performed on patients with non-eosinophilic asthma and found a 
statistically significant lower rate of exacerbations [163].  Aside from this, the study 
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did not demonstrate any benefits in measures of lung function, quality of life scores 
or asthma control when comparing treatment to placebo.   
Our findings were consistent with those in a large [n=1142] study by Albert et al[146] 
in patients with COPD demonstrating no clinical benefits of azithromycin in current 
smokers.  Our study extends the current evidence that azithromycin should not be 
given to current smokers with asthma.   
Reviewing the wider use of macrolides in asthma most studies have used 
clarithromycin with a few using roxithromycin.  The most consistent and 
reproducible finding has been improvement in bronchial hyper-responsiveness [154, 
156, 237, 245].  The azithromycin-related studies detailed above also demonstrated 
improvements in bronchial hyper-responsiveness.   
Sputum and serum cytokine concentrations were measured in the current study and 
have been measured in others.  Clarithromycin has been shown to reduce sputum 
and blood eosinophil counts  [237] as well as sputum cytokine levels [153, 237] as has 
roxithromycin[245].  The presented study found no significant reduction in either 
sputum cell counts or sputum or serum cytokine levels.  Administration of 
clarithromycin was associated with an improvement in the dose response of 
lymphocytes to dexamethasone in-vitro [169] and clinically, reduced the steroid dose 
requirement in steroid dependant asthma [152].  Our study also looked at 
lymphocyte proliferation responses in-vitro and found no change in the inhibitory 
effects of exogenous dexamethasone after azithromycin.  No other study utilising 
azithromycin has looked specifically at this effect.  Our study group was 
representative of those previously found to have corticosteroid insensitivity [117] and 
the in-vitro assays were intended to identify if steroid sensitivity had been restored.  
There was no statistical evidence for change in steroid sensitivity [Table 6.43].  
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Only two studies have demonstrated an improvement in FEV1 following treatment, 
both using clarithromycin[154, 155], one of which [Kostadima et al], although 
demonstrating statistical significance, did not correspond to a clinically significant 
improvement.   
Measures of asthma control or quality of life have been variably studied using 
different macrolides.  The findings lack any consistency with contradictory outcomes 
between studies of clarithromycin [152, 153, 157] and within studies of azithromycin 
[161, 163].  Our study found no improvements in any of the symptom score or quality 
of life outcomes.   
8.4. Pre-study hypothesised mechanism of action of macrolides in 
smokers with asthma 
Current evidence has suggested a number of mechanisms whereby macrolide 
antibiotics may exert their anti-inflammatory effects [55].  The laboratory assays for 
the present clinical study were chosen prospectively to identify potential 
mechanisms.  The lack of any clinical efficacy means there is no mechanism of action 
per se, but this does not exclude the possibility that azithromycin may have had some 
effect on biomarkers, for example, in sputum differential cell counts; cytokine 
expression in serum or sputum; inflammatory cell behaviour; or exhaled gases 
without any measurable effects in any clinical outcomes.   
In summary, there were no changes in any of the laboratory biomarker outcomes.  
Whilst there was an isolated statistical change in airway wall flux of NO [Jaw] and in 
the concentration alveolar NO [Calv], the former was an adverse change.  These 
conflicting findings suggest that no firm conclusion can be made on the effect of 
azithromycin on airway inflammation in asthma as assessed by extended flow 
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measurements of nitric oxide.  This is unlikely to be reflective of any effect by the 
study drug and may just be a chance finding. 
Macrolides may have corticosteroid-sparing effects, first shown with troleandomycin, 
but the use of this macrolide has been limited due to adverse effects [203].  
Corticosteroid-sparing efficacy is limited to case reports [204] and small open-label 
pilot studies [169], which demonstrate improvement in laboratory biomarkers, for 
example there was an enhanced sensitivity of lymphocyte proliferations to 
suppression by dexamethasone in-vitro. Although macrolide antibiotics are inhibitors 
of CYP3A4 [133] and can increase the plasma concentration of CYP3A4 substrates, 
which include fluticasone and budesonide, this mechanism is unlikely to contribute 
to the localised therapeutic effects of inhaled corticosteroids on the airways of 
patients given macrolides. 
Smokers with COPD have decreased histone deacetylase-2 [HDAC2] activity in 
alveolar macrophages, and this may lead to increased inflammatory gene expression 
and reduced sensitivity to corticosteroids [205] and a similar mechanism may occur in 
smokers with asthma [170].  Erythromycin can increase HDAC2 levels in vitro [171], 
suggesting a mechanism by which macrolides therapy may restore corticosteroid 
sensitivity and improve asthma control in smokers with asthma.  
The functional effect of azithromycin on cytokine production has been assessed by 
many investigators.  What is clear is that macrolides as a family can alter the 
production of cytokines both in-vivo and in-vitro.  Azithromycin has many anti-
inflammatory effects [188] including down-regulation of production of pro-
inflammatory mediators e.g. prostaglandin E2, nitric oxide and cytokines TNF-α, IL-
8, IL-1β, growth-related oncogene [GRO]-α and soluble vascular cell adhesion 
molecule [sVCAM]-1. Many of these are chemotactic, activation and survival factors 
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for neutrophils.  IL-1 is sufficient to induce neutrophil accumulation in the lung 
[189], GM-CSF is a neutrophil survival factor [190], and both are derived from 
macrophage and airway epithelial cells and are central to the homeostatic response to 
airway infectious inflammation [186]. In a murine model of LPS-induced pulmonary 
neutrophilia, azithromycin or clarithromycin were able to reduce airway neutrophilia 
with striking reductions of IL-1 and GM-CSF [191].  In a murine CF cell model 
azithromycin reduced production of IL-1β, CCL2 and TNFα [183] in harvested 
alveolar macrophages in-vitro. 
Clarithromycin, when given to subjects with refractory asthma, was associated with a 
significant reduction in airway IL-8 levels and neutrophil numbers [153].  Subgroup 
analysis showed that airway IL-8 protein and gene expression was predominantly 
reduced in the non-eosinophilic asthmatic patients.  Similarly, azithromycin reduced 
airway IL-8-mRNA in patients with post-transplant bronchiolitis obliterans syndrome 
[BOS] following 3 months treatment [145].  In a mouse model of allergic asthma pre-
treatment with azithromycin led to attenuation of IL-5 and IL-13 production in 
response to allergen in BAL fluid, and also reduction in the chemokines CCL2, CCL3 
and CCL4 [241].  These studies were replicated in patients.  TH2 lymphocytes from 
blood samples from from asthmatic children, when treated with azithromycin and 
then stimulated in-vitro, demonstrated a reduction in the production of IL-5 
compared to untreated cells [192].  Putative mechanisms of clarithromycin function 
suggest altered DNA binding activity of the transcription factors NF-kB and AP-
1[185, 194], causing inhibition of synthesis and/or secretion of these   pro-
inflammatory cytokines [55]. 
Cellular changes in response to treatment with macrolides have also been observed.  
Azithromycin causes increased phagocytosis by alveolar macrophages of apoptotic 
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bronchial epithelial cells and neutrophils in patients with COPD [246].  Classically-
activated macrophage [M1] phenotypes, induced by stimulation with interferon 
[IFN]γ and bacterial lipopolysaccharide [LPS] are associated with microbicidal and 
cytotoxic function, and pro-inflammatory cytokine production [37].  Alternatively-
activated [M2] phenotypes induced by IL-4/13 are associated with Th2-type, 
immunosuppressive and remodelling responses. Azithromycin reduced the 
production of pro-inflammatory IL-1β, and tumour necrosis factor [TNF]α in mouse 
M1 macrophages [183] and polarised cells towards M2, with  reduced pro-
inflammatory IL-12 and IL-6, and increased anti-inflammatory IL-10 [184].   
A component of macrolide anti-inflammatory activity may be a consequence of the 
reduction in bacterial load afforded by the antibiotic effects [176] distinct from its 
anti-inflammatory activity [133].  This concept may be valid when macrolides are 
given to patients with Mycoplasma or Chlamydia infection, but does not explain why 
submicrobicidal concentrations of azithromycin can attenuate the production of IL-8 
and GM-CSF from bronchial epithelial cells in response to LPS [247].  Again, the 
concept of reducing bacterial burden falters when azithromycin is given to patients 
with CF who are chronically colonised by P. aeruginosa [248];  macrolides do not have 
significant anti-pseudomonal activity, and so the improvement in inflammation 
cannot be attributed to an antibacterial effect. 
8.5. Generic issues relevant to clinical trials 
8.5.1. General issues in proof of concept studies 
Proof of concept studies are used in a variety of ways to answer research questions 
[249] including feasibility, safety or drug efficacy in the present study.  Other 
considerations need to be reviewed before a proof of concept study can be performed, 
including:  
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 process – recruitment and retention rates;  
 resources – assessing time and resource problems 
 management – challenges of the participating centres in managing the study   
This study was intended to answer a scientific question.  This was accomplished and 
in order to do this we had to overcome problems in the process, resource and 
management.   
Recruitment is a common problem in clinical studies, and this was observed here.  
This was successfully addressed [discussed in section 8.5.3], but doing so required 
additional resources in terms of staff numbers, availability and training, and an 
extension to the study.  This challenge was also met with success, partly by utilising 
the assistance of GP colleagues to contact GP practices and patients directly, but also 
in the opening of a second recruitment site.  This required additional management in 
order to ensure adequate training at the second site, the appropriate availability of 
resources [equipment and office space] and the correct maintenance of regulatory 
paperwork.  Other unexpected delays were also encountered – the manufacturer of 
the IMP initially offered placebo with an 8 month shelf life and although this was 
finally resolved once the medication did arrive it was embargoed due to poor and 
damaged labelling.  These delays led to a change in the plan for analyses of the 
laboratory specimens.  It had been my intention to complete all the clinical work in 
the first 2 years and spend the third year analysing the stored plasma and sputum 
specimens.  Unfortunately due to the delays detailed above, the majority of the third 
year was spent on patient visits and data collection, with less time available for bench 
work.  The difficulties faced with recruitment have been detailed further in Appendix 
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8 and formed the basis for the writing of a manuscript looking at the patient flow in 
three studies performed at the Asthma Research Unit [250, 251] 
The study is of considerable scientific importance.  There is an unmet need for 
treatment in a group of patients where the current mainstay treatment; 
corticosteroids lacks efficacy and azithromycin represents a strong candidate drug 
[based on sound scientific evidence] that might confer benefit by restoring scientific 
sensitivity.  This was a small study by comparison to large Phase III investigations. 
As such any findings need to be balanced by careful interpretation of methods by 
which it was conducted, and hence the presumed validity of its findings.  We 
recruited a very well defined cohort which was well balanced in baseline 
characteristics of placebo and active groups.  The study design was a randomised, 
placebo controlled, double blind study gives additional confidence in the results.  The 
appropriate regulatory, safety requirements and reporting were followed and our 
sponsor monitored the study closely to ensure compliance. 
Whilst there is a considerable burden of administration in running a clinical trial it is 
strictly necessary to ensure both patient safety and scientific integrity. 
8.5.2. Regulatory issues: pre-study problems 
The introduction of the EU clinical trial directive in 2005 had wide ranging impacts 
on the performance of clinical trials and research within the UK almost as soon as it 
was introduced[252, 253].  Of concern is the long term impact on academic research 
within the UK.  Observational evidence has found there to be a 5.3% average annual 
diminution of clinical drug trials in the UK, with the decrease being caused by a 
decline in academic trial activities[254].  The layers of bureaucracy have increased 
and are now significant burdens to researchers.  This and an over-riding fear that 
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even minor breach of the regulations could lead to site closure or even the order to 
cease all research related activities by the sponsor cause significant anxiety and 
inhibition from pursuing innovative research.  Every stage of the current study was 
delayed due to the requirements and time required to obtain approvals from the 
MHRA, ethics and sponsor.  In particular there is no difference in the sponsor 
monitoring requirements between low or high risk studies.  Our study utilised an 
already licensed medicinal product with almost 20 years post marketing safety 
surveillance, yet there was no proportionality to the risk assessment or the delay this 
incurred. 
The clinical trial directive is now about to undergo its first major revision since its 
introduction[255] and clearly we would hope that any changes will be beneficial to 
hypothesis testing studies such as the one presented here. 
8.5.3. Generic recruitment issues 
As with many clinical studies, recruitment of randomised subjects proved extremely 
challenging.  A number of problems were encountered.  Following the delays in 
ethical and R&D approval, the next difficulty to overcome was recruitment of GP 
practices to allow patient searches to be performed.  Reasons to decline participation 
included workload, lack of remuneration, and scepticism over the scientific merit of 
the study or implications for practice should it prove positive.  The patient responses 
rate based on our experience of previous studies was felt to be acceptable, but 
unfortunately these potential subjects were not readily converted in to randomised 
patients.  Previous studies had a randomisation rate of far in excess of ours, with over 
1 in 2 of those screened being randomised [251].  At the time of our recruitment this 
had dropped to just above 1 in 3 [Figure 5.1].  Our rate of recruitment and the targets 
required are displayed in Figure 8.1.  Patients were generally very keen to be 
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involved and only a small number refused consent at the initial study visit.  The 
problem in randomisation rate was recognised early and several steps were taken to 
remediate this: 
 The protocol was changed to allow patients to remain on combination inhaler 
and reduce the requirement to wean and reduce the likelihood of loss of 
control during the run-in period 
 A second site was opened 
 Additional support was made available to telephone and book suitable 
patients for screening 
The protocol amendment to change the run in medication and open the second site 
required a further application to ethics, R&D and the MHRA for approval.  Again 
there was delay in each of these steps.  Whilst changing the study run-in medication 
led to a significant increase in the randomised patients, opening a second site did not.  
Nevertheless all these efforts had the desired effect and the randomisation target was 
achieved and hence the study became adequately powered. 
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Figure 8.1: Cumulative recruitment by month during the study 
 
 
8.6. Strengths and limitations of the study 
8.6.1. Factors potentially contributing to lack of clinical efficacy 
8.6.1.1. Patient population 
A Canadian cross-sectional population study of asthma prevalence and severity 
reported that 78.9% of patients could be described as having mild to moderate 
asthma [256] according to the Canadian Asthma Consensus guidelines, which 
compares well to the patients recruited to the current study.  This is therefore an 
appropriate patient group to study.  If milder patients are treated with combination 
inhalers and additional leukotriene receptor antagonists then findings in this group 
will become less generalizable to the wider asthma clinical population.   
Baseline measures of our study group demonstrated that they had relatively mild 
asthma with FEV1 >75% predicted and low measures of airway inflammation [PC20 
<2.22mg/ml with mean percentage eosinophils of 1.38% in induced sputum cytology].  
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These are important features in patients recruited to this type of trial as clinical 
stability is essential during the run-in period and is required to ensure progress 
through to randomisation.  Screening a more severe patient group could have limited 
the recruitment further and excluded them from the study.  All of our patients 
remained symptomatic as evidenced by the baseline mean ACQ of 1.74 when 
grouping all subjects together.  This allowed the opportunity to improve the asthma 
control in our group. 
Smokers with asthma tend to represent a population of asthmatics with an airway 
neutrophilia.  Evidence suggests that airways with neutrophilic inflammation have a 
better response to azithromycin [145] but unfortunately our population was neither 
neutrophilic or eosinophilic [6.1.2].  Severe asthmatics tend to be neutrophilic and the 
failure to identify a positive response to azithromycin in the present study could be 
due to our asthma study population being clinically too mild to identify a signal.   
8.6.1.2. Macrolide used 
Azithromycin is a derived compound of erythromycin[133] and its prolonged half-life 
of 40 hours allows it a convenient once daily dosing regimen.  Antibiotic efficacy of 
the various macrolides and spectrum of activity are subtly different but in terms of 
antimicrobial efficacy there are no direct comparison studies between different 
macrolides.  The anti-inflammatory properties of macrolides have never been directly 
compared in efficacy studies and probably never will.  The initial studies in 
obliterative bronchiolitis utilised erythromycin, but this has now been replaced by 
azithromycin with no reported decrement in survival [257].  Hence our choice of 
macrolide was based the convenience of administration and safety profile.  
Azithromycin benefits by not having the propensity for GI side effects of 
erythromycin and also lacks the significant interactions of either erythromycin or 
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clarithromycin.  Despite the beneficial interaction profile, large numbers of 
prospective subjects were not invited for screening visits at the point of telephone 
pre-screening because of the presence of interacting medications.   
8.6.1.3. Dose 
We administered a dose of 250mg once daily azithromycin.  This is based on the 
available published evidence in asthma related studies and studies in other airway 
disease.  The majority of other studies utilised intermittent dosing – twice or thrice 
weekly of azithromycin.  This was common in studies of post-transplant bronchiolitis 
obliterans syndrome where 250mg was give three times per week [144, 258].  Studies 
in cystic fibrosis used weight dependant dosing of 250 or 500 mg daily [137] or three 
times per week [259].  Similar regimens have been used in non-CF bronchiectasis with 
500mg administered twice weekly[139].   
Asthma related studies have utilised azithromycin in an even wider dosing interval, 
with positive outcomes.  The study by Hahn et al administered 600mg thrice weekly 
for the first week then at weekly intervals[161].  Other azithromycin-asthma studies 
have administered 250mg twice weekly[159] or 10mg/kg in children for 3 consecutive 
days per week over an 8 week period[160]. 
The pharmacological properties of azithromycin lend it to an intermittent dosing 
regimen.  It has a half-life of 40 hours and accumulates within the cytoplasm of 
inflammatory cells, having high tissue concentrations relative to serum[133].  It was 
therefore appropriate for us to use a dose of 250mg.  Daily dosing allowed the 
subjects to follow a regular routine and hence improved compliance.  We 
hypothesised that 250mg once-daily would be an adequate dose to generate a 
positive response in our subjects.  Higher doses [500mg] have been used and it is 
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possible that repeating our study with this increased dose may lead to a positive 
response.   
8.6.1.4. Duration of treatment 
The duration of the study drug treatment was 12 weeks.  Treatment regimens in 
similar studies of 6-16 weeks with clarithromycin [152, 153, 155] have been used with 
success in non-smoking asthmatics.  Longer treatment durations have been used in 
studies where the primary endpoint is improvement in exacerbation frequency [138, 
146] or in post-transplant BOS where the endpoint is reduced evidence of disease 
progression.  Within the cohort of patients with BOS, the response was noted after 12 
weeks treatment[258].  Very short treatments have been used in acute-asthma studies 
of 10 days[164, 169] and 3 weeks[157].  This evidence suggests that shorter durations 
of treatment of 6-8 weeks are adequate to obtain positive outcomes in asthma studies 
with azithromycin [159-161].  It was therefore appropriate for us to choose a 12 week 
treatment duration.  We were utilising daily dosing, which many studies did not, and 
hence we believed this would be sufficient to produce a response in our patient 
group.  Our study, although negative, was performed using a dose and duration of 
treatment of known efficacy in other airway diseases.  The negative response is 
unlikely to be due to inadequate dosing [we demonstrated compliance >95%] or 
treatment length. 
8.6.1.5. Outcome measures 
8.6.1.5.1. Efficacy 
Only two outcome measures demonstrated a statistically significant difference 
following 12 weeks of treatment with azithromycin.   
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The LCQ when divided in to its individual domains found the psychological domain 
to deteriorate over the 12 weeks.  When the domains were combined the total-LCQ 
score had dropped almost reaching a statistically significant difference p=0.06.  The 
absolute difference was -1.06.  If this had dropped further and reached significance it 
would still have been well within the minimal clinical important difference of 2.56, 
therefore any deterioration observed within this study would have had no clinical 
significance.   
Measurements of alveolar nitric oxide [Calv] demonstrated an increase which was 
statistically significant p=0.01, with airway wall flux of nitric oxide [Jaw] 
demonstrating an increase with a trend towards statistical significance, p=0.06.  These 
results need interpreted with caution.  The Calv concentration demonstrated a small 
but statistically significant increase when calculated using linear-regression but when 
calculated using a non-linear-regression method, the same measurements did not 
produce a statistically significant result, p=0.38 [see section 6.6.2].  The clinical 
interpretation of these derived measurements has not been validated and hence 
normal ranges for of Calv and Jaw have not been defined in non-smokers or smokers 
with asthma.  It is difficult therefore to determine a minimal important difference.  It 
is unlikely that these changes represented any change to underlying airway 
inflammation. 
8.6.1.5.2. Immunological outcomes 
The immunological measurements showed uniformly no significant effect of 
azithromycin treatment.  None of the serum or sputum biomarkers demonstrated any 
change.  This is consistent with the negative clinical and physiological findings of the 
study.  We measured a large panel of pro-inflammatory and anti-inflammatory 
cytokines as well as sputum cytology and blood monocyte and lymphocyte activity 
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and airway wall inflammation.  Funding for the biomarker aspect of the study limited 
the measurements within our study group to 20 in each treatment arm for the soluble 
biomarkers, although almost an entire dataset was available for the inflammatory 
sputum cell counts.  It was anticipated that measuring this pragmatic sample sub-
group would give representative results for the entire group.  The study was not 
powered for changes in inflammatory endpoints but it was felt that sample 
measurement would at least provide pilot data for future power analysis. 
8.6.1.5.3. Exacerbations 
Reporting of exacerbation frequency is given as an annualised rate and hence studies 
to assess this tend to be of much longer duration e.g. 6-12 months[130, 238, 260-262].  
The present study comprised a treatment period of 12 weeks.  This is insufficient to 
accurately comment on any change in exacerbation frequency.  Whilst exacerbations 
were recorded as part of the adverse event reporting requirements this was not 
analysed to assess any change.  To do so would require a study of several hundred to 
several thousand patients, with considerable resource implications.  Other studies 
have looked at exacerbation rates in non-smokers with asthma[238] and found no 
improvement in the treatment group with azithromycin.  This was a small study 
n=109 and did not provide any supporting evidence for their sample size calculation 
and hence the possibility exists, the sample was too small to detect any difference at 
6-months.  We are therefore unable to provide any more comment than to say there 
was no difference in exacerbation rates between the two groups in our study, p=1.00.   
8.6.1.6. Power of the study 
The original power calculations indicated a sample size of 68 would give an 80% 
power to detect a difference in means of 25L/min in peak expiratory flow [PEF] 
[primary endpoint], assuming a standard deviation of  36L/min, using a two sample 
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t-test with a 0.050 two-sided significance level[129].  We planned to recruit a total of 
80 subjects, with the final number being 77.  This ensured that we met the 
requirement of at least 68 subjects completing [71 completed].  Fewer patients 
provided sputum samples thus limiting the potential of the trial to find significant 
differences between the groups.  Secondary and exploratory endpoints were intended  
as “exploratory and hypothesis generating”, rather than definitive. 
8.6.1.7. Compliance 
Drug compliance across the two groups was greater than 90%.  Unfortunately there is 
no readily available method to corroborate medicine use as in the case of statins 
where the lipid profile will alter and can be easily measured in a hospital 
biochemistry lab.  To establish compliance we simply asked patients to record drug 
consumption on a daily basis in their diary card and confirmed this with tablet 
counts.  Overall compliance was probably helped by the azithromycin being well 
tolerated. 
8.7. Patient Safety 
Oral erythromycin prolongs cardiac repolarisation and is associated with case reports 
of torsades de pointes.  A large retrospective epidemiological study reported that the 
risk of sudden death from cardiac causes among patients currently using 
erythromycin was twice as high as those not using any antibiotic and the adjusted 
rate of sudden death from cardiac causes was five times as high among those who 
concurrently used CYP3A inhibitors along with erythromycin [263], although this 
adverse effects is rare [55].  Recent work has also identified the possibility that 
azithromycin may also lead to an increase in cardiovascular death [264];  this study 
was a retrospective observational study and it could not be confirmed that there is a 
causal link between the azithromycin and increase in mortality.  However there is 
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good evidence of survival benefit in prescribing macrolides in severe community 
acquired pneumonia [265], and this appears to contradict the findings of Ray et al 
[264].   
Our study had one cardiovascular death, but this occurred three weeks after the last 
dose of IMP.  History of cardiovascular disease was not a direct exclusion to the 
study, but past history of atrial or ventricular tachyarrhythmia was.  Subjects had to 
have a normal QTc for entry criterion and therefore we selected a study population 
that may have been less likely to develop cardiovascular complications, furthermore 
there was no statistical difference in QTc following 12 weeks of treatment.  Whilst 
these concerns may be valid it does not explain why patients with severe community 
acquired pneumonia have an overall survival advantage when placed on macrolides.  
The study presented here was never designed to test safety but we can say that the 
study drug did not lead to any increase in QTc and hence our study patients should 
not have been at any greater risk of arrhythmias or possible adverse cardiovascular 
events.  This is supported in a longer duration study [6-months] where no adverse 
cardiovascular events were reported[238].   
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8.8. Implications for future research 
8.8.1. Conclusions & future directions 
This randomized controlled study tested the hypothesis that azithromycin when 
added to regular inhaled corticosteroids could improve lung function, asthma 
control, airways inflammation and bacterial colonization in adult smokers with 
asthma.  We found that there were no clinically important changes in both the 
primary endpoint, morning PEF, and in a range of clinical indices of current asthma 
control and measures of airway inflammation after 12 weeks of treatment.  This is the 
first study to test the efficacy of the macrolide antibiotic azithromycin in smokers 
with asthma.  Smokers with asthma are an understudied population of patients that 
do not respond well to steroids.  These current medications are being used on the 
basis of limited evidence because there has been general exclusion of smokers from 
RCT’s.  The randomised controlled study presented here provides clear evidence that 
the macrolide antibiotic azithromycin administered daily at a dose of 250mg confers 
no additional benefit over usual therapy. 
8.8.2. Overview of alternative treatment management of smokers with 
asthma 
The evidence for the effectiveness of smoking cessation in smokers with asthma is 
rather limited[266-268].  When smokers are monitored during the quitting process 
there are improvements in asthma control and lung function at 6 weeks[268].  These 
subjects were not monitored for long enough to determine if there was a recovery of 
airway sensitivity to corticosteroids, however longer periods of cessation [>1yr] in a 
separate study appears to confer a degree of restoration of corticosteroid 
sensitivity[43].  There is evidence that smoking cessation is associated with a 
reduction in airway inflammation; with lower sputum neutrophil counts 6 weeks 
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after smoking cessation compared with smokers with asthma[268].  Every effort 
should be made to encourage and support smokers in their attempts to quit.  To this 
end patients should be offered drug-treatment such as nicotine replacement therapy, 
nicotine receptor antagonist varenicline or the antidepressant buproprion[269].   
Inhaled β2 adrenoreceptor agonists have a central role in the management of asthma 
but currently there are no studies that have specifically examined the effect of 
cigarette smoking on the β2 adrenoreceptor and its behaviour and expression in vivo 
in the context of asthma.  With the development of newer ultra-long acting β2 
agonists such as indacaterol, there now exists the possibility to examine the effects of 
this newer drug class in smokers with asthma.  The current license for this drug is 
currently only for COPD in the UK.  Studies are underway for its use in asthma 
[NCT00529529, NCT01609478] but these all exclude current smokers.   
There is ample clinical evidence for a reduced therapeutic response to inhaled 
corticosteroids in smokers with asthma [270] but this may not apply to all smokers 
with asthma [271].  In addition administration of inhaled corticosteroid for a long 
duration might have beneficial effects on the rate of decline in lung function[272] that 
is not apparent in heavy smokers [272].  In all likelihood, in the knowledge that 
current smokers with asthma have more severe symptoms and following 
international guidelines, it would be more common to see patients placed on 
combination inhalers.   
Combination therapy with an inhaled corticosteroid and LABA is central to the 
management of chronic asthma [2].  A post hoc analysis of data collected from the 
GOAL trial looking specifically at smokers with asthma found reduced exacerbation 
rates with combination therapy compared to ICS [inhaled fluticasone] alone[273].  
However the level of control was still inferior to that achieved by never smokers with 
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asthma using the same combination.  This has been supported by a prospective study 
comparing the combination inhaled therapy of salmeterol/fluticasone versus a double 
dose of the fluticasone component in smokers with asthma.  The group on 
combination therapy had significant reductions in airway hyper-responsiveness and 
improved airway calibre[274].  Taken together it could be suggested that 
international guidelines should include specific guidance on smokers with asthma 
being treated with combination inhalers earlier as well as advising on smoking 
cessation. 
Leukotriene receptor antagonists [LTRA] are currently included in guideline 
recommendations for patients not controlled on regular inhaled therapies[2].  An 
initial proof-of-concept study utilising the LTRA montelukast found there to be an 
increase morning PEF in smokers with mild asthma but not in non-smokers with 
mild asthma [275].  This observation was extended by the findings of another larger 
study looking specifically at smokers with asthma where treatment with montelukast 
led to increased asthma control [276];  so far, this study has only been reported in 
abstract form. 
The once daily selective anti-muscarinic tiotropium has become well established in its 
use for COPD since the publication of the UPLIFT trial[277].  At present, no trials 
have been carried out in smoking subjects with asthma, although one study has been 
performed in subjects with features of both asthma and COPD.  This demonstrated 
that tiotropium improved in lung function and reduced reliever use [278].  
Unfortunately this study did not report the response in current smokers 
[approximately 40-45% of the randomised subjects] compared with ex-smokers.  The 
high proportion of current smokers and the fact that there was a positive 
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improvement suggests that there may be a response in this patient group.  Further 
investigation is clearly warranted to clarify this in smokers with asthma. 
Theophylline is currently recommended as an add-in therapy in subjects with asthma 
who are not controlled on regular inhaler therapy [2], with the exact mechanism 
being poorly understood and current smoking leads to enhanced clearance of 
theophylline due to induction of CYP1A2.  The standard dose is thought to act 
principally as a bronchodilator through cyclic AMP phosphodiesterases [279].  
Theophylline has a number of immunomodulatory properties that include a 
reduction in the proliferative response of lymphocytes to mitogens, a reduced IL-5 
mediated eosinophils survival and eosinophilic cationic protein production and an 
increase in IL-10 by peripheral blood mononuclear cells[280].  Specific studies have 
been performed in smokers with asthma and this is detailed in Section 8.8.5.   
Omalizumab is a monoclonal anti-IgE immunoglobulin and has demonstrated 
efficacy in improving asthma control and reducing the frequency of exacerbations in 
allergic asthma[132, 281].  Unfortunately these major studies excluded current 
smokers and ex-smokers.  Of note, smokers tend to have a reduced responses to 
common allergens, with evidence of a reduction in Th2 responses[282].  Nevertheless 
elevated serum total IgE in this group suggests a role for anti-IgE therapy.  Due to the 
cost implications of treatment it would be highly beneficial to have sound 
investigational evidence looking specifically at the effect of omalizumab in smokers 
with asthma. 
8.8.3. Non-smokers with asthma 
There is now a considerable evidence base for all of the aforementioned class of 
medicines to be used in non-smokers with asthma.  This study looked at the potential 
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beneficial effects of the macrolide antibiotic azithromycin.  There continues to be no 
consensus on whether macrolide antibiotics can be recommended for general use in 
patients with poorly controlled asthma.   
8.8.4. Non-antibacterial macrolides 
Recent development of chemically modified non-antibiotic macrolides that maintain 
anti-inflammatory properties may overcome the risk of contributing to emerging 
microbial drug resistance. EM703 is a 12-membered-ring derivative of erythromycin 
that is devoid of anti-bacterial actions but exhibits anti-inflammatory properties.  For 
example, EM703 inhibits transforming growth factor-β induced proliferation, 
transcription of type I collagen and collagen production of both human and murine 
lung fibroblasts [283, 284] and NFB activation and IL-8 production in human 
bronchial epithelial cells [285].  In addition, EM703 can increase HDAC2 levels in 
vitro [171], suggesting a possible mechanism by which this compound may restore 
corticosteroid sensitivity in COPD and in smokers with asthma [170, 205].  There is 
evidence in the patent literature of novel compounds that are claimed to demonstrate 
dissociation of anti-inflammatory from antibiotic effects.  A derivative of the 
macrolide azithromycin [CYS0073] has been developed that has anti-inflammatory 
actions in the absence of any bactericidal properties [148].  This candidate molecule 
has been found to reduce inflammation in animal models of inflammatory bowel 
disease and rheumatoid arthritis [148].  If similar anti-inflammatory effects are found 
in experimental models of airway inflammation then this molecule could be 
developed as a potential therapy for chronic inflammatory airway diseases in man. 
Macrolide antibiotics have the ability to accumulate in inflammatory cells including 
neutrophils, monocytes and alveolar macrophage as well as epithelial cells [133].  Due 
to this property, non-antibiotic macrolides have been developed that are conjugated 
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with a second, pharmacologically active drug that has anti-inflammatory properties 
and as such, these compounds are used to transport the active moiety into the cell 
and thereby increase local anti-inflammatory drug action.  Using this property 
macrolides have been developed that act as a drug carrier for an active compound, 
such as a corticosteroid[286], cyclo-oxygenase or 5-lipoxygenase inhibitor[287], which 
is covalently bound to the macrolide.  Macrolide conjugates have been patented that 
include pyrrolizine and indolizine compounds that act as inhibitors of 5-
lipooxygenase and cyclooxygenase[287] or that contain coumarins[288].  Macrolide 
conjugate compounds that include a corticosteroid can bind to the glucocorticoid 
receptor, accumulate in cells and can inhibit T cell proliferation, IL-2 production and 
ovalbumin-induced airway inflammation in mice [286].  In addition the intracellular 
localisation of the active compound such as a corticosteroid limits the likelihood of 
systemic adverse effects and ensures a localised anti-inflammatory action of the active 
compound.  There are no published reports on the clinical efficacy and anti-
inflammatory effects of non-bacterial macrolides in the treatment of airway diseases. 
8.8.5. Other treatments for smokers with asthma 
Standard asthma therapies are licensed from data obtained in non-smokers with 
asthma, and in addition, smokers with asthma have a different type of inflammation 
compared with non-smokers with asthma.  Meeting the needs of this patient group 
with new or novel therapies could revolutionise the long term prospects in morbidity 
and mortality as well as social and health economic benefits of reduced burden on 
healthcare and fewer lost days to illness in the workplace.   
Recent work has suggested alternatives to standard forms of smoking cessation 
therapy.  A phase I/II trial for a nicotine vaccine in humans has confirmed safety and 
immunogenicity [289].  This novel approach aims reduce the pleasurable surge of 
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nicotine sought by the [ex-]smoker.  If successful this could increase smoking 
cessation and subsequent relapse rates.  A monoclonal antibody has also been 
developed separately to reach the same goal [290].  It remains to be seen in larger 
Phase III trials if both these approaches will be effective. 
Another approach is to restore corticosteroid sensitivity.  Smokers have reduced 
HDAC activity [117] and so it would follow that if HDAC activity could be restored 
there could potentially be a restoration of corticosteroid response.  Pre-clinical and 
pilot studies in smokers with asthma have shown that low-dose oral theophylline can 
restore HDAC activity [291] with a measurable therapeutic response of improved 
lung function in [292].  Given the suggested benefit further larger trials need to be 
considered.  
The ability for low-dose theophylline to successfully increase HDAC activity has led 
to greater scrutiny of the underlying mechanism.  This has led to the discovery that 
theophylline inhibits phosphotidylinostol-3 kinsases [PI3K] specifically subtype p110-
δ [293].  Successful pilot studies with a theophylline-related PI3K-inhibitor compound 
have been performed ex-vivo in peripheral blood mononuclear cells harvested from 
patients with COPD, demonstrating a restoration in steroid sensitivity [294].   
Theophylline is a non-specific phosphodiesterase inhibitor but its bronchodilator 
effect is thought to arise from inhibition of the subtype phosphodiesterase-4.  Two 
specific inhibitors of this enzyme have been developed – cilomilast and roflumilast.  
Of these, only roflumilast has shown significant benefit in non-smoking asthmatics 
[295].  There are currently no studies investigating the potential benefits in smokers 
with asthma, but it is now likely given the findings in the pilot studies that further 
trials may be carried out.  
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The thiazolindinedione rosiglitazone belongs to a family of drugs which act on the 
nuclear hormone receptor peroxisome proliferator-activated receptor [PPAR]-γ.  A 
proof-of-concept study was performed with rosiglitazone in a group of smokers with 
asthma and demonstrated a bronchodilator effect after 4 weeks of treatment [296].  
Concern exists over the side-effect profile of this class of medicines and so it remains 
to be seen if further steps can be taken to make them a clinically relevant class of 
drugs for asthma. 
Statins have pleiotropic anti-inflammatory actions.  Large retrospective observational 
studies suggest there is a beneficial effect when given to asthmatics [297] and that 
they can slow the decline in lung function in current or ex-smokers independent of 
the presence of underlying lung disease [298].  With particular relevance to the 
current study there is prospective randomised controlled trial data which found there 
is improvement in airway inflammation and quality of life when atorvastatin is given 
to adult asthmatics [299] and in smokers with asthma [251].  Some of the evidence for 
statin use can be contradictory with other studies finding no benefit [300].  Large high 
quality studies will be required to determine if clear efficacy exists. 
Oxidative stress is thought to play a role in the pathogenesis of asthma [301] and 
COPD [302].  Cigarette smoke is the leading cause of COPD in the developed world 
thought to be caused by the amount of oxidative compounds per inhalation.  Patients 
with COPD on the widely prescribed mucolytic [and anti-oxidant] drug carbocisteine 
have been shown to have reduced frequency of exacerbations [303].  The likelihood of 
extreme oxidative stress in the airways of smokers with asthma makes this an area of 
worthwhile investigation. 
Smokers with asthma form a large proportion of patients; roughly 40% in our 
experience and these do not respond well to treatment.  Understanding the 
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mechanism may provide scientific rational for new treatments that would also benefit 
ex-smokers and possibly smokers with other inflammatory disease that may be 
treatment refractory. 
In conclusion; we have shown that azithromycin is unlikely to improve asthma 
control in smokers with asthma and at present cannot be recommended for use in this 
group. 
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Appendix 2: Asthma Quality of Life Questionnaire 
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Appendix 3: Leicester Cough Questionnaire 
 
 272 
 
 
 
 
 273 
 
 
Appendix 4: Patient Diary Card 
Subject number________________ 
Initials: ____ ____ ____ 
       
 Date/Month DD/MM/YY        
M
O
R
N
IN
G
 
Peak flow [best of 3]        
Was blue [reliever] inhaler 
used in the 4 hours before  
peak flow testing?  
Yes 
No  
Yes 
No  
Yes 
No  
Yes 
No  
Yes 
No  
Yes 
No  
Yes 
No  
Did you wake up with asthma 
symptoms? 
No = 0;  Once = 1 
More than once = 2 
Awake “all night” =3 
0 
1 
2 
3 
0 
1 
2 
3 
0 
1 
2 
3 
0 
1 
2 
3 
0 
1 
2 
3 
0 
1 
2 
3 
0 
1 
2 
3 
 
E
V
E
N
IN
G
 
Night  peak flow [best of 3]        
Was blue inhaler taken within 4 
hours of night peak flow ? 
Yes 
No  
Yes 
No  
Yes 
No  
Yes 
No  
Yes 
No  
Yes 
No  
Yes 
No  
1.How often did you 
experience asthma symptoms 
today? 
 
0                                       6 
 
0= none of the time 
6 = all of the time 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
2. How much did your asthma 
symptoms bother you today? 
 
0                                       6 
 
0= not at all bothered  
6 = severely bothered. 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
3. How much activity could you 
do today? 
 
0                                       6 
 
0= more than usual activity 6= 
less than usual activity. 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
4. How often did your asthma 
affect your activities today? 
 
0                                       6 
 
0=none of the time  
6=all of the time. 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
0 
1 
2 
3 
4 
5 
6 
5. How many puffs of the blue 
inhaler did you use today? 
       
6. Have you taken your study 
tablets today? 
Yes  
No   
N/A 
Yes  
No   
N/A 
Yes  
No   
N/A 
Yes  
No   
N/A 
Yes  
No   
N/A 
Yes  
No   
N/A 
Yes  
No   
N/A 
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Appendix 5: GINA Severity Classification 
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Appendix 6: Nebuliser calibration - methacholine 
 
Flow Preweight 
[g] 
Postweight[g] Difference in 
weight 
Average Output   ml Output 
/min 
2 35.38 35.327 0.053    
 35.334 35.29 0.044 0.0485 0.02425 
3 35.335 35.205 0.13    
 35.368 35.24 0.128 0.129 0.0645 
4 35.438 35.178 0.26    
  35.389 35.137 0.252 0.256 0.128 
5 35.456 35.04 0.416    
 35.464 35.026 0.438 0.427 0.2135 
6 35.483 34.948 0.535    
 35.551 34.923 0.628 0.5815 0.29075 
 Average     
2 0.02425     
3 0.0645     
4 0.128     
5 0.2135     
6 0.29075     
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Appendix 7: Cytokine analysis quality control 
Spiking of selected sputum samples with a single amount of each of the cytokines. 
 Amount added (pg) Amount recovered (pg) 
  Mean S.D. 
IL-1  444 488.2 235.4 
IL-2  333 218.7 111.8 
IL-4  417 260.6 110.7 
IL-5  667 827 455 
IL-6  133 227.2 91.8 
IL-8  256 493 1240 
IL-10  267 604.5 236.8 
TNF  167 245.9 108.6 
INFα  250 301.7 118.6 
IFNγ  694 500.3 225.1 
GM-CSF  750 979.3 354.2 
RANTES  56 234.9 99.6 
 
Graph below is a comparison of the amounts added vs mean amount recovered in 
table above 
 
 
r=0.643, p<0.001 
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Appendix 8: Recruitment Challenges in Primary Care Randomised 
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Abstract  
Introduction:  
There is a paucity of information regarding the challenges faced by those recruiting to randomised 
controlled trials (RCTs) from primary care. Here, we describe three primary care RCTs involving 
adults with asthma to illustrate the difficulties faced and highlight potential strategies to improve 
recruitment.  
Methods:  
We reviewed the participant flow charts and trial documentation relating to three trials in order to 
establish recruitment details with a particular focus on Trial 3.  Trial 1 examined the effect of improved 
home ventilation on asthma control and house dust mite allergen levels.  Trial 2 examined whether 
short-term treatment with atorvastatin improves lung function, asthma control and quality of life in 
smokers with asthma.  Trial 3 examined whether short-term treatment with azithromycin improves 
lung function, asthma control and quality of life in smokers with asthma. 
Results:  
Recruitment rates across the three trials ranged from: 19% [68/444] to 40% [63/157] of practices invited; 
and 9% [715/8398] to 16% [820/4986] for patients. Strategies to improve recruitment included: 
employment of additional staff; direct telephone calls to patients; protocol amendments to broaden 
participation rates; addition of a second recruiting site. 
Conclusion:  
Achieving completion targets in primary care based RCTs is labour intensive.  Close monitoring of 
recruitment targets is essential to identify problems early and allow remedial action. Recruitment can 
be improved with increased administrative support, closer partnership with primary care and direct 
contact with potential recruits. Openly acknowledging and addressing the challenges of recruitment 
will mean fewer trials are underpowered providing better returns for grant awarding bodies. 
Word Count: 250 
 
Introduction 
Recruitment to randomized controlled trials [RCTs] is acknowledged to be challenging [1]. Less than a 
third of clinical trials successfully recruit 100% of their target, with 45% recruiting less than 80% of 
target.  Consequently, over half of all clinical trials request an extension for recruitment [2].  Failure to 
achieve recruitment targets adds expense and logistical difficulties.  Crucially this may result in a 
study being underpowered and unable to confidently answer its original research question.  There is a 
paucity of information regarding the challenges faced by investigators from primary care [3] and how 
this can be overcome.  A recent literature review has highlighted the need for research in this sphere, 
focusing particularly on the development of a repository of evidence based techniques and methods to 
aid those conducting primary care based RCTs [4].  Few recruitment methods employed by researchers 
in primary care are evidence based [5].  A Cochrane review quantified the effects of strategies to 
improve the recruitment of participants to RCTs [6].  Interventions such as telephone reminders to 
non-responders, use of opt-out rather than opt-in procedures for contacting potential trial participants, 
and open design were the most effective [6].  However, the latter two suggestions may be impractical 
for certain RCTs.  It is noteworthy that this review intended to compare primary versus secondary care 
studies, but could not, because of the small number of eligible primary care studies.  In this paper, we 
describe three separate primary care based RCTs featuring participants with asthma.  These three 
RCTs illustrate the scale of recruitment difficulties.  We focus particularly on the most recent trial [Trial 
3], which, by learning from the preceding two studies, reached targets for completion.  We aim to 
highlight the strategies employed to overcome recruitment challenges and discuss how these can be 
implemented to RCTs in general.   
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Methodology 
We scrutinized three trials undertaken by the University of Glasgow Asthma Research Unit at 
Gartnavel General Hospital, Glasgow in collaboration with General Practice and Primary Care, 
University of Glasgow [7-9].  These three trials recruited predominantly from primary care.  We also 
examined documents [protocols; ethics applications; amendments; patient databases and response rate 
records; CONSORT reports; subjects screening logs; reasons for screen-failure] detailing methods of 
recruitment throughout the lives of the trials, in order to identify potential strategies for improving 
future trial recruitment, focusing attention the most recent trial [9].   
The first trial assessed the use of ventilation units in dwelling houses to establish if improved 
ventilation impacted on asthma control and house dust mite allergen levels [7].  Patients in this trial 
were contacted using a combination of media advertising, and personal phone calls to family 
practitioners by a respiratory physician.   
The second trial examined whether short term treatment with atorvastatin improves lung function, 
asthma control, and quality of life in people with asthma who smoke [8].  The third trial asked the 
same question but tested azithromycin.  A primary care research network, the Scottish Primary Care 
Research Network [SPCRN] supported Trials 2 and 3.  Both of these trials used similar methods to 
contact potential patients; family practitioners were contacted by mail in the first instance.  If practices 
agreed to participate a researcher or staff member from SPCRN would arrange to visit the practice to 
identify study eligible patients and send out study invites. 
The focus of this paper is the most recent RCT [Trial 3] [9], in addition, details from the other two trials 
are provided to illustrate that recruitment challenges were generic and not specific to any one trial, 
trial medications, or specific patient groups. 
During each trial, recruitment rates were monitored with details of the patient response rate, screening 
attendance, screen fail rate [with categorization of cause], randomization rate and completion rate 
circulated between all members of the study team on a bi-weekly basis.   
The inclusion/exclusion criteria, recruitment methodology, and summary of protocol for each trial are 
detailed in Table 1. 
Results 
Recruitment 
Recruitment results for all three studies are detailed in Figure 1 and Table 2.  These show the low rates 
of participation by both family practices, ranging from 12-40%, and patients, ranging from 9-16% 
across the three trials.  Trial 3, had a particularly low ratio of patients invited, to patients randomized 
(0.013%).  A similar pattern was found in Trial 2.  Only Trial 3 had an extension to the timeframe of the 
study to facilitate patient recruitment.  There was a six-month lead time from employment of the 
clinical research fellow, until final approval was given to commence screening, with the study closing 
to new patients exactly 24-months later.   
Administrative Support 
A key reason for success in achieving the target number to complete in Trial 3 was the early 
recognition that randomization rates were lower than expected [Figure 1].  In January 2010, an 
additional staff member was seconded to the study one day per week to facilitate recruitment.  Figure 
1 illustrates the positive effect this had on screening and subsequent randomization numbers [vertical 
arrows].  By November 2010, this secondment ended, with a negative impact on recruitment rates 
thereafter.  A new staff member was seconded from January 2011, and once more an increase in the 
screening and randomization rate can be observed. 
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Participation by Family Practices 
Family practitioners were asked to permit access to computer registries and screen the list of potential 
patients to ensure unsuitable patients [e.g. terminally ill] were excluded.  Although this limited input 
was clearly specified on the study information leaflets, and the subsequent practice workload being 
minimized by the study team, the majority of family physicians cited lack of time and current 
workload as the reason for non- participation.  This problem was partially overcome by having a 
family practitioner seconded to the study telephoning practices that had responded negatively, and 
discuss the trial directly with family physicians.  Non-responding practices were also contacted and 
practitioners were reassured about the minimal volume of work involved.  Consequently the pool of 
practices agreeing to participate was increased by a further 10, to a total of 84. 
Patient participation 
This poor response rate had been identified in previous studies within our unit [10] and elsewhere [11] 
and in anticipation of this, ethical approval had been sought and granted to permit follow up phone 
calls to non-responders.  Although labour intensive, this strategy did improve recruitment [Figure 1 – 
arrows].  Pre-emptory ethical approval reduced the lead time in commencement of this method, hence 
maximizing the time available to reach the recruitment targets. 
Increasing the patient pool 
A second site was opened, extending the geographical reach of the study.  The original study approval 
was for one health board area within Scotland [Greater Glasgow and Clyde], with a patient population 
of 1.2 million.  The study recruitment area was extended to include additional catchment areas, still 
recruiting predominantly from primary care, providing an additional pool of 367,000 patients.  This 
extension was not as helpful as originally envisaged.  There were delays in getting additional ethical 
and research governance approvals, and fewer practices than expected agreed to participate, often 
citing the large distances which patients would have to travel as a the main barrier.  These limitations 
led to only eight patients being screened, and none being randomized.   
Protocol amendments 
The original trial protocol required patients be maintained on short- acting-β2-agonists and low-dose 
[400mcg daily] inhaled beclometasone or equivalent.  Weaning and withdrawal of long-acting β2-
agonist [LABA] had a negative impact on recruitment in two ways. Many patients experienced an 
apparent deterioration in asthma control, precluding them from subsequent randomization and a 
proportion of patients declined participation as they preferred not to interfere with their medication 
regimes.  The study protocol was amended during the trial to allow patients to remain on their LABA. 
Peak expiratory flow [PEF] technique is effort dependent and this was identified as a cause of high 
screen fail rates during the run-in phase.  A baseline PEF reading was set at the initial screening visit, 
based on the results during that visit.  Patients monitored their PEF daily at home twice daily for 4 
weeks.  Providing there was no evidence of exacerbation at the baseline visit the patient could then be 
randomized.  Patients were advised that if their PEF fell below a threshold they should contact the 
research team.  Less than 36% [20/56] of the patients who screen failed due to falling PEF contacted the 
research team, the rest continued for the screening period with levels below their alert level.  A 
proportion of these patients had no clinical deterioration in asthma control, with the drop in PEF being 
accounted for due to poor technique when performing measurements unsupervised at home.  This 
phenomenon led to numerous patient exclusions.  This issue was difficult to address, with increasing 
tuition on PEF technique appearing to make little difference when patients returned home to perform 
recordings unsupervised.   
Discussion  
This report suggests that there are two specific areas presenting challenges to investigators recruiting 
from primary care: firstly encouraging family practice involvement, and secondly encouraging patient 
participation  Recruiting from primary rather than secondary care is generally viewed as more 
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challenging, but there is little in the way of formal comparisons [4, 12, 13].  The CONSORT statement 
does not require provision of such information [14] and hence the full extent of recruitment difficulties 
are rendered invisible when trials are reported.  Primary care involvement in recruitment varies and 
results in difficulty establishing the magnitude of the challenges faced by recruitment in primary 
versus secondary care.  This can range from as little as allowing research teams to access primary care 
databases, allowing mailings to specific patient populations, or formally recruiting, consenting and 
even undertaking the intervention.  Our findings suggest several key areas for investigators to 
consider when planning RCTs, both in relation to improving partnership with primary care, 
anticipating recruitment challenges, and regarding disease specific issues, in this case asthma.  Several 
studies suggest that minimizing physician workload is crucial to maximizing participation and 
retention in clinical trials [4, 15-18].  However, despite efforts to emphasize the minimal work this 
study entailed, the majority of family physicians suggested workload was the reason for not 
participating.  Finding the right balance in the practice-information-sheet regarding workload seems 
equally as important as the patient-information-sheets.  Personal phone calls to family physicians in 
trials 1 and 3 did aid recruitment, and been found elsewhere [19].  In addition the peer-to-peer 
approach was also beneficial in our studies as in others [19].  Financial incentives have been advocated 
by some, but there is conflicting evidence of its effectiveness.  Studies, with much larger financial 
incentives than our trial still reported poor recruitment [16, 20], whilst others found benefits [21].  
Generally, the literature regarding physician attitudes to financial payments suggests that this has little 
bearing on the decision to participate [5, 22-24]. However, more recent studies suggest that financial 
payment may actually be more important than previously recognized [16, 17, 20, 25].  Again, this 
information is rarely reported, making it difficult to draw firm conclusions on this issue.  In Trial 3, 
approximately half the patients who responded positively to the initial mailing were excluded.  
Telephoning patients is a useful recruitment method with known positive effects on recruitment [21] 
but in Trial 3 particularly, a significant amount of time was lost telephoning patients who were not 
suitable.  This raises the question of whether the search undertaken in the practices could have been 
more specific and excluded patients on certain medications or with insufficient symptoms. This 
strategy could be considered for future studies; however there are risks that patients who would be 
eligible could be missed. 
 
Importance of patient participation rates 
Patient participation rates were low across all three trials, ranging from 9-16%.  There appears to be no 
available data on what ‘average’ participation rates are, and often trials do not specifically volunteer 
this information.  Patient participation rates to family physician mailings range from as low as 7% [26], 
to as high as 55% [20].  The authors from the latter trial felt that their high participation rate reflected 
specific targeting of individuals with known cardiovascular disease in a secondary prevention 
intervention. 
Anticipating difficulties 
Close monitoring of recruitment rates allowed early identification of slow recruitment rates and was 
crucial in alerting the investigators to institute changes in order to achieve target randomization in trial 
3, albeit with the a 6 months extension.  A range of strategies, recommended in the general literature 
on RCT recruitment, were used to maximize success.  Recruitment difficulties were anticipated, and 
strategies were already in place, to be utilized as soon as rates were identified as unsatisfactory.  
Importantly, a significant amount of time and resources were invested in adding a second recruitment 
site in this study, which yielded limited benefits.  It has been suggested previously that increasing 
eligibility of participants to the available recruitment site is more effective than the inclusion of 
additional sites, which our experience would corroborate [18].  Also, flexibility of the funder to allow 
protocol changes, and importantly the time to allow protocol changes to take effect was critical in our 
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study, and elsewhere in the literature [27].  Dedicated enrollers were utilized as an adjunct with 
significant impact. This has been identified elsewhere as an important factor in recruitment [28].   
Trial specific issues 
Specific issues were identified which contributed to the problems with recruitment. The number of 
patients who screen-failed [67% of 234] due to a deterioration in asthma control was a major hurdle to 
achieving the randomization target [Table 3].  This was in part ameliorated by the change in protocol 
to allow continuation of LABA.  The loss of these patients who had undergone a lengthy screening 
visit represented a significant waste of investigator time, and consideration of how to minimize this is 
important for future trials. 
Limitations 
While this paper addresses an important issue for primary care investigators, it has a number of 
limitations.  The trials described all focused on one disease area. Whilst the findings resonate with the 
limited literature on primary care trials, it will be important to explore whether primary care trials in 
other disease areas encounter the same difficulties. Secondly, the trials described were all conducted in 
one country, Scotland, and it is possible that recruitment may be less difficult in other nations.  
However, our findings are consistent with the current evidence that recruitment to randomized 
controlled trials is difficult, with targets often missed, leading to underpowered trials, or requiring 
extension of recruitment phases and additional funds.  The issues are present in countries other than 
the UK [2, 12, 15, 29].  In addition, we presented the details of three trials to demonstrate that the 
difficulties described in the most recent were evident with different research personnel, and also in 
non-drug trials [7, 8].  Finally, this paper provides a retrospective account of the recruitment challenges 
faced. Ideally future studies would be prospective and might use qualitative methods to help increase 
understanding of the difficulties faced.  
Conclusion 
Achieving the completion target in primary care based RCTs is extremely labour intensive.  Close 
partnership working between research units and primary care practitioners, increased access to 
primary care patient databases and direct contact with potential recruits is beneficial.  Close 
monitoring of recruitment targets is essential in order to identify problems early, and allow remedial 
action to be taken.  Based on our experience we recommend obtaining ethical approval for strategies to 
be deployed in the face of recruitment difficulties during the initial ethics application, rather than 
applying for amendments once difficulties arise, a strategy which proved successful in this latter trial.  
Increased transparency about the magnitude of recruitment difficulties is required to allow more 
realistic estimates of recruitment timescales and costs.  This is unlikely to happen unless the 
CONSORT statement is extended to require reporting of such information.  There are increasing calls 
for recruitment information to be provided on public registers of clinical trials such as 
ClinicalTrials.gov [30].  For primary care asthma trials, consideration should be given to methods to 
minimize “false” deterioration of patients during the run-in period due to poor PEF technique. 
The bulk of health care is delivered within primary care, and thus recruitment from primary care for 
RCTs is essential.  If we are to achieve recruitment targets, meet end points and provide a better return 
for grant awarding bodies, it is essential for more primary care trials to meet recruitment targets. 
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Figure and Table Legends 
 
Figure 1:  Cumulative recruitment for Trial 3. 
Table 1.  Description of featured trials 
Table 2.  Recruitment figures for featured RCTs 
Table 3.  Reasons for screen-failure in Trial 3 
 
 
 
 
Figure 1:  Cumulative recruitment for Trial 3. 
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Table 1. Description of featured trials 
 
  
 Trial 1 [2009] [7]: Trial 2 [2011] [8]: Trial 3 [Completed September 2011]: 
Title Effect of improved home 
ventilation on asthma control 
and house dust mite allergen 
levels 
Effects of short-term treatment with 
atorvastatin in smokers with asthma - 
a randomised controlled trial 
Effect of macrolides on asthma control, 
airway inflammation and bacterial 
colonization in smokers with asthma. 
Inclusion 
Criteria 
Age 16 to 60 years 
 
asthma symptoms for > 1 
year 
 
on regular ICS 
 
daily symptoms 
 
reversible airflow obstruction 
 
minimum FEV1 > 50% 
predicted at baseline 
 
no exacerbations in the 
preceding month 
aged 18 to 60 years 
 
asthma symptoms for > 1 year 
 
 
current smokers 
 
reversible airflow obstruction 
 
aged 18 to 70 years  
 
asthma symptoms for > 1 year 
 
 
current smokers 
 
reversible airflow obstruction  
 
maintain asthma without exacerbations 
on beclometasone 400mcg/day & SABA 
as required, for 4 weeks pre-screening, 
requiring weaning off other asthma 
medications e.g. LABA 
Exclusion 
Criteria 
were likely to move house 
 
had a pet that provoked 
symptoms 
already on a statin, or a medication 
which could interact with statins 
asthma exacerbation within the 
preceding 6 weeks 
ex-smokers or those who planned to quit 
 
unstable asthma 
 
respiratory infection within the preceding 
4 weeks 
 
allergy to, or on medication with 
interactions with, azithromycin 
Recruitment 
methods 
Participants were recruited 
from family practices and 
hospital clinics 
Participants were recruited from 
family practices, hospital clinics and 
research databases 
Participants were recruited from family 
practices, hospital clinics and research 
databases.  
GP Practice 
reimbursement 
Practice time reimbursed at   
hourly rate £39 for GP, 
£15.53 for practice nurse, 
£12 for practice manager 
£25 per practice £101 per practice 
Protocol Baseline screening visit, with 
diary of preceding 2 weeks 
PEF readings 
 
Randomized to receive 
ventilation unit or placebo 
unit  
 
Attended for follow up visits 
at 3, 6, 9 & 12 months 
(measuring PEF twice daily 
for preceding 2 weeks) 
weaned off ICS and LABA, for 2 
weeks prior to randomization 
 
randomized to atorvastatin or 
placebo for 8 weeks, with ICS 
commenced in both groups at week 
4 
 
Short acting β2 agonists allowed 
throughout 
 
minimum of 4 further visits required 
for completion of the study  
attended for clinical screening, informed 
consent & issuing of diary & electronic 
PEF meter to record their PEF daily 
 
Four weeks later diary and PEF readings 
examined to ensure no exacerbations  
 
Randomized to 12 weeks of azithromycin 
or placebo 
 
5 visits over the 12 week period 
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Table 2.  Recruitment figures for featured RCTs 
 Trial 1 Trial 2 Trial 3 
Target to Randomize 128 80 80 
Target to Complete n/a 68 68 
Total number of GP practices invited  157 438 444 
Positive GP practice responses (% of invited)  63 (40%) 54 (12%) 84 (19%) § 
Total number of patients invited 4986 2839 8398 
Positive responses received from patients (% of invited) 820 (16%) 331 (12%) 
 
715 (9%) 
 
Assessed for Eligibility 820 286 705 
Excluded by telephone /pre visit screening 
 
Not meeting eligibility criteria 
 
Unwilling/unable to consent 
338 
 
n/a 
 
n/a 
111 
 
n/a 
 
n/a 
370 
 
347 
 
23 
DNA initial appointment n/a 44 101 
Attended initial appointment  482 131 234 
Consented 482 129 225 
Screen failed 319 ‡ 53 148 
Randomised (% of those consented) 119 (25%) 71 (55%) 77 (34%) 
Completed  100 60 71 
§  includes 4 practices in responding post recruitment closure; 80 practices visited.  10 practices 
agreed during post-invitation phone call 
‡ includes participants whose houses were not suitable for installation of the ventilation system 
n/a  not available/applicable 
 
 
 
Table 3.  Reasons for screen-failure in Trial 3 
Reason Trial 3 
 n 
Exacerbation of asthma 56 
DNA Visit 2 37 
Not symptomatic enough (ACQ<1) 11 
Withdrew 10 
Prolonged QTc on ECG 7 
No reversibility/methacholine negative 7 
Unable to wean off asthma medications 4 
Abnormal blood tests 4 
Other 12 
Total 148 
 
 
